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GENOME-WIDE ANGIOTENSIN II REGULATED MIRNA EXPRESSION 
PROFILING: A SMOOTH MUSCLE-SPECIFIC MIRNA SIGNATURE 
 
 
JACQUELINE R. KEMP 
 
ABSTRACT 
 
Renin-angiotensin system (RAS) activation and phenotypic modulation of 
vascular smooth muscle cells (VSMCs) are common characteristics associated with 
human diseases, such as pulmonary hypertension, atherosclerosis and stroke. While 
elevation of the RAS hormone product, angiotensin II (AngII) is a well-established risk in 
these diseases; the mechanism of activation of RAS and modulation of VSMC phenotype 
by AngII is vague, suggesting that novel global regulators may mediate the risk by AngII. 
MicroRNAs (miRNAs) represent one such class of potential global regulators. MiRNAs 
are small (~22 nt), endogenous, non-coding RNAs that act as post-transcriptional 
regulators of physiological processes.  MiRNAs primarily function by binding to 
complementary target sites in the 3’-untranslated regions (3’-UTR) of mRNAs, causing 
translational repression and/or mRNA destabilization.   
 
To elucidate the global miRNA expression profile following chronic Angiotensin 
II Type 1 Receptor (AT1R) activation by AngII, we performed microarray analysis in 23 
biological and technical replicates derived from humans, rats and mice. We 
 ix 
pharmacologically distinguished the AT1R-regulated miRNA profiles by comparing 
technical replicates treated with the specific AT1R-blocker, losartan and biological 
replicates following chronic AT2R activation by AngII. Thirty-two miRNAs are AngII-
regulated universally. Most other miRNAs are regulated in a treatment- or species-
specific manner. A few miRNAs are unique to specific cell types.  
 
We have previously shown that a single miRNA can have multiple targets, 
potentially providing simultaneous regulation of the genes involved in a physiological 
pathway and accounting for a complex phenotype, such as human heart failure (JBC 284: 
27487-27499). In the current study, we explored the extent to which AngII/AT1R-
regulated miRNAs contribute to maintenance of RAS homeostasis and phenotypic 
modulation of VSMCs. A distinct AngII-regulated miRNA expression pattern emerged in 
the human and rat VSM cell lines in the profiling experiment, which was validated in our 
independent samples.  Of the 17 miRNAs comprising the VSMC expression pattern, we 
selected miR-483 as a representative candidate for further study because of its location 
within the genome and its ability to potentially target multiple components of RAS. In 
addition, we show evidence that suggests muscle cell-specific expression of miR-483.  
We incorporated a miR-483 expression cassette into two distinct cell lines as a means to 
determine post-transcriptional inhibition of specific RAS component gene expression.  
The functionality of miR-483, in terms of modulating the cellular phenotype, was 
assessed in a wound-healing assay. Overall, miR-483 regulates both RAS and AngII-
activated migration; specifically in VSMCs. Our results further suggest that following 
inhibition of several AT1R-activated kinases, the AngII-regulated MEK1 kinase signaling 
 x 
cascade most effectively mediates the steady state pool of miRNAs, which includes 
downregulation of mir-483. In this context, JAK2 inhibition is somewhat effective. This 
results in activation of RAS and switching of the VSMC phenotype associated with 
pathological states in vivo, such as hypertension. Further insight into these mechanisms 
will be valuable for a greater understanding of AngII biology.  In the context of 
determining the full capacity of RAS as an intrinsic regulatory system, AngII-regulated 
miRNAs will likely have a strong influence on cardiovascular disease.   
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CHAPTER I 
INTRODUCTION 
 
 
1.1 The Renin-Angiotensin System (RAS) 
 
1.1.1 The Circulating Axis of RAS 
The Renin-Angiotensin System (RAS) has been a key target for the management 
of cardiac and vascular abnormalities since its discovery and has been found to be 
increasingly complex.  RAS is an elaborate endocrine system that globally regulates 
numerous physiological processes, such as blood pressure maintenance, 
electrolyte/volume homeostasis, vascular tone, facilitation of catecholamine release (e.g., 
epinephrine and norepinephrine) from the brain and aldosterone release from the adrenal 
gland. Increasing evidence has pointed to a role for Angiotensin II (AngII), the major 
bioactive product of RAS, in disease states (Aplin et al., 2008, Taubman, 2003, Forbes, 
2011). AngII has the capability to induce numerous intracellular signaling events that can 
ultimately lead to global gene expression changes and pathological conditions, including 
hypertension, heart failure (HF), renal and inflammatory diseases (Teerlink, 1996).  
The classical, circulating axis of RAS is activated in response to decreased plasma 
sodium and fluid volume, resulting in the secretion of renin from the juxtaglomerular 
cells of the kidney.  The enzyme renin releases the N-terminal decapeptide angiotensin I 
(Ang I) from a liver-produced serpin, angiotensinogen (AGT), by proteolytic cleavage. 
Angiotensin converting enzyme-1 (ACE-1), abundant in the endothelial lumen of the 
pulmonary microvasculature, hydrolyzes the C-terminal dipeptide to produce the 
octapeptide hormone, AngII (Figure 1.1) (Lavoie and Sigmund, 2003, Teerlink, 1996).  
AngII then interacts with specific receptors on the plasma membrane to elicit a cellular 
response. The physiological importance of AngII cannot be overstated. The biological 
result of circulating AngII is widespread and diverse, giving the system an endocrine 
characteristic.  Notably, AngII is also formed by an alternative pathway, in which 
chymase, a serine protease highly expressed in the heart, vasculature, and kidney in 
humans, is capable of local AngII production from its precursor Ang I (Forbes, 2011).    
 
AngII has a short half-life in circulation; therefore, the peptide hormone is readily 
cleaved by amino- and carboxy- peptidases, resulting in production of additional 
angiotensin peptides (e.g., Ang III, Ang3-8, Ang IV, Ang1-7) (Figure 1.2) (Forbes, 2011).  
Each of the angiotensin metabolites exerts biological effects, some of which are distinct 
from the functions of AngII (Lavoie and Sigmund, 2003).   
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Figure 1.1. The classical circulating axis of RAS. Decreased blood pressure stimulates 
the release of renin from the kidney. Renin cleaves angiotensinogen to produce Ang I, 
which is in turn cleaved by ACE-1 to produce AngII. AngII is the major bioactive 
product of RAS, regulating blood pressure through vasoconstriction and stimulation of 
aldosterone and vasopressin release. AngII is capable of giving rise to pathological 
conditions such as cardiac and vascular hypertrophy and end-organ damage.  
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Figure 1.2. Additional RAS components. The peptide hormone, AngII can be readily 
cleaved, resulting in the production of additional angiotensin peptides (shown in red).  
The angiotensin peptides exert distinct biological effects. Adapted from (Hunyady and 
Catt, 2006). 
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For example, a homolog of ACE-1, ACE-2, was discovered and shown to degrade AngII, 
yielding Ang1-7 and leading to activation of a second major axis of RAS, the ACE-
2/Ang1-7/Ang1-7 Receptor axis (Zhang et al., 2010, Santos et al., 2003).  This axis has 
been proposed to have a vasoprotective role in pathophysiology of the cardiovascular, 
renal, pulmonary, and central nervous systems and is considered counter-regulatory to the 
classical circulating axis (Zhang et al., 2010, Santos et al., 2003).  Furthermore, a protein 
has recently been discovered, which binds and activates renin in tissues, the renin 
receptor. The physiological role of these new RAS components is not completely 
resolved, but they may exert considerable impact on local AngII generation and effect 
mediation in tissues (Bader et al., 2001). 
 
1.1.2 Role of G-Protein Coupled Receptors (GPCRs) in Mediating RAS Effects 
AngII affects various cell systems by binding to seven-transmembrane, cell 
surface, GPCRs (Mehta and Griendling, 2007). GPCRs constitute a vast integral 
membrane protein family that encompasses a wide-range of functions; therefore, they are 
divided into classes, of which the rhodopsin-like family accounts for nearly 85% of the 
GPCR genes (Rosenbaum et al., 2009). The AngII receptors are included within the 
rhodopsin-like family and are a member of the subgroup of peptide receptors. The 
characteristic feature of the rhodopsin family is the presence of conserved amino acid 
sequences that suggest common structural features and activation mechanisms. 
 
GPCRs are the largest family of cell surface receptors, having a major role in 
signal transduction.  They mediate responses to extracellular ligands by binding, 
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facilitating a conformational change in the receptor, and activating intracellular 
heterotrimeric G-proteins (Karnik et al., 2003, Rosenbaum et al., 2009).  The GPCR 
activates the intracellular G-protein by facilitating the exchange of bound GDP for GTP.  
In so doing, the G-protein’s α subunit, together with the GTP, can dissociate from the β 
and γ subunits to elicit activation of effectors such as adenylyl cyclase and 
phospholipases, which in turn changes the levels of intracellular second messengers, such 
as calcium and cAMP (Figure 1.3) (Pierce et al., 2002). In addition to the canonical 
signaling events initiated by G-protein signaling, studies have also shown alternative 
signaling pathways that are related to diverse functions of these receptors. GPCRs, for 
example, can also signal in a G-protein-independent manner, which leads to activation of 
mitogen activated protein kinases (MAPKs) (Miura et al., 2004).  Numerous G proteins 
exist, including Gαs, Gαi/o, Gαq/11, and Gα12/13. Each of these G proteins causes distinct 
functional consequences within the cell, due to the varying subunits present (Karnik et 
al., 2003, Rosenbaum et al., 2009).   
 
A common feature of GPCRs is that they exhibit a degree of basal activity in the 
absence of an agonist, which can be reduced in the presence of an inverse agonist. 
Agonists are ligands that fully activate the receptor beyond the basal level.  Conversely, 
antagonists compete with other ligands without affecting the basal activity (Kobilka, 
2007). GPCRs transmit extracellular signals across the cell membrane as a response to a 
wide variety of ligands, including hormones, ions, neurotransmitters, proteins/peptides, 
fatty acids, small molecules, and physical stimuli such as light, smell, taste, and 
 7 
mechanical stretch (Rosenbaum et al., 2009).  Thus, GPCRs are extremely relevant in cell 
signaling, pharmacology, physiology, and pathophysiology.   
 
Due to their involvement in many biological functions, GPCRs are also extremely 
important in drug discovery.  Nearly 50% of all modern human therapeutics is targeted to 
only a few GPCRs. Understanding the full capacity of GPCR signaling in physiology and 
pathophysiology is a critical aspect of receptor biology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
Figure 1.3. Prototypical GPCR activation. Upon activation of a GPCR, the GDP of the 
G-protein is exchanged with GTP, resulting in dissociation of the α and βγ subunits of the 
heterotrimeric protein. The dissociated subunits further activate intracellular downstream 
effectors, which in turn alter the levels of second messengers.  
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1.1.3 AngII-induced Pleiotropic Signaling Events: The AngII Receptors 
AngII functions as a master regulator of cardiovascular and renal system 
homeostasis. As its name implies, the net effect of AngII action is a potent constriction of 
vessels in most vascular beds (Aplin et al., 2008, Taubman, 2003, Touyz and Schiffrin, 
2000).  In recent years, AngII has been shown to play a pivotal role in mediating cell 
proliferation and/or apoptosis and fibrosis through activation of intracellular signaling 
molecules in a variety of cell types, including cardiac myocytes, fibroblasts, renal 
mesangial and epithelial cells, endothelial cells (ECs), and vascular smooth muscle cells 
(VSMCs) (Bell and Madri, 1990, Kim and Iwao, 2000, Lijnen and Petrov, 1999, Ohtsu et 
al., 2006).   
 
AngII elicits many diverse physiological effects in various tissues due to 1) its 
ability to bind to different receptor subtypes; 2) receptor coupling to distinct second 
messenger pathways; and 3) tissue specificity of the receptor subtypes (Berk, 2003).  
Cellular responses to AngII are dependent on two pharmacologically distinct GPCR 
subtypes, the Angiotensin II Type 1 Receptor (AT1R) and the Angiotensin II Type 2 
Receptor (AT2R), both of which have similar affinity for the agonist, AngII (Aplin et al., 
2008, de Gasparo et al., 2000, Hunyady and Catt, 2006, Miura and Karnik, 1999). 
 
1.1.3.1 The AT2R 
The AT2 receptor subtype shares approximately 34% sequence homology with the 
AT1R, but unlike its RAS counterpart, the precise role of the AT2R is debatable.  The 
gene for the AT2R is located on the X chromosome within exon 3 of the AGTR2 gene 
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and is approximately 50 Kb.  While the signaling mechanisms induced by activation of 
the AT2R remain poorly understood, it is known that the type 2 receptor is abundantly 
expressed in the developing fetus, owing to a role in physiological development.  The 
AT2R is expressed at low levels in the normal adult cardiovascular system, but it may 
increase in density in tissues under pathological conditions, in which inflammation and 
tissue remodeling occur (e.g., myocardial infarction, hypertension, atherosclerosis, 
diabetes mellitus, neointima formation after vascular injury) (Lemarie and Schiffrin, 
2010, Booz and Baker, 1996).  The proposed increase in AT2R expression during 
pathology can be viewed as fetal gene-reactivation, which is a prominent feature of the 
disease state of the cardiovascular system (Paul et al., 2006). 
 
Many studies have suggested that the AT2R is constitutively active and does not 
require binding of AngII to induce intracellular signaling cascades. For example, Miura 
and Karnik found that overexpression of the AT2R alone determined whether cultured 
fibroblasts, epithelial, or VSMCs underwent apoptosis in the absence of AngII (Miura 
and Karnik, 2000).  The AT2R has been implicated in cardiovascular disease as a 
beneficial moiety due to its proposed vasodilatory role, ability to inhibit cell growth, 
induce apoptosis, and inhibit activation of mitogen activated protein kinases (MAPKs) – 
functions that appear to counterbalance the actions of the AT1R (Table I.I) (Miura et al., 
2010, Berk, 2003).  Three main events have been described for the function of the AT2R 
in signal transduction: 1) phosphatase activation causing protein dephosphorylation; 2) 
activation of the bradykinin/nitric oxide/cGMP pathway; and 3) stimulation of 
phospholipase A2 and release of arachidonic acid (Blume et al., 2001, Matsubara, 1998).  
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The AT2R-selective antagonists, PD123319 and PD123177, are capable of inhibiting 
these signaling events by displacing the receptor’s agonist (Gallinat et al., 2000, Verdonk 
et al., 2012). 
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Table I.I. Differential effects of AngII stimulation of the AT1 and AT2 receptors. 
Adapted from (Silverstein and Ram, 2005). 
 
 
AT1 Receptor Stimulation 
     Increased vasoconstriction 
     Increased cardiac contractility and hypertrophy 
     Increased vascular smooth muscle proliferation 
     Increased extracellular matrix production 
     Increased tubular sodium reabsorption 
     Increased synthesis and secretion of aldosterone  
     Increased secretion of vasopressin 
     Increased noradrenergic activity 
     Cell growth and proliferation 
AT2 Receptor Stimulation 
     Regulation of:  
          Cell growth and proliferation 
          Cell differentiation 
          Extracellular matrix composition 
           Left-ventricular remodeling 
          Fetal tissue development 
          Apoptosis 
     Vasodilation 
     Antiproliferation 
     Increased neuronal regeneration 
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1.1.3.2 Significance of the AT1R 
The human AT1R (hAT1R) is ubiquitously expressed in the cardiovascular system 
and mediates the major cardiovascular effects of AngII (Dinh et al., 2001) (de Gasparo et 
al., 2000).  The gene for the hAT1R (AGTR1) is approximately 50 Kb in size and located 
within exon 5 on chromosome 3 in the genome (de Gasparo et al., 2000, Elton and 
Martin, 2007).  A prototypical GPCR, the AT1R has been characterized by molecular 
cloning, mutagenesis, and molecular pharmacology studies to be functionally activated 
upon high-affinity AngII binding and shown to rapidly undergo desensitization and 
internalization (Elton and Martin, 2007).  
 
Under normal conditions, AngII activated AT1R generates acute responses by 
coupling to the Gq-PLC pathway, leading to production of the second messengers, 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG).  Production of IP3 and DAG 
leads to Ca2+ mobilization and activation of protein kinase C (PKC), respectively (Mehta 
and Griendling, 2007, Hunyady and Catt, 2006).  AT1R activation is associated with a 
rapid increase in tyrosine phosphorylation of various signaling molecules (Yin et al., 
2003).  Phosphorylation leads to induction of growth-promoting signals such as mitogen-
activated protein kinase (MAPK)/extracellular signal-related kinase (ERK), 
phosphatidylinositol 3-kinase/Akt, and JAK-STAT signaling (Saito and Berk, 2002).  
These cytoplasmic signaling cascades ultimately propagate to the nucleus upon chronic 
AT1R activation.  In the nucleus, gene expression is either induced or repressed by 
distinct transcription factors (e.g., NFAT, MEF2, GATA, and STAT), following binding 
to response elements in the promoters of genes (Figure 1.4) (Hunyady and Catt, 2006, 
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Saito and Berk, 2002, Friddle et al., 2000). Additionally, Gβγ, through interaction with 
histones and transcription factors, modulates transcription in response to AT1R activation 
in cells (Bhatnagar et al., 2013). The pleiotropic signaling events that occur in response to 
AngII and result in changes in gene expression of a set of AngII responsive genes are 
ultimately responsible for phenotypic modulation of target cells (Hunyady and Catt, 
2006).  
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Figure 1.4. Major AT1R signal transduction pathways. Binding of AngII to the AT1R 
activates the Gq-coupled signaling pathway, leading to activation of PLC, which results 
in mobilization of Ca2+. AT1R activation leads to phosphorylation of multiple signaling 
pathways and induction of growth-promoting signals.  
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1.1.4 Consequences of AT1R Signal Transduction: Tissue RAS Over Activity  
In addition to systemic RAS, the components of RAS with the exception of renin 
are also expressed at variable levels throughout tissues, including the brain, heart, 
vasculature, pancreas, adipocytes and kidneys, allowing for local production of AngII 
peptides (Bader et al., 2001, Paul et al., 2006).  Tissue RAS regulates long-term and 
chronic responses to locally produced AngII in these tissues, thus, implicating AngII in 
the progression of development and growth, regulation of metabolic pathways, learning 
and memory.  Importantly, tissue RAS primarily functions independently of circulating 
RAS; therefore, it has a critical role in pathophysiological conditions, acting as a 
paracrine or autocrine system (Bader et al., 2001, Nakashima et al., 2006).  These 
conditions include inflammation, oxidative stress, hypertension, thrombosis, end-stage 
renal disease, coronary artery disease, cardiovascular hypertrophy and HF (Figure 1.6) 
(Daugherty and Cassis, 2004, Margulies et al., 2009, Mehta and Griendling, 2007).  As a 
result, fine control mechanisms regulating the effectiveness of tissue RAS is a major 
research frontier.    
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Figure 1.5. Effects of tissue RAS over activity. The components of RAS are expressed 
at variable levels through many major tissue types. This leads to local production of 
AngII and progression of pathophysiological conditions.   
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Genomic and proteomic advances have established that GPCRs regulate global 
gene expression programs, leading to processes such as differentiation, proliferation, and 
apoptosis in a variety of cell types (Karnik et al., 2003, Rosenbaum et al., 2009). Two 
main cell types directly and adversely affected by an increase in local AngII action are 
VSMCs and ECs due to the high density of AT1 receptors present within these cells.  
Ultimately, tissue RAS contributes to the maintenance of cardiovascular homeostasis by 
the impact on vessel function mediated through the AT1R. Extensive research into the 
precise signal transduction mechanisms that are critical for modulation of EC and VSMC 
phenotype and function are important to fully characterize the molecular effects of AngII.  
In particular, animal models as well as cellular studies have sought to examine the effects 
of AngII as a mediator of the development of vascular diseases.   
 
Cardiac fibroblasts and myocytes are additional cell types that express AT1 
receptors. AngII was found to exhibit growth-promoting effects in the heart more than 
30 years ago. Furthermore, in the heart, these effects were thought to be most relevant by 
inducing hypertrophy and fibrosis (Bader and Ganten, 2008). The results of animal 
studies, including the angiotensin type 1 receptor gene (Agtr1)-null mice (Oliverio et al., 
1998), tissue targeted AT1R transgenic (TG) mice (Paradis, 2000), and gain of function 
AT1R mutant knock-in mice (Billet et al., 2007), indicate that the AT1R mediates 
hypertrophic and proliferative effects of AngII. The AT1R is an AngII-activated growth 
promoter in tissues and indeed overexpression of AT1R correlates with a higher risk for 
cardiac hypertrophy, vascular thickening and ultimately tissue fibrosis. A hallmark of 
pathogenesis of human cardiovascular disease (CVD) is the overexpression of the AT1R 
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and most CVDs respond favorably to therapy with AT1R-selective drugs (Aplin et al., 
2008). 
 
It has become increasingly clear that tissue RAS is not an isolated entity, but can 
interact with circulating RAS as well as other peptide systems on multiple levels. In 
response to either systemically or locally generated AngII, the AT1R mediates the 
contractile response of VSMCs by PLC-dependent mechanisms leading to an increase in 
intracellular calcium. It also functions indirectly, by stimulating the synthesis of other 
vasoconstrictors. At the cellular level, the endothelium dysfunction that occurs in 
response to AngII is primarily due to an increase in adhesion, migration, and proliferation 
of ECs. In the presence of AngII, there is increased expression of the vasoconstrictor, 
endothelin, which can act to potentiate the action of PDGF (Rossi et al., 1999).  
Moreover, using an animal model overexpressing the AT1 receptor only in endothelial 
cells, Ramchandran et al. demonstrated that AngII also acts as a vasodilator, when 
interacting with the AT1R on these cells (Ramchandran et al., 2006). AngII promoted 
tissue factor and initiator of coagulation expression, both of which could lead to a 
coagulant property of AngII (Taubman, 2003, Touyz and Schiffrin, 2000).  
 
The global mRNA expression regulated by the AT1R (transcriptome) is a 
persistent response of AT1R signaling that is widely studied in both physiological and 
pathological settings. That is, if the activity of the AT1R is not properly regulated, AngII 
stimulus becomes chronic and can damage the tissue, as well as contribute to lasting 
cardiovascular disorders. The long-term research aim in this area is to elucidate how 
normal gene regulatory mechanisms are altered in response to over activity of the RAS in 
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different pathological settings. Typical transcriptional regulatory mechanisms are 
significantly altered in the experimental models. In a recent study, Yue et al. discovered 
that chronic AT1R activation mediates gene expression through U-STAT3 by a 
mechanism distinct from that of physiological regulator phospho-STAT3. This accounts 
for a dual role of STAT3 in regulating physiological and pathological gene expression 
programs (Yue et al., 2010).  Yue et al. discovered nuclear accumulation of 
unphosphorylated STAT3 (U-STAT3) which activates “renegade” transcription of genes 
such as osteopontin (OPN), connective tissue growth factor (CTGF), regulator of G 
protein signaling 2 (RGS2), and alpha-1 skeletal muscle actin, leading to hypertrophy and 
HF in mice (Yue et al., 2010). This study suggested that chronic AngII/AT1R signaling 
might alter the structure and dynamics of chromatin in target cell nuclei, such that latent 
regulatory sites on promoters of genes may be rendered potent for promoting 
overexpression (Yue et al., 2010).  
 
Ultimately, the physiological role of this local system is the maintenance of 
homeostasis at the tissue level. The local generation of AngII has been demonstrated for 
all tissues relevant for cardiovascular control (Bader and Ganten, 2008). Tissue RAS 
plays an important role in conveying and amplifying the effects of circulating AngII, 
thereby modulating cardiovascular parameters and mostly accelerating the pathogenesis 
of cardiovascular diseases. Overall, tissue RAS forms the basis for the understanding of 
the extraordinary therapeutic efficiency of drugs inhibiting the RAS. 
 
1.1.5 Effectiveness of Drugs Targeting the RAS 
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The RAS has been a therapeutic target for cardiovascular diseases for decades. 
Drugs targeting significant components of circulating RAS, such as ACE inhibitors and 
antagonists for the AT1 receptor can effectively lower blood pressure and RAS-induced 
pathologies. Very recently, inhibitors of the enzyme renin were also approved for clinical 
use (Staessen et al., 2006). The efficiency of these drugs is partially based on the fact that 
they not only inhibit the classical RAS in the circulation, but also local RAS in tissues 
(Bader and Ganten, 2008).  
 
ACE inhibitors compete with Ang I binding, preventing AngII formation 
mediated by ACE-1 in the circulation and tissues (Doulton et al., 2005).  The beneficial 
effects of these pharmacologically distinct agents extend to the nonhemodynamic 
functions of RAS, which suggests that RAS blockade is an overall effective means for 
organ protection, not merely for blood pressure reduction.  These therapeutic agents have 
been used in the treatment of renal, cardiovascular, and cerebrovascular diseases, 
showing that RAS has a global biological effect within the body (Doulton et al., 2005, 
Miura et al., 2011).   
 
An additional treatment option for controlling RAS is the use of AT1R-selective 
drugs (i.e., AT1R blockers [ARBs]), which halt or reverse the pathological vascular 
remodeling and cardiac dysfunction that occur in response to over activity of AngII at the 
molecular level (Aplin et al., 2008, Burnier, 2001, Miura et al., 2011).  This suggests that 
the AT1R contributes to phenotypic changes at the cellular level in vivo (de Gasparo et 
al., 2000, Hunyady and Catt, 2006).  ARBs, a widely used class of anti-hypertensive 
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drugs, are well tolerated with fewer side effects than ACE inhibitors. Irrespective of 
whether AngII is generated systemically or by non-ACE mediated pathways, ARBs 
specifically block AngII binding to the AT1R, and thereby target AT1R-regulated gene 
expression changes (Miura et al., 2011).  Several ARBs available for the treatment of 
RAS associated disorders are losartan and candesartan, for treatment of hypertension and 
hypertrophy, irbesartan, for treatment of diabetic nephropathy, and valsartan, for 
treatment of heart failure in people who cannot tolerate ACE inhibitors (Silverstein and 
Ram, 2005).  
 
1.2 Regulation and Characteristics of Vascular Smooth Muscle Cells 
 
1.2.1 The Vascular Smooth Muscle Cell (VSMC) and Its Function 
Lying within the tunica media of blood vessels, smooth muscle cells (SMCs) are 
essential for accurate performance of the vasculature.  By contraction and relaxation, 
these specialized cells alter the luminal diameter, which allows blood vessels to maintain 
a homeostatic blood pressure (Rensen et al., 2007). VSMCs are innervated primarily by 
the sympathetic nervous system through adrenergic receptors.  Activation of α-adrenergic 
receptors causes vasoconstriction, while activation of β-adrenergic receptors causes 
vasodilation.  In addition, within seconds to minutes of binding to AT1Rs, AngII causes 
Ca2+ mobilization from the sarcoplasmic reticulum and promotes the interaction of actin 
and myosin filaments to allow for contraction of cells. Excessive vasoconstriction leads 
to hypertension, whereas excessive vasodilation leads to hypotension.  Notably, due to 
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their function of carrying blood away from the heart to all other organs and tissues, 
arteries have a great deal more smooth muscle than veins.  
 
VSMCs perform additional functions, which become important during 
physiological conditions, or following vascular injury.  In these cases, VSMCs will 
synthesize increased amounts of extracellular matrix (ECM) components and exhibit 
increased rates of migration and proliferation.  Due to these characteristics, VSMCs are a 
prime candidate for both short-term regulation of vessel diameter, and also for long-term 
adaptation, involving vessel remodeling and changes in cell number (Rensen et al., 2007, 
Gabbiani et al., 1981).  
 
1.2.2 Modulation of VSMC Phenotype 
The different functions that VSMCs exert are translated into distinct 
morphologies, expression of SMC-specific genes, and varying degrees of proliferative 
and migratory potential (Rensen et al., 2007). When the prime function of a VSMC is 
contraction, the cytoplasm is filled with myofilaments, and when it is repair (synthesis of 
matrix and/or cell division), the morphology changes to fit the altered functional demand 
(Figure 1.5). Contractile SMCs are elongated, spindle-shaped cells with many contractile 
filaments throughout the cytoplasm of the cell.  Synthetic SMCs exhibit cobblestone 
morphology and contain a high number of organelles necessary for protein synthesis.   
 
VSMCs undergo reversible phenotypic switching from a quiescent, contractile 
phenotype, in which cells have a unique repertoire of filamentous proteins (e.g., α-
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smooth muscle actin and smooth muscle-myosin heavy chain), agonist-specific receptors 
and signaling molecules necessary for contraction to a synthetic state where cells exhibit 
poor contractibility, changes in lipid metabolism and high production of ECM 
components (Bell and Madri, 1990).  In general, synthetic SMCs exhibit higher migratory 
potential and proliferative rates than contractile SMCs. SMCs with different phenotypes 
typically express varying levels of marker proteins, rather than completely different 
marker proteins (Table I.II.) (Rensen et al., 2007).  
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Figure 1.6. Characteristics of contractile and synthetic SMCs. Contractile SMCs are 
elongated, spindle-shaped cells, whereas synthetic SMCs are less elongated and have 
cobblestone morphology. From (Rensen et al., 2007).  
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Table I.II. Genes associated with a particular SMC phenotype.  
 
Marker Protein Phenotype Specificity 
     α1 integrin, β1 integrin, α7 integrin,  
     Myocardin, N-/T-cadherin 
     C > S 
     α-SMA, γ-SMA      C > S 
     Desmin      C > S 
     SM22α       C > S 
     ACLP, APEG-1, CRP-2      C 
     SM-calponin, h-caldesmon, meta-vinculin      C > S, C, C > S 
     SM-MHC, Smoothelin      C > S, C 
     CRBP-1, Smemb       S > C  
     PDGF-A, ICAM-1, MGP      S 
     I-caldesmon      S 
     OPN       S > C 
     Collagen I, Moesin, Collagenase IV,    
     Connexin43, MMP isoforms, Syndecan-1/-4 
     S > C 
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Currently, two marker proteins that provide the best definition of a mature 
contractile SMC phenotype are SM-MHC and smoothelin. In humans and rodents, 
respectively, Smemb/non-muscle MHC isoform-B and CRBP-1 represent suitable 
synthetic SMC markers, since these proteins are quickly and markedly upregulated in 
proliferating SMCs (Rensen et al., 2007). 
 
The remarkable ability of VSMCs to shuttle between phenotypes is not unique to 
this cell type. However, modulation of the VSMC phenotype is the best example of this 
physiological phenomenon due to the ability of the cell to constantly maintain its 
contractile capability. This is because there are many intermediates between the two 
extreme ends of VSMC morphology (i.e., synthetic and contractile states) that can occur.  
When a fibroblast, for example, undergoes differentiation and switches to a 
myofibroblast, the process is irreversible (Misra et al., 2010).  That is, the myofibroblast 
cannot switch back to a fibroblast or the synthetic phenotype.  
 
AngII affects virtually all vascular cells (e.g., endothelial cells, SMCs, fibroblasts, 
monocytes/macrophages, and cardiac myocytes), and thus, is critical in disease 
development. Changes in the phenotype and morphology of these cells, variable gene 
expression, and enhanced responsiveness to stimuli lead to vascular pathology. 
 
1.2.3 AngII-mediated Vascular Damage  
As a growth factor, AngII regulates VSMC survival, growth, and hypertrophy.  In 
particular, activation of RAS is a highly effective and selective stimulus for the 
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differentiation of quiescent VSMCs into the metabolically active, proliferative and 
migratory phenotype (Ohtsu et al., 2006, Touyz and Schiffrin, 2000, Bell and Madri, 
1990).  Evidence points to AngII being directly involved in pathological disease states, 
which are related to VSMC growth and vessel wall integrity, such as hypertension, 
atherosclerosis, diabetes, cardiac remodeling, asthma, aneurysm formation, and 
inflammatory responses to vessel injury (Daugherty and Cassis, 2004, Kim and Iwao, 
2000, Hunyady and Catt, 2006).   
 
AT1 receptors are highly abundant in VSMCs.  AngII is known to promote its 
effects in VSMCs by acting directly through the AT1R, indirectly through the release of 
other factors, and possibly through cross-talk with intracellular signaling pathways of 
other growth factors (Touyz and Schiffrin, 2000). 
 
Besides VSMC contraction, AT1R-mediated pathways also activate various 
downstream proteins that further enhance growth, adhesion, and migration related 
signaling. Upon induction of intracellular signaling cascades in VSMCs, AngII activates 
the AT1R and consequently various protein kinases (e.g., receptor or non-receptor 
tyrosine kinases). Cellular protein synthesis and metabolism, transport, volume regulation, 
gene expression, and growth all depend on MAPKs (Mehta and Griendling, 2007). AngII 
mediates cell survival via p38/MAPKAPK-2, and PDK 1/Akt. Cell growth and 
hypertrophy are mediated by AngII-mediated MAP kinases (e.g., p38MAPK, ERK1/2 
and JNK, and the JAK/STAT pathway), which all lead to changes in transcription of 
cellular proteins. Epidermal growth factor receptor (EGFR), platelet derived growth 
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factor receptor (PDGFR), c-Src, and FAK are additional protein kinases that can be 
activated by AngII in VSMCs (Daugherty and Cassis, 2004, Taubman, 2003).   
 
AngII is also known to generate intracellular reactive oxygen species (ROS) in 
VSMCs via a NADH/NADPH oxidase-dependent means, where ROS play a role in 
further activation and modulation of the above mentioned signaling cascades (Harrison et 
al., 2003, Irani, 2000). ROS mediate signaling in pathways causing hypertension and 
vessel inflammation. AngII promotes production of chemokines (IL-8, osteopontin, 
MCP-1), cytokines (IL-6, IL-12, TNFα), adhesion molecules (ICAM-1, VCAM-1, 
selectins, integrins), metalloproteinases, and growth factors (VEGF, TGFβ, PDGF, 
CTGF), all of which contribute to cell migration and enhanced extracellular matrix 
production, ultimately leading to inflammation, fibrosis and/or cell proliferation (Ruiz-
Ortega et al., 2001, Touyz and Schiffrin, 2000). In addition, early studies demonstrated 
that AngII is capable of inducing the proto-oncogenes c-Fos, c-Jun, and c-Myc, which 
encode transcription factors that act as cell growth and differentiation mediators 
(Taubman, 2003). Overall, through increased activation of the factors mentioned above, 
AngII mediates vascular damage (Daugherty and Cassis, 2004, Irani, 2000). 
 
The effects that AngII has on the vasculature are similar to those events that it 
modulates in cardiac myocytes, fibroblasts and renal epithelial cells; whereby, the 
hormone induces changes in protein production and activation of various intracellular 
signaling cascades (Kim and Iwao, 2000).  Overall, these alterations lead to vessel 
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remodeling and ultimately, cardiovascular diseases (Kim and Iwao, 2000, Friddle et al., 
2000).  
 
1.3 Characteristics of micro-RNAs (miRNAs) 
 
1.3.1 MiRNA Discovery 
In 1993 Victor Ambros, Rosalind Lee, and Rhonda Feinbaum reported that they 
had discovered single-stranded non-protein-coding regulatory RNA molecules in the 
model organism C. elegans (Lee et al., 1993) . Previous research revealed that the lin-4 
gene was responsible for the repression of the protein LIN-14 during larval development 
of the worm; however, the mechanism for control of LIN-14 remained unknown.  
Ambros and colleagues found that lin-4, unexpectedly, did not encode a regulatory 
protein, but gave rise to small RNA molecules, 22 and 61 nucleotides in length, which 
were called lin-4S (short) and lin-4L (long). Sequence analysis showed that lin-4S was 
part of lin-4L, in which lin-4L was predicted to form a stem-loop structure with lin-4S 
contained in the 5’ arm. It was discovered that lin-4S was partially complementary to 
several sequences in the 3'-untranslated region (3’-UTR) of the messenger RNA encoding 
the LIN-14 protein (Lee et al., 1993); therefore, Ambros and colleagues hypothesized that 
lin-4 could regulate LIN-14 through binding of lin-4S to the lin-14 transcript in a type of 
antisense RNA mechanism. In 2000, the Ruvkun lab characterized another C. elegans 
small RNA regulatory molecule, let-7.  Let-7 was conserved in many species, including 
vertebrates (Reinhart et al., 2000). These discoveries confirmed that a class of small 
RNAs with conserved sequences and functions existed. These molecules are now known 
 31 
as microRNAs (miRNAs). 
 
MiRNAs were not recognized as a distinct class of regulators with conserved 
functions until the early 2000s.  In 2006, Andrew Z. Fire and Craig C. Mello won the 
Nobel Prize for their work on RNA interference (RNAi) in C. elegans, which describes 
gene silencing by double-stranded RNA, (Fire et al., 1998) exactly what the Ambros and 
Ruvkun labs observed.  RNAi is the activated product when double-stranded RNA 
duplex molecules exist in the cell. The RNAi, forming specific protein complexes 
activates biochemical machinery, which degrades those mRNA molecules that carry a 
silencing code identical to that of the double-stranded RNA. When such mRNA 
molecules disappear, the corresponding gene is silenced and no protein is made. RNAi is 
used to regulate gene expression in the cells of humans as well as worms. Interestingly, 
miRNAs can also form a double-stranded structure with RNAi, the translational silencing 
complex to block protein synthesis, lowering the expression of that particular gene.  
 
Since the first report, the miRNA field has grown tremendously, becoming an 
integral component of how researchers view gene expression regulation.  To date, 
miRNA research has revealed multiple roles in transcript degradation and translational 
suppression and possible involvement in transcriptional and translational activation 
(Vasudevan et al., 2007, Buchan and Parker, 2007).  MiRNAs have been linked to post-
transcriptional regulation of at least 60% of protein encoding genes, modulating virtually 
all biological processes, including differentiation, proliferation, and organ development 
(Bartel, 2009, Fabian et al., 2010).  More than one-thousand miRNAs have been 
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annotated in human, rat and mouse genomes, of which expressed miRNAs are generally 
found in a tissue specific manner (Lagos-Quintana et al., 2002).  
 
1.3.2 Biogenesis and Function of miRNAs 
Genes that encode for miRNAs are distributed across chromosomes either 
individually, or in clusters, in which two or more miRNA genes are transcribed from 
physically adjacent miRNA genes. Usually miRNA clusters consist of two or three 
genes, however, larger miRNA clusters exist. For example, the miR-17-92 cluster is 
found on human chromosome 13 and is composed of six miRNAs. This miRNA 
cluster is involved in cellular processes, ranging from tumor formation to the 
development of heart, lungs, and immune system (Zhang et al., 2012). Whether 
expressed individually or in conjunction with additional miRNAs, these small, non-
coding RNAs have a significant biological impact. 
 
The majority of genes for animal miRNAs, positioned along intronic or intergenic 
regions of the genome, are initially transcribed by RNA polymerase II and to a lesser 
extent by RNA polymerase III into a several hundred-nucleotide long stem-loop primary 
miRNA (pri-miRNA). Pri-miRNAs are enzymatically processed to be endogenous 
regulators, first in the nucleus as ~70 nucleotide long precursor miRNA (pre-miR) 
hairpins by the enzyme Drosha and its obligate partner DGCR8. DGCR8 recognizes the 
double-stranded RNA and then associates with Drosha to form the “microprocessor” 
complex. A single pri-miRNA may contain from one to six miRNA precursors.  The pre-
miRNA is shuttled into the cytosol via Exportin-5/Ran-GTP where it is further processed. 
 33 
Cytoplasmic processing occurs by the RNase III enzyme Dicer complexed with different 
RNA-binding/modifying proteins (e.g., TRBP).  The activity of Dicer yields an imperfect 
miRNA:miRNA* duplex. Generally, only one strand of the duplex is functional. Selected 
on the basis of its thermodynamic instability, the single-stranded, guide RNA (miRNA) 
of approximately 18-25 nucleotides will be incorporated into a ribonucleoprotein 
complex. The complementary passenger strand (miRNA*) is typically degraded.  The 
core component of the ribonucleoprotein (miRNP) complex is a member of Argonaute 
protein family (Ago1 to Ago4) (Figure 1.7) (Bartel, 2009, Shukla et al., 2011, Winter et 
al., 2009, Bartel, 2004). The Ago protein will orient the mature miRNA with its target 
mRNA, ultimately causing regulation of translation or stability of target mRNAs.  
 
Mechanistically, miRNAs have a cis-acting regulatory function to post-
transcriptionally modulate at least 60% of protein encoding genes (Bartel, 2009), with 
which they form imperfect hybrids, with the target sites in the 3’-UTR of mRNAs 
(Fabian et al., 2010). The miRNA-mRNA hybrids are directed to mRNA cleavage, 
translational repression, or mRNA deadenylation. MiRNAs are capable of directing 
cleavage of endogenous and artificial substrates, containing highly complementary 
binding sequences; however, the majority of interactions between miRNA and mRNAs in 
animals are only partially complementary, and thus, translational inhibition predominates 
(Hutvagner and Zamore, 2002). It has been speculated that miRNAs suppress translation 
by inhibiting the processes of initiation or elongation.   
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Figure 1.7. Canonical pathway of miRNA biogenesis and modes of action.  Canonical 
miRNA maturation includes the production of the pri-miRNA by RNA polymerase II or 
III and cleavage by the microprocessor complex Drosha–DGCR8 in the nucleus. The pre-
miRNA hairpin is exported from the nucleus by Exportin-5–Ran-GTP.  In the cytoplasm, 
Dicer and TRBP cleave the pre-miRNA to its mature length. The functional strand of the 
mature miRNA is loaded with Ago2 proteins into the RISC, where it guides RISC to 
silence target mRNAs through mRNA cleavage, translational repression or deadenylation, 
whereas the passenger strand (black) is degraded. From (Fazi and Nervi, 2008). 
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A single miRNA can regulate multiple mRNAs to varying degrees; in addition, a 
single mRNA can be targeted by multiple miRNAs. A miRNA, miRNA cluster, or 
members of a miRNA family tend to target multiple mRNA transcripts within common 
cellular response pathways (e.g. proliferation, apoptosis, angiogenesis, or fibrosis). 
Because of this function, miRNAs are considered to be essential for protein quality 
control and homeostasis and when misregulated, can result in developmental defects and 
disease (Bartel, 2009, Fabian et al., 2010).  
 
1.3.3 MiRNAs in Human Health and Disease 
An important distinction between disease and healthy states in tissue homeostasis 
resides in the regulatory networks that distinguish these states. As the miRNA field grows, 
there is increasing recognition that miRNA networks are often associated with tissue 
dysfunction.  Because of their global function, miRNAs are vital regulators of 
homeostatic protein levels and when deregulated, can alter developmental fate and 
physiological processes (Shukla et al., 2011, Bartel, 2009).  Many researchers have 
reported links between altered miRNA homeostasis and pathological conditions, such as 
cancer, psychiatric and neurological diseases, cardiovascular disease, and autoimmune 
disease. MiRNA deficiencies or excesses have been correlated with a number of 
clinically important diseases.   
 
Dysregulation of miRNA expression in cancer has suggested that miRNAs can act 
as oncogenes (“oncomiRs”), by decreasing expression of tumor-suppressor genes or as 
tumor-suppressors, by targeting oncogenic mRNA for translational silencing (Esquela-
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Kerscher and Slack, 2006). Mirs-17-92 and miR-21 have been identified as oncomiRs 
and are linked to regulators of the cell cycle to promote proliferation. (Nana-Sinkam and 
Croce, 2011, Pandit et al., 2011). An example of a tumor suppressor miRNA is let-7.  
When overexpressed, this miRNA has been shown to inhibit tumor development and 
growth (Nana-Sinkam and Croce, 2011).   To add to the complexity, the cell and tissue 
context of miRNA expression can be critical to understanding the overall pathobiology of 
cancer. For example, miR-31 seems to be pro-oncogenic in lung cancer, but protective in 
breast cancer. In addition, an observed increase in miR-3 occurs in lung cancer cell lines 
and knockdown reduces cellular growth and colony formation (Liu et al., 2011). 
 
Specific and global alteration of miRNA expression profiles has been shown in 
heart and kidney, two main organs that are pathophysiologically affected by AngII (Bhatt 
et al., 2011, Elton et al., 2010, Ikeda and Pu, 2010, Scalbert and Bril, 2008, Small and 
Olson, 2011). In the kidney, collagen production during diabetic nephropathy (miRs-192, 
-216a, and -217), fibrosis, (miR-21, and miR families -29, and -200), acute kidney injury 
(miRs-132, -362, -379, -668, and -687), polycystic kidney disease (miRs-15a and -17), 
kidney cancer (miRs-210, -155, -185, -21, 483-3p, and -562), and hypertensive kidney 
sclerosis (miRs-200a-b, -141, -429, -205, and -192) exhibit altered expression of 
miRNAs (Li et al., 2010).  
 
Regulation of cardiac structure and function by miRNAs can also have deleterious 
implications. Recent studies have established essential roles for miRs in cardiac 
development and cardiac health. For example, cardiac cell fate decisions (miR-1-2), 
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hyperplasia (miR-1-2), hypertrophy (miR-1, -133, -21, -23a, -24, -195, -199a, 208, -214), 
apoptosis (miR-1, -133), contraction (miR-208), electrical conductance (miR-1-2, -133, -
208), and cardiomyocyte fibrosis (miR-21, -29) can be strongly modulated by miRNAs.  
In addition, early studies implicate specific miRNAs as contributors to vascular disease 
(e.g., miR-155, -143, -145, -21, 126) (Dorn, 2011, van Rooij et al., 2008).   
 
In a previous study, we have shown an altered miRNA expression profile in 
dilated cardiomyopathic human hearts. MiRs-1, -29b, -7, and -378 were downregulated in 
end-stage dilated cardiomyopathy; whereas, miRs-214, -342, -125b, and -181b were 
upregulated. The altered miRNAs target gene networks (e.g., NFκB) that account for 
compensatory remodeling in human HF. These novel studies suggest that mRNA and 
miRNA profiles, together, contribute to AT1R biology in health and disease (Naga Prasad 
et al., 2009, Naga Prasad and Karnik, 2010). It is unknown, however, miRNAs that are 
involved in AngII and ARB mediated vascular pathologies, which is a major drawback to 
fully understanding the signaling pathways mediated by RAS. 
 
1.3.4 Therapeutic Potential of miRNAs 
It is well established that miRNAs act as negative regulators of gene expression 
via various mechanisms. Because individual miRNA often regulate the expression of 
multiple target genes with related functions, modulating the expression of a single 
miRNA can, in theory, influence an entire gene network and thereby modify complex 
disease phenotypes. Thus, molecules that alter the function or abundance of specific 
miRNAs represent a new strategy for treating human disease.  
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The molecular mechanism by which miRNAs regulate gene expression is still not 
fully understood, nor is the complete repertoire of mRNAs targeted by each miRNA 
known. However, continual advances in the field points to effective strategies for 
modulating expression of miRNAs, allowing them to have therapeutic potential.  MiRs-
155 (inflammation), -122 (Hepatitis C virus), -208 (cardiac remodeling), -21 (fibrosis, -
92a (neoangiogenesis), -33 (metabolic disease), -103/107 (metabolism), -15 family 
(cardiac regeneration and injury) are multiple examples of instances where controlling 
expression of the miRNA would show therapeutic promise (van Rooij et al., 2012).   
 
To understand the roles of miRNAs in biological systems, it is important to be 
able to artificially increase or decrease their function or abundance.  Expression of 
exogenous small RNAs in cells is possible through transient or stable transfection or viral 
transduction of a pri-miRNA transgene, pre-miRNA, or mature miRNA/miRNA*. 
MiRNAs can also be targeted for inhibition by using antisense oligonucleotides, which 
will bind miRNAs and prevent them from interacting with mRNA target genes (i.e., 
antagomirs) (van Rooij et al., 2012).  Studies have examined various chemical 
modifications of antagomirs to improve their in vitro and in vivo stability and to improve 
their in vivo delivery. Modifications include, 2′-O-methoxyethyl, 2′-fluoro and 2′, 4′-
methylene (locked nucleic acids (LNAs)), which have greater affinity to bind and inhibit 
miRNAs and are more resistant to degradation (Broderick and Zamore, 2011).  
 
 39 
Delivery of therapeutic miRNAs to its target tissue is a challenge. Anything with 
a diameter larger than 5nm, including therapeutic RNAs, cannot cross the capillary 
endothelium and will remain in circulation until filtered by the kidneys. Therefore, local 
delivery increases its bioavailability in target tissues and minimizes uptake in non-target 
tissues.  Local delivery is, unfortunately, limited to the eye, skin, mucous membranes and 
tumors. Alternatively, systemic delivery into the bloodstream is challenged by the 
immune response of the body.  In some cases, where direct delivery is not possible, 
nucleic acids can be encapsulated in lipids, forming vesicles (e.g., PEGylated liposomes, 
lipidoids and biodegradable polymers) and enhancing intracellular delivery (Broderick 
and Zamore, 2011). The advantage of using lipid delivery is that these lipid particles can 
be tailored to 1) enable fusion with the cytoplasmic, endosomal or nuclear membrane and 
2) promote endosomal release once inside the cell.  
 
In the anti-miRNA therapeutics field, numerous clinical trials are being actively 
pursued, particularly for those miRNAs mentioned above.  The pharmacokinetics (fate of 
the drug in the body), pharmacodynamics (time course and nature of pharmacological 
effects), and absorption, distribution, metabolism, and excretion of the delivered 
antagomirs are critical aspects that are taken into account when moving from the bench to 
a clinical trial.  In addition, the toxicity of the agent must be addressed to determine the 
most effective dose and dose regimen that is safe and free of unwanted side effects (van 
Rooij et al., 2012).     
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A significant drawback to miRNA-targeted therapies is the extreme potential for 
off-target-effects.  Although a miRNA might target related genes, the fact still remains 
that a single miRNA can target many genes and the genes that are targeted are cell type–
dependent, meaning that many genes can be unintentionally turned off and cause 
additional deleterious outcomes (van Rooij et al., 2012). There are a lot of unknowns 
surrounding the mode of action of the different antagomirs; however, the interest 
surrounding miRNAs as novel therapeutic entities is tremendous and the anticipated 
success of these early forerunners will likely spur the search for additional miRNA 
therapeutic targets.  
 
1.3.5 Regulation of RAS Components by miRNAs 
Variations in the genotype of many of the RAS components (e.g., AGT, ACE1, 
AT1R) are associated with altered activity and function and may have significant clinical 
implications (Pontremoli et al., 2000).  For example, a wide range of known stimuli can 
regulate AT1R expression at the transcriptional level (e.g., NO, peroxisome proliferator-
activated receptor (PPAR)-γ suppress receptor density, while IL-6, glucocorticoids, and 
insulin-like growth factor cause upregulation) (Elton and Martin, 2007).  In recent years, 
several studies have investigated the ability of miRNAs to regulate AT1R expression and 
expression of other GPCRs.  From regulated expression of β2-adrenergic receptors by 
let-7f to controlling AT1R density by various miRNAs binding to either the 3’UTR or a 
region of the protein-coding portion of the gene, miRNAs have a powerful function in 
controlling receptor expression, and thereby function within the cell (Wang et al., 2011, 
Elton et al., 2010).   
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Recently, it has been demonstrated that miR-155 regulates the expression of the 
AT1R. In human lung fibroblasts, miR-155 translationally repressed the expression of 
AT1R and the inhibition of miRNA expression by anti-miR-155 or by transforming 
growth factor-β1 (TGF-β1) treatment substantially increased AT1R protein levels, which 
may have a role in the treatment of blood pressure (Martin et al., 2007b, Martin et al., 
2007a).  MiR-155 has been shown to interact with the silent polymorphism (+1166A/C) 
of the human AT1R gene in ECs and VSMCs. Martin and colleagues showed that when 
the +1166C-allele polymorphism is present in the 3’UTR of the gene, the ability of miR-
155 to interact with the cis-regulatory site is decreased, leading to translational repression 
of the AT1R (Martin et al., 2007b). The same group showed, for the first time, that 
miRNAs (i.e., miR-132) could also bind to sequence recognition sites harbored in the 
coding region of the hAT1R mRNA and suppress its translation (Elton, 2008).  
Furthermore, miR-802 in the GI tract specifically, has been shown to regulate AT1R 
expression through binding to the 3’UTR of the AGTR1 gene. In the absence of this 
miRNA, researchers observed increased hAT1R levels and AngII/AT1R signaling 
(Sansom et al., 2010).  MiRNAs have also been shown to regulate additional components 
of RAS.  Specifically, rats experiencing nonpathological left ventricular hypertrophy 
induced by exercise had altered expression of specific miRNAs targeting RAS genes.  
MiR-27a and -27b targeting ACE were increased and miR-143 targeting ACE2 was 
decreased in the heart (Fernandes et al., 2011).  Finally, Boettger et al. demonstrated that 
miR-145, which is enriched in mouse VSMCs, targets mouse ACE1 mRNA, leading to 
thinning of the arterial tunica media in the absence of the miRNA (Boettger et al., 2009).  
The miR-145 deficient mice had a decrease in the number of contractile VSMCs and an 
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increase in the number of proliferative VSMCs, which gave rise to a defect in AngII-
induced contractility and blood pressure maintenance (Elia et al., 2009). These examples 
show the potent ability of small RNAs to have a widespread effect on overall AT1R 
signal transduction and function through changing mRNA expression of RAS 
components.   
 
1.3.6 AngII Regulation of Small Ribonucleic Acids 
Establishing AngII/AT1R activation as a broad cellular agonist has provided the 
foundation to undertake further comprehensive analyses of AngII effects on gene 
expression induction.  Understanding the role of AngII regulated small ribonucleic acids 
(RNAs) is an area of interest that will provide additional insight into the ability of AngII 
to modulate physiological and pathological phenotypes.  GPCR regulated miRNA 
(miRNome) expression, particularly AT1R regulated miRNA expression, is an area of 
mounting interest to researchers. The consequence of an important regulatory system, 
such as RAS, modulating miRNA gene expression has not been extensively studied, but 
promises to have a significant impact on the field of AngII biology.  Specifically, 
miRNAs that are involved in AngII and ARB mediated vascular pathologies are not 
known, which is a major drawback to fully understanding the signaling pathways 
mediated by RAS.   
 
Recent work by Jeppesen and colleagues shows that cardiac fibroblasts and 
HEK293N cells overexpressing the AT1R have a differential miRNA profile in response 
to AngII/AT1R activation, compared to control cells (Jeppesen et al., 2011). In a Gq/11-
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dependent manner, miR-29b, -129-3p, -132, -132* and -212 were upregulated in their 
system, suggesting a possible role for these miRNAs in AngII mediated cardiovascular 
biology (Jeppesen et al., 2011). This study has shown that the AT1R is an ideal model 
system for exploring the GPCR regulated miRNome.  Additionally, researchers have 
shown that circulating levels of vascular and inflammation-associated miRNAs are 
significantly downregulated in patients with coronary artery disease, which is an 
important aspect of AngII biology (Fichtlscherer et al., 2010).  Determining the AT1R 
regulated miRNome and its effect on the pleiotropic signaling events of the AngII/AT1R 
interactions will introduce a distinct regulatory axis into RAS as a whole.  
 
4.1 Significance of Current Work 
In both physiological and pathological settings, if the activity of AngII as a broad 
cellular agonist is not properly regulated, AngII stimulus becomes chronic and can 
damage the tissue, as well as contribute to lasting cardiovascular disorders (Mehta and 
Griendling, 2007).  It’s well established that activation of the AT1R by AngII leads to an 
increase in protein coding genes and protein expression. A novel are of research is the 
pursuit of understanding the regulation of expression and processing of miRNAs, which 
is stringently controlled within a cell. The role of miRNAs must be a critical aspect of 
effectiveness of vital hormones such as AngII. The miRNAs may also be involved in 
modulation of beneficial tissue response to treatment of cardiovascular pathologies using 
blockade of RAS. This aspect of AngII biology has not been studied, but acquisition of 
knowledge of AngII modulating miRNA gene expression promises to have a significant 
impact on the field. 
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Increasing evidence points to the realization that the AT1R-mediated gene 
expression models in various tissues and disease states are incomplete without the 
accompanying miRNA profile.  In this study, we documented the global AngII-regulated 
miRNA expression profile for various model systems of human, mouse and rat origin.  
The biological and technical replicates included cardiac tissue, cardiac myocytes, VSMCs 
and epithelial cells. Our goal was to observe the established equilibrium of the miRNA 
pool that would persist following chronic AngII treatment in each model as a means to 
ultimately observe a common AngII responsive miRNA signature. We pharmacologically 
distinguished the AT1R-regulated miRNA profiles by comparing technical replicates 
treated with the specific AT1R-blocker, losartan and biological replicates following 
chronic AT2R activation by AngII. We observed 32 miRNAs that were universally 
regulated by AngII. Most other miRNAs were regulated in a treatment- or species-
specific manner. In addition, a few miRNAs were unique to specific cell types.  
 
In the current study, we also explored the extent to which AngII/AT1R-regulated 
miRNAs contribute to maintenance of RAS homeostasis and phenotypic modulation of 
VSMCs, which are an important cell type that can be adversely affected by a local 
increase in AngII action. The balance between VSMC phenotypes depends on the 
expression of different intracellular proteins, secretion of cytokines and chemokines, and 
deposition of ECM components (Figure 1.8) (Ruiz-Ortega et al., 2001, Daugherty and 
Cassis, 2004, Touyz and Schiffrin, 2000). Understanding the role that miRNAs may play 
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in the regulation of AngII-induced VSMC phenotypic alterations will be an important 
aspect for determining the full capacity of AngII/AT1R activation on vascular diseases.    
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Figure 1.8. Effects of AngII on VMSCs. It has been well established that upon 
stimulation with AngII, the AT1R becomes activated leading to an increase in protein 
coding genes and protein expression. Receptor activation ultimately manifests as a 
specific VSMC phenotype due to a host of alterations, including changes in gene 
expression, the secretion of cytokines and chemokines, and increased protein and ECM 
synthesis. Whether the effect AngII has on VSMCs is mediated through miRNA 
expression and regulation is unknown.  
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A distinct AngII-regulated miRNA expression pattern emerged in the human and 
rat VSM cell lines in the profiling experiment, which was validated in our independent 
samples.  Of the 17 miRNAs comprising the VSMC expression pattern, we selected miR-
483 as a representative candidate for further study because of its location within the 
genome and its ability to potentially target multiple components of RAS. Overall, we 
show evidence that indicates muscle cell-specific expression of miR-483 and regulation 
of tissue RAS and AngII-mediated migration by miR-483; specifically in VSMCs. Our 
results further suggest that the AngII-regulated MEK1 kinase signaling cascade most 
effectively mediates the steady state pool of miRNAs, which includes downregulation of 
mir-483. This results in activation of RAS and switching of the VSMC phenotype 
associated with pathological states in vivo, such as hypertension.  
 
Our findings are significant in the context of determining the full capacity of RAS 
as an intrinsic regulatory system.  AngII-regulated miRNAs will likely have a strong 
influence on cardiovascular and renal disease states.  Further, understanding their 
expression and regulation could be applied to other biological systems in which ligand-
induced GPCR activation or inhibition induces changes in gene expression and formation 
of pathologies.     
 
 
 
 
 
CHAPTER II 
MATERIALS AND METHODS 
 
 
2.1 Construction of Plasmids 
 The hemaglutinin (HA)-tagged AT1R gene was subcloned into the shuttle 
expression vector, pcDNA3.1 (+) (Life Technologies, NY, USA), which contains unique 
EcoR1 and Not1 restriction sites (Figure 2.1 A). An EcoR1 restriction site on the 5’ end 
and a Not1 restriction site on the 3’ end flank the synthetic rat AT1R gene. HA-AT1R was 
previously sequenced and cloned into the pMT3 expression vector; therefore, the gene 
was removed for subcloning using the appropriate restriction enzymes.  The digest was 
fractionated on a 1% agarose gel and isolated by QIAquick Gel Extraction Kit (Cat. No. 
28704; QIAGEN, Valencia, CA, USA).  The insert was ligated into the pcDNA3.1 (+) 
expression cassette (Figure 2.1 B).  The HA-tagged AT2R gene was cloned into pcDNA 
3.1 (+), previously.  
Figure 2.1. Subcloning of HA-AT1R gene in pcDNA3.1 expression vector. A) 
Schematic representation of pcDNA3.1 cloning vector. PCMV, cytomegalovirus promoter; 
T7, promoter/priming site; EcoR1-Not1, cloning sites for expression, BGH pA, 
polyadenylation sequence; SV40, origin of replication; SV40 pA, early polyadenylation 
signal; NeoR, neomycin resistance gene; pUC, origin of replication; AmpR, ampicillin 
resistance gene.  B) Schematic representation of subcloning HA-AT1R gene into 
pcDNA3.1 (+) vector.   
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Pre-miR-483 was designed to have a completely complementary hairpin sequence and to 
be oriented in the 3’5’ direction to allow for optimal expression of miR-483-3p in 
mammalian cells (Figure 2.2).  
 
The 76-nucleotide sequence was synthesized and cloned into the expression 
vector pRNA U-6.1/Hygro by GenScript (Figure 2.3 A) (GenScript, NJ, USA) ad 
provided as mini-prep DNA. Upon receipt, the pRNA U6.1-miR483 construct was 
transformed into competent FB10B cells. The plasmid was isolated using the GenElute 
HP Plasmid Maxiprep Kit (Cat. No. NA0300; Sigma-Aldrich, MO, USA) (Figure 2.3 B).  
 
The 3’-UTRs of human AGT, ACE-1, ACE-2, and AGTR2 were generated using 
polymerase chain reaction (PCR) amplification and cloned into the psiCHECK™-2 dual 
luciferase reporter expression vector, which contains unique Xho1 and Not1 restriction 
sites   (Figure 2.3 A) (Cat. No. C8021; Promega, WI, USA).  Genomic DNA was isolated 
from human kidney epithelial (HEK) cells using the DNeasy Blood and Tissue Kit (Cat. 
No. 69506; QIAGEN) and served as the DNA template for each individual PCR reaction.  
Sense and antisense primers were designed to be complementary to each 3’-UTR 
sequence and harbor nucleotide changes to incorporate restriction sites specific for Xho1 
and Not1 enzymes (Table II.I.). 
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Figure 2.2. MiRNA insert for expression construct. The insert sequence was designed 
for expression of miR-483-3p in mammalian cells. Magenta, BamHI restriction site; teal, 
purine for transcription initiation; yellow, sense (miR-483-3p); green, loop; red, antisense 
(mir-483-5p); purple, termination signal; aqua, HindIII restriction site.  
 
 
MiR-483 Hairpin Nucleotide Sequence 
GGATCCCGTCACTCCTCTCCTCCCGTCTTTTGATATCCGAAGACGGGAGGAGAGGAGTG
ATTTTTTCCAAAAGCTT 
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Figure 2.3. MiR-483 in pRNA U6.1 expression vector.  A) Schematic representation of 
pRNA U6.1/Hygro cloning vector. U6, promoter; T7, primer; BamH1-HindIII, cloning 
sites for expression; SV40, origin of replication; Hygromycin, resistance gene; pUC, 
origin of replication; Ampicillin, resistance gene.  B) Schematic representation of 
isolating plasmid DNA for transfection.   
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The 3’-UTR of each gene was PCR amplified in the presence of FailSafe enzyme 
(Cat. No. FS99060; Epicentre Biotechnologies, WI, USA) using 10pmol/µl of sense and 
10pmol/µl antisense primer. The parameters used for the PCR reaction were an initial 
denaturing step of 5 min at 95°C followed by 30 cycles of 94°C for 1 min, 55°C for 1 
min, and 72°C for 1.5 min and then a final extension at 72°C for 10min.  The PCR 
products were fractionated on a 1% agarose gel and isolated using QIAquick Gel 
Extraction Kit (QIAGEN), digested with Xho1 and Not1, and purified with QIAquick 
PCR purification Kit (Cat. No. 28104; QIAGEN). The purified products were ligated into 
psiCHECK-2 and transformed into competent FB10B cells. The plasmids were isolated 
using the GenElute HP Plasmid Maxiprep Kit (Sigma-Aldrich) (Figure 2.3 B). The 
sequence of each 3’-UTR construct was verified using automated DNA sequencing 
(Figure 2.4).   
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Table II.I. Primers used for 3’-UTR amplification. Green, G clamp; aqua, Xho1 
restriction site; red, stop codon; magenta, Not1 restriction site.  
 
Primer Sequence (5’   3’) bp %GC TM 
     
AGT 
sense 
GGGGCTCGAGTGAGGCCAGGGCCCCAGAACACAG 34 71 86 
AGT 
antisense 
GGGGGCGGCCGCGGAGGCTTATTGTGGCAAGAC 33 70 87 
ACE-1 
sense 
GGGGCTCGAGTGAGGTGACCCGGCTGGGTCGGCC 34 77 89 
ACE-1 
antisense 
GGGGGCGGCCGCGGGAGGGCAGGACCTTTAATTG 34 71 88 
ACE-2 
sense 
GGGGCTCGAGTAGAAAAATCTATGTTTTTCCTC 33 42 70 
ACE-2 
antisense 
GGGGGCGGCCGCGAGTGTGTAAATCTAGCATTTATTG 37 54 81 
AGTR2 
sense 
GGGGCTCGAGTTACGTGAGAGCAAAATGCATG 32 53 77 
AGTR2 
antisense 
GGGGGCGGCCGCCTTCCAATTAAAAATTTTATTTATATG 39 41 77 
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Figure 2.4. Cloning of 3’-UTRs in psiCHECK-2 expression vector. A) Schematic 
representation of psiCHECK-2 cloning vector. HSV-TK, promoter; hluc+, Firefly 
luciferase gene; SV40, late poly (A) signal; AmpR, ampicillin resistance gene; SV40, 
early enhancer/promoter; T7, promoter; hRluc, Renilla luciferase gene; Not1-Xho1, 
cloning sites for expression; Synthetic poly (A). B) Schematic representation of 
subcloning HA-AT1R gene into pcDNA3.1 (+) vector.   
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Figure 2.5. Nucleotide Sequences of 3’-UTRs. The 3’-UTR sequence of AGT, ACE-1, 
ACE-2, and AGTR2 was verified by automated DNA sequencing.  Aqua, Xho1 
restriction site; red, stop codon; green, miR-483-3p native binding site; magenta, Not1 
restriction site.   
 
AGT 3’-UTR Nucleotide Sequence 
CTCGAGTGAGGCCAGGGCCCCAGAACACAGTGCCTGGCAAGGCCTCTGCCCCTGGCCTT
TGAGGCAAAGGCCAGCAGCAGATAACAACCCCGGACAAATCAGCGATGTGTCACCCCCA
GTCTCCCACCTTTTCTTCTAATGAGTCGACTTTGAGCTGGAAAGCAGCCGTTTCTCCTT
GGTCTAAGTGTGCTGCATGGAGTGAGCAGTAGAAGCCTGCAGCGGCACAAATGCACCTC
CCAGTTTGCTGGGTTTATTTTAGAGAATGGGGGTGGGGAGGCAAGAACCAGTGTTTAGC
GCGGGACTACTGTTCCAAAAAGAATTCCAACCGACCAGCTTGTTTGTGAAACAAAAAAG
TGTTCCCTTTTCAAGTTGAGAACAAAAATTGGGTTTTAAAATTAAAGTATACATTTTTG
CATTGCCTTCGGTTTGTATTTAGTGTCTTGAATGTAAGAACATGACCTCCGTGTAGTGT
CTGTAATACCTTAGTTTTTTCCACAGATGCTTGTGATTTTTGAACAATACGTGAAAGAT
GCAAGCACCTGAATTTCTGTTTGAATGCGGAACCATAGCTGGTTATTTCTCCCTTGTGT
TAGTAATAAACGTCTTGCCACAATAAGCCTCCAAAAAAAAGCGGCCGC 
 
ACE-1 3’-UTR Nucleotide Sequence 
CTCGAGTGACCCGGCTGGGTCGGCCCTGCCCAAGGGCCTCCCACCAGAGACTGGGATGG
GAACACTGGTGGGCAGCTGAGGACACACCCCACACCCCAGCCCACCCTGCTCCTCCTGC
CCTGTCCCTGTCCCCCTCCCCTCCCAGTCCTCCAGACCACCAGCCGCCCCAGCCCCTTC
TCCCAGCACACGGCTGCCTGACACTGAGCCCCACCTCTCCAAGTCTCTCTGTGAATACA
ATTAAAGGTCCTGCCCTCCCGCGGCCGC 
 
ACE-2 3’UTR Nucleotide Sequence 
CTCGAGTAGAAAAATCTATGTTTTTCCTCTTGAGGTGATTTTGTTGTATGTAAATGTTA
ATTTCATGGTATAGAAAATATAAGATGATAAAGATATCATTAAATGTCAAAACTATGAC
TCTGTTCAGAAAAAAAATTGTCCAAAGACAACATGGCCAAGGAGAGAGCATCTTCATTG
ACATTGCTTTCAGTATTTATTTCTGTCTCTGGATTTGACTTCTGTTCTGTTTCTTAATA
AGGATTTTGTATTAGAGTATATTAGGGAAAGTGTGTATTTGGTCTCACAGGCTGTTCAG
GGATAATCTAAATGTAAATGTCTGTTGAATTTCTGAAGTTGAAAACAAGGATATATCAT
TGGAGCAAGTGTTGGATCTTGTATGGAATATGGATGGATCACTTGTAAGGACAGTGCCT
GGGAACTGGTGTAGCTGCAAGGATTGAGAATGGCATGCATTAGCTCACTTTCATTTAAT
CCATTGTCAAGGATGACATGCTTTCTTCACAGTAACTCAGTTCAAGTACTATGGTGATT
TGCCTACAGTGATGTTTGGAATCGATCATGCTTTCTTCAAGGTGACAGGTCTAAAGAGA
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GAAGAATCCAGGGAACAGGTAGAGGACATTGCTTTTTCACTTCCAAGGTGCTTGATCAA
CATCTCCCTGACAACACAAAACTAGAGCCAGGGGCCTCCGTGAACTCCCAGAGCATGCC
TGATAGAAACTCATTTCTACTGTTCTCTAACTGTGGAGTGAATGGAAATTCCAACTGTA
TGTTCACCCTCTGAAGTGGGTACCCAGTCTCTTAAATCTTTTGTATTTGCTCACAGTGT
TTGAGCAGTGCTGAGCACAAAGCAGACACTCAATAAATGCTAGATTTACACACTCAAAA
AAAAAAAAGCGGCCGC 
 
AGTR2 3’UTR Nucleotide Sequence 
CTCGAGTTACGTGAGAGCAAAATGCATGTAATCAACATGGCTACTTGCTTTGAGGCTCA
CCAGAATTATTTTTAAGTGGTTTTAATAAAATAATAAAATTTCCCCTAATCTTTTCTGA
ATCTTCTGAAACCAAATGTAACTATGTTTTATCGTCCAGTGACTTTCAGGAATTGCCCA
TTGTTTTTCTGATATGTTTGTACAAGATTGTCATTAGTGAGACATATTTACAACCTAGA
AGTAACTGGTGATATATCTCAAATTGTAATTAATAATAGATTGTGAATAATGATTTGGG
GATTCAGATTTCTCTTTGAAACATGCTTGTGTTTCTTAGTGGGGTTTTATATCCATTTT
TATCAGGATTTCCTCTTGAACCAGAACCAGTCTTTCAACTCATTGCATCATTTACAAGA
CAACATTGTAAGAGAGATGAGCACTTCTAAGTTGAGTATATTATAATAGATTAGTACTG
GATTATTCAGGCTTTAGGCATATGCTTCTTTAAAAAAGCTATAAATTATATTCCTCTTG
CATTTCACTTGAGTGGAGGTTTATAGTTAATCTATAACTACATATTGAATAGGGCTAGG
AATATAGATTAAATCATACTCCTATGCTTTAGCTTATTTTTACAGTTATAGAAAGCAAG
ATGTACTATAACATAGAATTGCAATCTATAATATTTGTGTGTTCACTAAACTCTGAATA
AGCACTTTTTAAAAAACTTTCTACTCATTTTAATGATTGTTTAAAGGTTTCTATTTTCT
CTGATACTTTTTTGAAATCAGTAAACACTGTGTATTGTTGTAAAATGTAAAGGTCACTT
TTCACATCCTTGACTTTTTAGATGTGCTGCTTTGATATATAGGACATTGATTTGATTTT
TATTATTAATGCTTTGGTTCTGGGTTGTTTCCTAAAATATCTGGGTGGCTTAAAAAAAA
CTCTTTAACTTGTAATAAACCCTTAACTGGCATAGGAAATGGTATCCAGAATGGAATTT
TGCTACATGGGGTCTGGGTGGGGGCAAAGAGACCCAGTCAATTACATGTTTGGTACCAA
GAAAGGAACCTGTCAGGGCAGTACAATGTGACTTTGAAAATATATACCGTGGGGGTAGT
TTTACCCTATATCTATAAACACTGTTTGTTCCAGAATCTGTATGATTCTATGGAGCTAT
TTTAAACCAATTGCAGGTCTAGATACCTCCTTCTCAGCACTATTAAAGCTCCTAAGTTA
GAGGAGTGCCTAAAACTGAGTTACCTAAAGTTTACTTACATTAAAGTATGAATATTAAT
TTTAGAAATTTGAGACTTTATTCTGTACCAGCCCTGTATAATAACAGGTTATCTAGGAC
CTTCCTCTGAGGTAGGTCTAAATACTGATCTCTGAGGCGGAACTAACGTTTTGGGGACT
CAGCATCTCTGCCAGGTTCCAGGATTATAGACAGAAGAGTCCTGTCATACCACTTTCTG
GAAAAGTCCTAATTTCATGTAATCCTTTTATTTTCAATAAAAACAAATAGCTAAATGTA
TAACCAACTATGATGTTATGTTTTCAATAATTTTGTAAAACAGCTCATATAAATAAAAT
TTTTAATTGGAAGAAAAAAAAAGCGGCCGC 
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2.2 Cell Culture Maintenance and Transfection 
For expression of HA-AT1R and HA-AT2R in mammalian VSMCs, we used the 
rat aortic smooth muscle cell (RASMC) line, which was obtained from American Type 
Culture Collection (Cat. No. CRL-2018; ATCC, VA, USA).  This cell line has been 
transformed with the large T antigen of SV40 (SV40-LT), which immortalizes the cell 
line and prevents them from dedifferentiating in culture.  Importantly, these VSMCs 
maintain the characteristics common to primary SMC cultures.  RASMCs were grown in 
100-mm culture dishes to approximately 40-50% confluency and transfected by 
Lipofectamine® Transfection Reagent (Cat. No. 18324; Life Technologies), according to 
the manufacturer’s instructions.  Briefly, 60 µl of Lipofectamine was added into 1.5 mL 
of OPTI-MEM reduced serum media and incubated for 5 min. Twenty-four micrograms 
of plasmid DNA (HA-AT1R or HA-AT2R) was added to an additional 1.5 mL of OPTI-
MEM and the two mixtures were combined and incubated for 20 min at room 
temperature.  The mixture was then added into the culture medium.  Twenty-four hours 
following transfection, the medium was removed and medium containing 200 µg/ml of 
geneticin was added. Receptor expression was confirmed by Fluorescence Activated Cell 
Sorting (FACS) Analysis, which is described in 2.3. The RASMC cell lines stably 
expressing HA-AT1R and HA-AT2R were established by geneticin selection (700 µg/ml).  
 
The human embryonic kidney, HEK-293 clonal cell lines stably expressing HA-
AT1R (5.1 pmol/mg) and HA-AT2R (5 pmol/mg) were established by geneticin selection 
(600 µg/ml) as described previously (31). The primary human aortic smooth muscle cells 
(HASMC, a gift from A. Majors, Department of Pathobiology, Lerner Research Institute 
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(LRI), Cleveland Clinic (CCF)) (Majors et al., 2002) were used between passage number 
3 and 6. The AT1R-expressing (0.9 pmol/mg) mouse atrial cardiomyocyte clonal line 
(HL-1-AT1R) was established by geneticin selection (800 µg/ml) of HL-1 cells (White et 
al., 2004). 
 
For expression of miR-483-3p, we used the RASMC, RASMC-AT1R, and HEK-
293T cell lines. The HEK-293T cell line is highly transfectable and has been transformed 
with the temperature sensitive SV40 T-antigen (Cat. No. CRL-11268; ATCC). 
Expression of miR-483-3p was carried out using the Amaxa Nucleofector™ Technology 
(Lonza, NJ, USA). The Nucleofector technology is a novel transfection technology 
especially designed for the needs of primary cells and difficult-to-transfect cell lines. It is 
a non-viral method, which is based on a unique combination of electrical parameters and 
cell-type specific solutions to allow DNA to directly enter the nucleus.  This procedure 
was performed according to the manufacturer’s instructions.  Briefly, cells were 
trypsinized and counted using an automated cell counter (Cellometer; Nexcelom, MA, 
USA).  Approximately 2 x 106 cells were suspended in Nucleofection Solution L 
(RASMCs and RASMCs-AT1R) (Lonza) or 1X phosphate buffered saline (PBS) (HEK-
293T). Two micrograms of plasmid DNA was added to the suspension and the mixture 
was placed into a cuvette. The cuvette was placed into the Nucleofector and the 
appropriate program was started (RASMCs – program 33, HEK-293T cells – program 
29). Post-nucleofection, 500 µl of medium was added to the cuvette and then pipetted 
gently into a 6-well culture dish. Approximately 72 hours post-nucleofection, the cells 
were passaged into a 100-mm culture dish, containing culture medium supplemented with 
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hygromycin.  Clones were picked and expression of miR-483-3p was analyzed by RNA 
solution hybridization, which is described in 2.12.  For each cell line utilized, a vector 
control was also made, which was hygromycin resistant.    
 
 A panel of cell lines was used to monitor miR-483-3p expression in various cell 
types. These cells included RASMC, RASMC-AT1R, primary rabbit aortic smooth 
muscle cells (RASMC, a gift from Edward F. Plow, Department of Molecular 
Cardiology, LRI-CCF), rat thoracic aortic smooth muscle cells (A7R5; Cat. No. CRL-
1444; ATCC), HASMC, rat coronary artery smooth muscle cells (RCASMC), primary 
bovine aortic endothelial cells (BAEC, a gift from Paul E. DiCorleto, Department of 
Cellular and Molecular Medicine, LRI-CCF), primary human umbilical vein endothelial 
cells (HUVEC, a gift from Paul E. DiCorleto, Department of Cellular and Molecular 
Medicine, LRI-CCF), breast adenosarcoma epithelial cells (MCF-7; Cat. No. HTB-22; 
ATCC), human adrenal carcinoma epithelial cells (NC1-H295R; Cat. No. CRL-2128; 
ATCC), mouse myoblast cells (C2C12; Cat. No. CRL-1772; ATCC), rat myocardial 
myoblast cells (H9C2; Cat. No. CRL-1446; ATCC), mouse atrial cardiomyocyte cells 
(HL-1), HL1-AT1R, pig kidney epithelial cells (LLCPK-1, obtained from the Department 
of Molecular Cardiology, LRI-CCF), rat kidney epithelial cells (NRK52E; Cat. No. CRL-
1571; ATCC), rat liver epithelial cells (WB; obtained from Cell Culture Core, Lerner 
Research Institute, Cleveland Clinic). Majority of the cell types were cultured to 
approximately 70% confluency in Dulbecco’s Modified Eagle Media (DMEM; 
Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; 
Thermo Fisher Scientific, Waltham, MA, USA). HUVECs were cultured in VascuLife 
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Basal Medium (Cat. No. LM-0002; Lifeline Cell Technology, MD, USA) supplemented 
with Lifeline’s EnGS LifeFactors Kit (Cat. No. LS-1019; containing L-Glutamine, FBS, 
rH EGF, Hydrocortisone hemisuccinate, Heparin, and EnGS).  
 
 HEK-293T-miR483 and the vector control HEK-293T cells were grown in 6-well 
plates to approximately 50-60% confluency and transiently transfected by Attractene 
Transfection Reagent (Cat. No. 1051561; QIAGEN) according to the manufacturer’s 
instructions. Briefly, 2 µg of plasmid DNA, harboring the 3’-UTR of select genes was 
diluted to 100 µl with OPTI-MEM. To the DNA, 4.5 µl of Attractene was added, mixed 
by gentle pipetting and incubated for 15 min at room temperature. The mixture was then 
added drop-wise to the culture medium and incubated until processing.  In experiments 
where an antagomir to miR-483-3p was utilized (Cat. No. MIN0002173; QIAGEN), 
0.005uM of the antagomir was mixed with the plasmid DNA and diluted to 100 µl with 
OPTI-MEM. Attractene was then added and the mixture was incubated for 15 min at 
room temperature.  
 
The HEK-293, HEK-293T, HEK-293T-miR483, HEK-AT1R, HEK-AT2R, 
RASMC, RASMC-AT1R, RASMC-AT2R, RASMC-miR483, AND HASMC were 
cultured in DMEM supplemented with 10% FBS (fetal bovine serum (FBS; Thermo 
Fisher Scientific, Waltham, MA, USA) and 100 IU penicillin/streptomycin (Sigma-
Aldrich). HL1-AT1R cells were cultured in Claycomb media supplemented with 10% 
FBS and 1% penicillin/streptomycin solution (Sigma-Aldrich). The HEK-293T-miR483 
and RASMC-miR483 clonal cell lines stably expressing pre-miR-483 were established by 
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hygromycin selection (100 µg/ml and 300 µg/ml, respectively). All cell types were 
cultivated at 37°C in a humidified atmosphere containing 5% CO2. 
 
2.3 FACS Analysis 
After 48 hours of incubation, HA-AT1R and HA-AT2R transfected cells were 
processed for a FACS Analysis.  The cells were washed with PBS and treated with cell 
dissociation solution for approximately 3-5 min until the cells lifted from the plate. Three 
milliliters of PBS was added and the cell solution was centrifuged at 700 RPM for 5 
minutes.  The cells were resuspended in 500 µl 1X PBS supplemented with 3% FBS. 
Twenty microliters of HA-fluorescein (FITC), High Affinity antibody (Cat. No. 1988506; 
Roche Molecular Biochemicals, IN, USA) was added to an additional 500 µl of PBS 
supplemented with 3% FBS. The cell suspension and HA-FITC solution were combined 
and incubated in the dark with end-over-end rocking at 4°C for 30 min. The cells were 
centrifuged at 700 RPM for 5 min and washed with 2 mL 1X PBS supplemented with 3% 
FBS.  The cells were again centrifuged at 700RPM for 5 min and washed an additional 
time.  The cells were resuspended in 3 mL sorting solution (1X PBS, 25 mmol HEPES), 
which had been filter-sterilized, and sorted. Sorted cells, positive for HA-AT1R or HA-
AT2R were collected in 100-mm culture dishes containing growth medium supplemented 
with 700 µg/ml of geneticin for selection.  The transfection efficiency of these cells was 
low, which is why the sort was necessary. The final population of cells collected 
exhibited receptor expression.   
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Figure 2.6. FACS analysis of transfected RASMCs. A) HA-AT1R cell sort data. B) 
HA-AT2R cell sort data. Black outline around events represents the gate used for sorting. 
FSC, forward scattered light; SSC, side scatter detector.  
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2.4 Immunocytochemistry 
 Following FACS analysis, RASMCs expressing HA-AT1R or HA-AT2R was 
plated onto fibronectin (Cat. No. 354008, BD Biosciences, CA, USA) coated coverslips 
and placed in 6-well culture dishes.  Cells were cultured for 24 hours in DMEM 
supplemented with 10% FBS and switched to serum-free DMEM 18 hours before 
processing.  Cells were washed twice with 1X PBS then fixed with 4% paraformaldehyde 
in 1X PBS for 15 min. Cells were washed 3 times with 1X PBS for 10 min each then 
permeabilized with 0.3% Triton X – 100 in 1X PBS for 20 min on ice. Cells were 
blocked with 5% nonfat dry milk in 1X PBS for 1 hour at room temperature then 
incubated overnight with mouse anti-HA monoclonal antibody (1:100) (Cat. No. 2362; 
Cell Signaling Technologies, MA, USA) in blocking buffer at 4°C.  The following day, 
cells were washed and incubated with AlexaFluor 488 anti-mouse antibody (1:2000) 
(Cat. No. 2350; Cell Signaling Technologies) for 1 hour at room temperature in the dark. 
Cells were then washed and the coverslips were mounted onto glass slides with 
Vectashield with DAPI Nucleic Acid Stain (Cat. No. H1200; Vector Laboratories, CA, 
USA) for confocal microscopy.  
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Figure 2.7. Expression of HA-AT1R and HA-AT2R in RASMCs.  A) Confocal image 
of HA-AT1R RASMCs (magnification X60). B) Confocal image of HA-AT2R RASMCs 
(magnification X60).  
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2.5 Ligand Treatment 
 When ≈70% confluent, cells were subjected to 4-hour starvation in serum-free 
DMEM. Then cells were treated with either 1µM [Sar1]AngII or 1µM Losartan or 
Candesartan for a 24-hour time period.  Untreated controls were kept in serum-free 
DMEM.  After 24-hour treatment, cells were trypsinized and pelleted by centrifugation 
(800 x g).  The cell pellets were washed with PBS, flash-frozen in liquid nitrogen and 
stored at -80°C until RNA was isolated.   
 
2.6 Samples for miRNA Profiling 
Characteristics and treatment conditions for twenty-three samples that were 
included in the miRNA profiling study are shown in Table II.II. The samples include a 
human embryonic kidney line expressing AT1R or AT2R, an immortalized rat aortic 
smooth muscle cell (RASMC) line expressing AT1R or AT2R and a mouse atrial cell line 
(HL-1) expressing AT1R (White et al., 2004). Two independent human aortic smooth 
muscle cell (HASMC) samples were profiled to reduce potential bias that may result 
from the variability in primary cells (passage # 2-3). Hearts were obtained from age and 
gender matched transgenic (TG) mice over-expressing the human AT1R under the mouse 
α-MHC promoter and corresponding littermate non-transgenic (NT) mouse lines in C3H 
and C57BL/6 genetic backgrounds (n = 3 each for TG and NT), which were previously 
obtained from Paradis et al (Paradis, 2000).  The cardiac hypertrophy and HF phenotype 
were assessed by 1) measuring the heart weight to body weight ratio, 2) measuring 
ejection fraction and wall thickness by echocardiography (to monitor ejection fraction 
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and wall thickness), and 3) expression of BNP as an independent marker of heart failure 
as reported previously (Yue et al., 2010).  
 
For primary comparison, correlations were made between the untreated and 
ligand treated cells or between NT and TG heart tissue samples. *Biological replicates 
control for biological diversity of a response, measure a quantity from different sources 
under the same condition and are often more powerful. Biological replicates in this study 
are defined as RNA isolated independently from multiple sources, each with a distinct 
genome under the same condition, AngII-activation of the AT1R. Technical replicates are 
defined as RNA isolated from an AngII-responsive source with same genome under 
different treatment conditions. 
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Table II.II. Characteristics of biological and technical replicates* utilized in the 
microarray analysis. 
 
Sample 
ID 
 
Cell/Tissue Type Experimental 
Condition 
Measure of 
AT1R Activation/Inhibition 
SK-1 HEK-AT1R Untreated Control 
SK-2 HEK-AT1R AngII ERK1/2, JAK, STAT3 
phosphorylation 
SK-3 HEK-AT2R Untreated Control 
SK-4 HEK-AT2R AngII - 
SK-5 HASMC Untreated Control 
SK-6 HASMC AngII ERK1/2 phosphorylation 
SK-7 HASMC Losartan ERK1/2 phosphorylation 
SK-8 HASMC Untreated Control 
SK-9 HASMC AngII ERK1/2 phosphorylation 
SK-10 HASMC Losartan ERK1/2 phosphorylation 
SK-11 HL1-AT1R Untreated Control 
SK-12 HL1-AT1R AngII ERK1/2, JAK, STAT3 
phosphorylation 
SK-13 RASMC Untreated Control 
SK-14 RASMC AngII ERK1/2 phosphorylation 
SK-15 RASMC Losartan ERK1/2 phosphorylation 
SK-16 RASMC-AT1R Untreated Control 
SK-17 RASMC-AT1R AngII ERK1/2, STAT3 
phosphorylation 
SK-18 RASMC-AT2R Untreated Control 
SK-19 RASMC-AT2R AngII - 
SK-21 Whole heart  
(C3H NT) 
Non-transgenic Control 
SK-22 
 
Whole heart  
(C3H TG) 
Cardiac-specific 
AT1R transgene 
overexpression 
ERK1/2, JAK, STAT3 
phosphorylation, Cardiac 
Hypertrophy & HF Phenotype 
 
SK-23 
 
Whole heart  
(C57BL/6 NT) 
Non-transgenic 
 
Control 
SK-24 Whole heart  
(C57BL/6 TG) 
Cardiac-specific 
AT1R transgene 
overexpression 
ERK1/2, JAK, STAT3 
phosphorylation, Cardiac 
Hypertrophy & HF Phenotype 
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2.7 Cardiac Tissue Harvest 
The C3H and C57BL/6 transgenic mouse lines over-expressing the human AT1R 
under the mouse α-MHC promoter were previously described by Paradis et al (Paradis, 
2000). NT and TG mice were cared for in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institute of Health (NIH 
publication No. 85-23, revised 1996) in the Biological Resources Unit of Lerner Research 
Institute. All experimental protocols described were reviewed and approved by the 
Animal Care and Use Committee at the Cleveland Clinic Foundation (CCF).  
 
Parameters of cardiac structure and function in individual mice were determined 
by echocardiography and were correlated to expression of HF marker genes as previously 
reported (Yue et al., 2010). Briefly, echocardiography was performed on conscious mice 
without anesthetic. Doppler images were recorded using a 13 MHz linear transducer 
(Vivid 7; GE-Vingmed, Horten, Norway) placed at the left sternal border of the chest and 
analyzed by using Prosolv Cardiovascular Analyzer (v 3.5) software. Parameters obtained 
were left ventricular (LV) mass, ejection fraction (EF), a measure of left ventricular 
function; fractional shortening (FS), a measure of contractility, and wet heart 
weight/body weight (HW/BW) (Yue et al., 2010).  Whole hearts from C57BL/6 and C3H 
mice with cardiac-specific AT1R overexpression (TG) and non-transgenic (NTG) (Yue et 
al., 2010) mice were harvested.  Upon removal, the heart was perfused in 0.1M KCL. 
Hearts were wrapped and flash-frozen in liquid nitrogen then maintained at -80°C until 
further analysis was performed.  
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2.8 RNA Isolation 
Total RNA was isolated from heart tissue (n = 3 each for TG and NT), utilizing 
the RNeasy Fibrous Tissue Kit (Cat. No. 74704; QIAGEN) under RNase free conditions, 
according to manufacturer’s protocol. Briefly, the heart was homogenized using a Mikro 
Dismembrator S (Sartorious Mechatronics Corp., Bohemia, NY, USA) in the RLT buffer 
with β-Mercaptoethanol added for 3 minutes at 1200 RPM.  Proteinase K was added to 
the homogenate and incubated at 55°C for 20 minutes.  The mixture was centrifuged at 
20-25°C and 5000 x g for 5 minutes.  The supernatant was transferred to a clean tube and 
100% ethanol was added to each lysate.  The sample was transferred to a midi spin 
column and centrifuged at 20-25°C and 5000 x g for 5 minutes, washed with the buffer 
provided then treated with a DNase I mixture at room temperature for 15 minutes.  The 
column was washed and dried by centrifugation (at 20-25°C and 5000 x g) before the 
RNA was eluted with RNase free water. 
 
 Total RNA was isolated from cells using the miRNeasy Mini Kit (Cat. No. 
217004; QIAGEN) under RNase free conditions, according to manufacturer’s protocol.  
Briefly, the cell pellet was lysed in QIAzol Lysis Reagent at room temperature for 5 
minutes.  To the homogenate, chloroform was added and incubated for 3 minutes at room 
temperature.  Following centrifugation for 15 minutes at 12,000 x g at 4°C, the upper 
aqueous phase was transferred to a new tube. To this 1.5 volumes of 100% ethanol was 
added and mixed and the mixture was pipetted into an RNeasy Mini spin column in a 
2mL collection tube and centrifuged at > 8000 x g for 15 seconds at room temperature.  
The sample was washed sequentially with buffers RWT and RPE and centrifuged for an 
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additional 15 seconds at > 8000 x g each.  The column was placed in a new collection 
tube and centrifuged at ≥14,000 x g for 1 minute.  Finally, the column was transferred to 
a new 1.5mL collection tube and the RNA was eluted by centrifugation at 8000 x g in 
50ul of RNase-free water.   
 
 A spectrophotometer reading was taken for each sample and a small aliquot was 
run on a 1% agarose gel to ensure RNA integrity (Figure 2.8). High-quality RNA 
preparations (A260/280 ratio >1.8) were submitted to the Genomics Core Facility 
(http://www.lerner.ccf.org/services/gc/) for RNA processing. 
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Figure 2.8. Agarose gel fractionation of RNA samples for microarray. One 
microgram of total RNA was dissolved in H2O in a total volume of 20 µl. Four 
microliters of 6X loading dye (Promega) was added. M, 2 µl of 1 Kb Plus DNA ladder 
(Life Technologies) mixed with 14 µl of TE buffer and 4 µl of 6X loading dye. Samples 
were run on a 1% agarose gel at 90 volts. Both 18S and 28S are visible on the gel for 
each RNA sample isolated (1-19).   
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2.9 RNA Processing and Profiling 
Two separate Mouse v2 MicroRNA Expression BeadChip arrays with UDG (Cat. 
No. MI-202–1124; Illumina, San Diego, CA, USA) were used for each sample, according 
to the manufacturers recommendations (Illumina MicroRNA Expression Profiling Assay 
Guide). This miRNA panel contained 656 assays to cover more than 96% of the miRNAs 
described in the miRBase release 12 database (http://www.mirbase.org). 
 
The chemistry utilized by the miRNA BeadArray is available at 
http://www.illumina.com/downloads/MicroRNAAssayWorkFlow.pdf. Five hundred 
nanograms of total RNA was polyadenylated, and then converted into cDNA using a 
biotinylated oligo-dT primer with a universal primer-tag sequence at its 5' end. This was 
followed by annealing of a miRNA-specific oligonucleotide pool (MSO) which consists 
of three parts: a universal PCR priming site at the 5' end, an address sequence 
complementary to a capture sequence on the BeadArray, and a microRNA-specific 
sequence at the 3' end. Extension of MSO was facilitated by addition of a polymerase, but 
only if their 3' bases were complementary to the cognate sequence in the cDNA template. 
Common primers were used to amplify the cDNA templates; the primer complimentary 
to the BeadArray was fluorescently labeled. The single-stranded PCR product was 
hybridized to the Sentrix Array Matrix (SAM), where the labeled strand binds to the bead 
on the array containing the complementary address sequence. The SAMs were imaged 
using an Illumina iScan Reader, which measures the fluorescence intensity at each 
addressed bead location. Intensity files were analyzed using BeadStudio version 3.1.1. 
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Expression levels were depicted as an average signal value and was compared with 
untreated or NTG samples as baseline.   
 
2.10 Statistical Analysis of miRNA Microarray Data 
Raw data were read and preprocessed in BeadStudio and exported for further data 
processing and analysis in R (www.r-project.org). Initially, three datasets were generated 
for all of the samples: 1) the raw expression dataset exported directly from BeadStudio 
(containing 656 genes); 2) the normalized dataset, which was obtained based on the raw 
dataset after force-positive background correction, log2 transformation, and quantile 
normalization (containing 655 genes); 3) the quality control (QC) filtered dataset, which 
was obtained based on the normalized dataset by selecting present probes using the 
detection threshold of 0.05 (containing 610 genes).   
 
In BeadStudio, we performed one sample to one sample comparisons using 
differential analysis with parameters set up as ‘quantile normalization, subtract 
background’. All differential expression was compared with a reference group (Ref 
Group) with Illumina custom Error Model. Raw p-values were from the Diff Pval column 
of the Differential Expression Genes results. Fdr p-values were obtained by applying 
multiple testing corrections using Benjamini and Hochberg False Discovery Rate (a Fdr 
p-value of <0.05 was considered statistically significant).  
 
Following quality control analysis, the expression and p-values were read in R for 
further graphical representation of the results (e.g., box plot, MA plot, volcano plots, 
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scatter plots). Hierarchical clustering was made on the three preprocessed datasets based 
on correlation distances in all cases.  Comparisons were made for all the sample pairs 
(untreated versus treated) and plotted as volcano plots, showing the relationship between 
–log10 (p-value) and log2 (fold change) of all the genes in each comparison.  Raw p-
values and fold change were calculated.  Genes were categorized as significantly 
expressed if their raw p-value was <0.001 and the fold change was > threshold or < 
1/threshold.  The threshold value of 1.2 – 1.3 cut-off for the threshold was adopted in our 
analyses, as recommended by Illumina (Chen et al., 2008).  
 
2.11 RT-qPCR Analysis 
The miScript PCR system (Cat. No. 218073, 218060; QIAGEN) was utilized 
according to the manufacturer’s protocol for miRNA validation in independent VSMC 
samples treated with AngII and Candesartan (Figure 2.9 A).  Two micrograms of 
template RNA was mixed with the 5x miScript RT buffer, RNase-free water, and the 
miScript reverse transcriptase mix.  The reaction was incubated for 60 minutes at 37°C 
followed by heating the samples at 95°C for 5 minutes.  For the qPCR, a reaction mix 
containing 2x QuantiTect SYBR Green PCR master mix, 10x miScript Universal Primer, 
10x miRNA specific primer, and RNase-free water was prepared. MiRNA-specific 
primers were designed to amplify the mature miRNA (Table II.III.)  The cDNA from the 
reverse transcription step was dispensed into the individual wells of a 96-well PCR plate 
and appropriate volumes of the reaction mix were added.  The plate was briefly 
centrifuged at 1000 x g to collect the reaction at the bottom of each well and qPCR was 
started using the Applied Biosystems 7500 real-time cycler (Applied Biosystems, CA, 
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USA). The thermal cycling parameters used for the qPCR reaction were an initial 
denaturing step of 15 min at 95°C followed by 40 cycles of 94°C for 15 sec, 55°C for 30 
sec, and 70°C for 30 sec. CT values recorded were analyzed, following normalization to 
RNU6 (Cat. No. MS00033740), an endogenous control, and standardization to the 
untreated samples.   
 
The miScript PCR system (QIAGEN) was also utilized for mRNA quantitation in 
VSMC-miR-483 and VSMC-vector control samples (Figure 2.9 B).  Two micrograms of 
template RNA was used for cDNA synthesis as detailed above. For the qPCR, a reaction 
mix containing 2x QuantiTect SYBR Green PCR master mix, 10x QuantiTect Primer 
Assay, and RNase-free water was prepared. The QuantiTect Primer Assays (QIAGEN) 
utilized included forward and reverse primers targeting AGT (Cat. No. QT00177478), 
ACE-1 (Cat. No. QT00180439), ACE-2 (Cat. No. QT02480100), AGTR2 (Cat. No. 
QT01081864) (Table II.III.)  The cDNA from the reverse transcription step was 
dispensed into the individual wells of a 96-well PCR plate and appropriate volumes of the 
reaction mix were added.  The plate was briefly centrifuged at 1000 x g to collect the 
reaction at the bottom of each well and qPCR was started using the Applied Biosystems 
7500 real-time cycler (Applied Biosystems). The thermal cycling parameters used for the 
qPCR reaction were identical to those used for miRNA quantitation. CT values recorded 
were analyzed, following normalization to GAPDH (Cat. No. QT00199633), an 
endogenous control.   
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The comparative CT method (ΔΔCT) of analysis was utilized to calculate fold 
change in expression for all RT-qPCR data.  This method involves comparing the CT 
values of the samples of interest (i.e., ligand treated sample) with a control (i.e., untreated 
sample). The CT values of both the control and the samples of interest are normalized to 
an appropriate endogenous housekeeping gene. ΔΔCT = ΔCT sample – ΔCT reference.  
Where, ΔCT sample is the CT value for any sample normalized to the endogenous 
housekeeping gene and ΔCT reference is the CT value for the control also normalized to 
the endogenous housekeeping gene. The fold change in gene expression is determined by 
calculating 2-ΔΔCT.  
 
For quantitation of mRNA in RASMC-AT1R, one microgram of total RNA was 
used for first-strand cDNA synthesis using the First Strand cDNA Synthesis Kit for RT-
PCR (AMV+) (Cat. No. 11483188001; Roche Diagnostics, IN, USA). Real-time qPCR 
was performed on the Applied Biosystems 7500 real-time cycler (Applied Biosystems) 
using QuantiTect SYBR Green PCR kit (QIAGEN), with the primers described below 
(Table II.IV.). The thermal cycling parameters used for the qPCR reaction were an initial 
denaturing step of 10 min at 95°C followed by 40 cycles of 95°C for 15 sec, 60°C for 1 
min. CT values recorded were analyzed, following normalization to GAPDH gene 
expression.   
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Figure 2.9. miScript principle. A) MiRNAs are polyadenylated by poly (A) polymerase 
and subsequently converted into cDNA by reverse transcriptase with oligo-dT priming. 
The cDNA is then used for real-time quantification of mature miRNA (using a miRNA-
specific primer and the miScript Universal Primer).  B) MiRNAs are converted into 
cDNA by reverse transcriptase using both oligo-dT and random priming. The cDNA is 
used for real-time quantification of mRNA (using a QuantiTect Primer Assay). From the 
miScript PCR System Handbook (2nd Ed. 2009).  
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Table II.III. MiRNA-specific primers.  
 
Primer Sequence (5’   3’) bp %GC TM 
     
miR-675-5p TGGTGCGGAAAGGGCCCA 18 66.67 70.47 
miR-343 GTCTCCCTTCATGTGCCCA 19 57.90 62.10 
miR-669C GGGGATAGTTGTGTGTGGATGT 22 50.00 60.93 
miR-467b* GGGGATATACATACACACACCA 22 45.46 57.10 
miR-218-1* GGGAAACATGGTTCCGTCAAG 21 52.39 63.79 
miR-32 GGGGGTATTGCACATTACTAAGT 23 43.48 58.42 
miR-682 GGCTGCAGTCACAGTGAAGT 20 55.01 59.06 
miR-1187 GGGGTATGTGTGTGTGTATGTG 22 50.00 58.56 
miR-297b-3p GGGGTATACATACACACATACC 22 45.46 53.43 
miR-188-5p GCATCCCTTGCATGGTGGA 19 57.90 65.41 
miR-106a:9.1 GGGCAAAGTGCTAACAGTGCA 21 52.39 63.55 
miR-466g GGGATACAGACACATGCACAC 21 52.39 58.88 
miR-325 GGGGTTTATTGAGCACCTCCTA 22 50.00 61.52 
miR-467a*, -467d* GGGGATATACATACACACACC 21 47.62 54.15 
miR-1198 GTATGTGTTCCTGGCTGGC 19 57.90 59.11 
miR-301b GGGCAGTGCAATGGTATTGTC 21 52.39 62.60 
miR-21* CAACAGCAGTCGATGGGC 18 61.12 61.45 
miR-483-3p TCACTCCTCCCCTCCCGT 18 66.67 63.07 
miR-297c GGGGATGTATGTGTGCATGTAC 22 50.00 60.01 
miR-669f GGGGCATATACATACACACACA 22 45.46 58.18 
miR-208a GGGGATAAGACGAGCAAAAAGC 22 50.00 63.33 
miR-33 GGGGGTGCATTGTAGTTGCATT 22 50.00 65.18 
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Table II.IV. Oligonucleotide primers for mRNA quantitation.  
 
Primer Sequence (5’   3’) bp % GC TM 
     
IGF2 Total 
sense 
CGCTTCAGTTTGTCTGTTCG 20 50.00 60.00 
IGF2 Total 
antisense 
GCAGCACTCTTCCACGATG 19 58.00 61.00 
IGF2 P1 
sense 
TTGCCACACAGTTTTCCCATTT 22 41.00 64.00 
IGF2 P1 
antisense 
TCCCAAATCAGACCCTTGTC 20 50.00 60.00 
IGF2 P2 
sense 
CAAGTGGATTAATTATACGCTTTCTG 26 35.00 60.00 
IGF2 P2 
antisense 
AGAGGCGGGTAGGCTCAC 18 67.00 60.00 
IGF2 P3’-UTR 
sense 
GCGTCCCCAGGTTTGCAGCT 20 65.00 69.09 
IGF2 P3’-UTR 
antisense 
GCGGCAGGCACAGGTGACAT 20 65.00 69.19 
GAPDH 
sense 
AGCCAAAAGGGTCATCATCTCTG 23 47.83 63.86 
GAPDH 
antisense 
CATGAGTCCTTCCACGATACCAAA 24 45.84 64.38 
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2.12 RNA Solution Hybridization Assay 
In addition to RT-qPCR, a RNA solution hybridization assay was used to detect 
and visualize miRNA expression. A DNA oligonucleotide template was designed to be 
specific for miR-483-3p and contain a T7 promoter sequence at the 3’ end for the action 
of RNA polymerase  (Figure 2.8 A).  The experimental probe was generated using the 
miRvana Probe Construction kit (Cat. No. AM1550; Life Technologies) via in vitro 
transcription, which resulted in a 33-nucleotide RNA probe with a 25-nucleotide 
protected sequence. A positive control probe (for miR-16, provided by Life 
Technologies) was generated in parallel and produced a 36-nucleotide RNA probe with a 
22-nucleotide protected sequence.  According to the manufacturer’s instructions, 2 µl of 
T7 promoter primer, 6 µl of DNA hybridization buffer, and 100 µM of the 
oligonucleotide template was mixed and heated to 70°C for 5 min. The mixture was then 
left at room temperature for 5 minutes to allow hybridization to occur. To the hybridized 
oligonucleotides, 2uL of 10X Klenow reaction buffer, 2uLof 10X dNTP mix, 4uL of 
nuclease-free water, and 2uL of Exo-Klenow was added. The solution was mixed by 
gentle pipetting and incubated at 37°C for 30 min.  At room temperature, 1 µl each of the 
double-stranded DNA template, 10X transcription buffer, 10 mM ATP, 10 mM GTP, and 
10 mM CTP were combined. To that mixture, 10 mM 32P labeled UTP and 2 µl T7 RNA 
polymerase were added.  The solution was mixed by gently pipetting and incubated at 
37°C for 10 min. The template DNA was removed by digesting the transcription reaction 
with 1 µl DNase I at 37°C for 10 min.  
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Following transcription, an equal amount of Gel Loading Buffer II was added to 
the DNase-treated reaction and heated at 98°C for 3 min. The newly synthesized probe 
was then gel purified at 25 mAmp. A 12% polyacrylamide gel (13x15cm x0.75mm – 7.2 
g Urea, 1.5 mL 10X Tris/Borate/EDTA, 4.5 mL 40% 19 acrylamide:1 bis acrylamide, 11 
mL nuclease-free water, 75 µl 10% ammonium persulfate, 15 µl TEMED). After 
electrophoresis the gel fragment containing the full-length transcript was excised. One 
hundred microliters of probe elution buffer was added to the gel slice and incubated at 
37°C for 30 minutes. The probe elution buffer, containing the eluted RNA was 
transferred to a clean microfuge tube and the elution step was repeated with an additional 
100 µl of probe elution buffer.  The elution fractions were pooled and the cpm/µl of the 
recovered RNA was determined by scintillation counting.  
 
For hybridization of the miR-483-3p-specific probe in total RNA samples isolated 
from cells of interest, we utilized the miRvana miRNA Detection Kit (Cat. No. AM1552; 
Life Technologies) according to the manufacturer’s instructions.  A master mix 
containing, 10 µl of 2X hybridization buffer, 5 x 104 cpm of labeled RNA probe, 2 µg 
sample RNA, enough yeast RNA to make 5 µg total RNA, and nuclease-free water up to 
20 µl was prepared.   Two no-target controls were also prepared for each RNA probe.  
These consisted of 5 x 104 cpm labeled probe, 5 µg yeast RNA, 10 µl 2X hybridization 
buffer, and nuclease-free water up to 20 µl. The experimental and control tubes were 
heated at 98°C for 3 min and then incubated at 42°C overnight to allow hybridization to 
occur.  
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Excess probe and unhybridized temple RNA was digested with 150 µl RNase 
A/T1 (1:100 dilution in RNase digestion buffer) at 37°C for 45 min the following day. 
One control (for each RNA probe) was not RNase digested. The RNase was inactivated 
with RNase inactivation/PPT solution and the probe and hybridized target were 
precipitated with 100% ethanol at -20°C for 1 hour.   The samples were centrifuged at 10, 
000 x g for 15 min at 4°C and the supernatant was carefully removed.  The protected 
fragments were air dried for 10 min at room temperature before suspending in gel loading 
buffer.  For experimental samples and the RNase digested controls, the pellets were 
resuspended in 5 µl of buffer. For the undigested control, the pellet was resuspended in 
10 µl of buffer and then diluted 1:4 in addition loading buffer. Each tube was vortexed 
for 15 sec then incubated at 98°C for 3 min. Each sample was loaded into a pre-run 15% 
denaturing polyacrylamide gel.  The gel was exposed to an intensifying screen overnight 
at room temperature and imaged the following day using a Storm 860 Phosphorimager 
(GE Healthcare Life Sciences, PA, USA).  Mean band intensity values were determined 
using the ImageQuant TL Software (v. 2003.03; GE Healthcare Life Sciences) for all 
samples.   
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Figure 2.10. Detection of short RNA molecules by solution hybridization. A) The 
DNA oligonucleotide template was designed to be specific to miR-483-3p (magenta) 
with an 8 base T7 promoter sequence at the 3’ end (green). The stretch of T residues 
(blue) will generate an antisense RNA probe with a stretch of As, which can’t be cleaved 
by RNase A/T.  In vitro transcription generated a probe specific for miR-16 and a probe 
specific for miR-483-3p.  B) Hybridization of the radiolabeled RNA probes was carried 
out in a step-wise fashion, which resulted in detection of miR-483-3p that could be 
visualized on a denaturing polyacrylamide gel.   
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2.13 Pharmacological Kinase Inhibition 
RASMC-AT1R cells subjected to serum starvation were treated with individual 
kinase inhibitors for a 1-hour period.  Inhibitors to PKC (5µM – 1-O-Hexadecyl-2-O-
methyk-rac-glycerol, Santa Cruz Biotechnology, Santa Cruz, CA, USA), MEK1 (10µM – 
PD98059, Cell Signaling Technology), JAK (5µM – JAK Inhibitor 1; EMD Chemicals, 
Darmstadt, Germany), JNK (1µM SP600125, A.G.Scientific, San Diego, CA, USA), and 
p38 (1µM – SB203580; Cell Signaling Technology) were reconstituted in DMSO. 
Following kinase inhibition, the cells were treated with 1µM [Sar1]-AngII for 5 minutes 
and then harvested (see 3.3 for specific details).  For RNA isolation, the cells were treated 
for 24-hour with 1µM [Sar1]-AngII.   
 
2.14 Protein Isolation  
Cells were placed on ice and washed three times with PBS, scraped from the 
plate, and pelleted by centrifugation at 3900 RPM for 5 min at 4°C.  Cells were lysed in 
1mL 1X PBS, containing 50µl PopCulture Reagent (Cat. No. 71187; Novagen, 
Darmstadt, Germany), 100 U of Benzonase Nuclease (Cat. No. 70664; Novagen), 100X 
protease inhibitor cocktail (Cat. No. P8340; Sigma-Aldrich), and 100X phosphatase 
inhibitor cocktail (Cat. No. 78426; Thermo Scientific, Rockford, IL, USA).  The lysates 
were incubated on ice for one hour then a standard Bradford Assay for protein estimation 
was performed using bovine serum albumin (BSA) as a concentration standard.     
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2.15 Analysis of ERK1/2 and STAT3 Phosphorylation 
Fifty µg of total protein isolated from RASMC-AT1R cells was used for the 
Western blotting assay. Fractions were boiled for 5 minutes and separated by SDS-PAGE 
(10%), and transferred onto a nitrocellulose membrane. After blocking in 150 mM of 
NaCl buffered with 10 mM of Tris and containing 0.1% Tween 20 and 5% milk powder, 
the membrane was incubated overnight in primary antibody specific for phospho-ERK 
44/42MAPK (Cat. No. 4370; Cell Signaling Technology) or phospho-STAT3 (Y705) (Cat. 
No. 9131; Cell Signaling Technology). The membrane was washed and then incubated in 
1:5000 diluted IgG secondary antibody labeled with HRP for 1h.  Using ECL Plus 
Western Blotting Reagent (GE Healthcare Life Sciences) specific bands were detected.  
The same blots were subsequently stripped and re-probed for total ERK 44/42MAPK (Cat. 
No. 9102; Cell Signaling Technologies) and total STAT3 (Cat. No. 9139; Cell Signaling 
Technology).  Densitometry analysis was performed for each experiment.  Mean band 
intensity values (of phosphorylation activity) were determined using the Kodak® 1D 
Image Analysis Software (Version 3.6.5 K2 – 1B5331010; Eastman Kodak Company, 
Rochester, NY, USA).  Phospho-ERK1/2 and phospho-STAT3 values were normalized 
to the total protein for each and compared to the untreated controls to determine the 
percent kinase inhibition.  
 
2.16 MiRNA Target Prediction  
MiRNAs represent an important class of small non-coding RNAs that regulate 
gene expression by targeting messenger RNAs.  Various Internet-based databases exist, 
of which 4 were utilized for this study that allow for determining potential mRNA targets 
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of known miRNAs. TargetScan is based on conserved seed pairing of miRNAs to their 
targets in animals (Lewis et al., 2005).  DIANA-microT 3.0 is an algorithm based on 
several parameters calculated individually for each microRNA and it combines conserved 
and non-conserved microRNA recognition elements into a final prediction score 
(Maragkakis et al., 2009). The PITA database incorporates the role of target-site 
accessibility, as determined by base-pairing interactions within the mRNA, in microRNA 
target recognition (Kertesz et al., 2007). Microcosm Targets uses the miRanda algorithm 
to identify potential binding sites for a given miRNA in genomic sequences. The current 
version uses dynamic programing alignment to identify highly complementary sites 
(Griffiths-Jones et al., 2006).  
 
The 3’-UTR of Renin (ENSG00000143839), Renin Receptor 
(ENSG00000182220), AGT (ENSG00000135744), ACE-1 (ENSG00000159640), ACE-
2 (ENSG00000130234), Chymase 1 (CMA1; ENSG00000092009), AGTR1 
(ENSG00000144891), AGTR2 (ENSG00000180772), AT4 Receptor 
(ENSG00000113441), and Ang(1-7) Receptor (ENSG00000130368) was uploaded into 
each of the above described databases.  The miRNAs that were predicted to bind as well 
as the region to which they would bind were recorded.   
 
2.17 Luciferase Reporter Assay 
 Changes in luciferase gene expression were measured using the Dual-Glo 
Luciferase Assay System (Cat. No. E2920; Promega). The principle of luciferase gene 
expression is detailed in Figure 2.10. Cells were grown in 6-well culture dishes. Forty-
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eights hours following transfection of the psiCHECK-2-3’-UTR DNA constructs, the 
cells were trypsinized, re-suspended in culture medium, and counted using the 
Cellometer.  The cells were then seeded onto a poly-L-lysine coated 96-well, white, flat-
bottom culture plate. Approximately 50,000 cells suspended in 50 µl of culture medium 
were plated per well and in triplicate.  An additional 50 µl of medium was added to the 
wells and the cells were allowed to adhere overnight.   
 
The following day, 75 µl of Dual-Glo Luciferase Assay Reagent was added to 
each well and incubated with gently rocking for 1 hour at room temperature.  Relative 
luminescence units (RLUs) for Firefly were read using the FlexStation 3 Multi-Mode 
Microplate Reader (Molecular Devices, LLC, CA, USA) at 0.5 sec integration and from 
the bottom of the plate.  Immediately following completion of the first luminescence 
reaction, 75 µl of Dual-Glo Stop and Glo reagent was added to each well.  The plate was 
incubated with gentle rocking for 1 hour at room temperature. Renilla luminescence was 
then read. The ratio of Firefly to Renilla luminescence was calculated for each well.  The 
ratio of the sample well(s) was normalized to the ratio of the control well(s).   
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Figure 2.11. Principle of luciferase gene expression. A) The psiCHECK-2 vector 
facilitates monitoring of changes in expression of a target gene fused to a reporter gene. 
Renilla luciferase is used as the primary reporter gene, and the 3’UTR is cloned into a 
multiple cloning region located downstream of the Renilla translational stop codon. 
Initiation of the RNAi process by synthetic miRNAs results in cleavage and subsequent 
degradation of the fused mRNA target. Measuring decreases in Renilla activity provides 
a convenient way of monitoring the RNAi effect. A second reporter gene, firefly 
luciferase allows normalization of Renilla luciferase expression. From Promega product 
resources. B) Biochemistry of firefly and Renilla luciferase expression.  Converting the 
chemical energy of luciferin oxidation through an electron transition, forming the product 
molecule oxyluciferin, produces light. Firefly luciferase, a monomeric 61kDa protein, 
catalyzes luciferin oxidation using ATP-Mg2+ as a cosubstrate. Likewise, Renilla 
luciferase, a monomeric 36kDa protein, catalyzes coelenterazine oxidation by oxygen to 
produce light.   
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2.18 Analysis of Endogenous RAS Components 
Fifty µg of total protein isolated from RASMC-miR483 cells was used for the 
Western blotting assay. Fractions were boiled for 5 minutes and separated by SDS-PAGE 
(10%), and transferred onto a nitrocellulose membrane. After blocking in 150 mM of 
NaCl buffered with 10 mM of Tris and containing 0.1% Tween 20 and 5% milk powder, 
the membrane was incubated overnight in primary antibody specific for AGT (Cat. No. 
ab108334; Abcam, MA, USA), ACE-1 (Cat. No. ab134709; Abcam), ACE-2 (Cat. 
No.AF933 R & D Systems, MN, USA and Cat. No. ab108252; Abcam) or AGTR2 (Cat. 
No. AT21-A and AT22-A; Alpha Diagnostic International, TX, USA). The membrane 
was washed and then incubated in 1:5000 diluted IgG secondary antibody labeled with 
HRP for 1h.  Using ECL Plus Western Blotting Reagent (Amersham Biosciences) 
specific bands were detected.  The same blots were subsequently stripped and re-probed 
for actin (Cat. No. MAB1501; Millipore, MA, USA). Densitometry analysis was 
performed for each experiment.  Mean band intensity values were determined using the 
Kodak® 1D Image Analysis Software (Eastman Kodak Company).  Total protein values 
were normalized to actin and compared to the vector control samples.  
 
2.19 Wound Healing Assay 
 The wound-healing assay was performed using Ibidi silicone culture inserts (Cat. 
No. 80241; Ibidi, LLC, WI, USA) according to the manufacturer’s instructions. The 
silicone insert creates a 500 µm cell-free gap (Figure 2.12. A). Following coating with 
fibronectin, the wells of a 6-well plate were washed twice with 1X PBS and the insert 
was adhered. Cells were trypsinized, counted, and resuspended in growth medium. 
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Approximately 7 x 105 cells in 70 µl of medium were seeded into each well of the insert 
and allowed to attach overnight.  The following day, the insert was removed with 
sterilized forceps and the cells were washed gently with 1X PBS three times. The cells 
were cultured in medium supplemented with 0.5% FBS and 1% penicillin/streptomycin, 
in addition to 1 µM [Sar1]AngII and/or 1 µM Candesartan.     
 The progression of wound healing was monitored over a 24-hour period of time 
using a Leica DMI6000 inverted microscope (at 10X magnification) equipped with dual 
Hamamatsu cameras (ImageEM and Orca-R2) EM-CCD, an environmental chamber 
(heat/CO2 incubator), and a motorized stage for capturing multiple time-lapse fields 
simultaneously. Images were collected in transmitted light mode every 15 minutes at five 
different locations along the wounded area.  The area of the wound at time zero and 8 
hours compared to the total area was quantified using ImagePro Plus 7.0 (Media 
Cybernetics, MD, USA) (Figure 2.12 B). Briefly, the images were processed using the 
large spectral filter and converted to grayscale.  Additionally, each image was processed 
for morphological characteristics to fill the gaps and enlarge protrusions to connect 
objects that are close together. The cell-free area and the area containing cells were 
measured for each image. The percent wound area was normalized to the total area for 
each image.  
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Figure 2.12. Wound-healing principle and analysis. A) The Ibidi silicone insert creates 
a 500 µm defined cell-free gap that prevents leakage during cultivation and no material 
being left behind after the insert’s removal. B) The area of the wound at time zero and 8 
hours compared to the total area was quantified for each image (red).  
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2.20 Statistical Analysis 
All data are expressed as mean ± SEM (n = 3 experiments performed under 
identical conditions). Statistical analyses were performed using GraphPad Prism© with an 
unpaired Student t-test.  A p-value <0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
GLOBAL MIRNA EXPRESSION PROFILING 
 
 
3.1 Introduction 
In order to fully understand AT1R-mediated gene expression, the expression 
profile of miRNAs in various tissues and disease states must be elucidated.  Of 
significant importance is documenting the AngII-regulated miRNA profile for 
cardiovascular cells, as a means to enhance our knowledge of AngII biology.  This study 
was designed for global miRNA expression profiling in biological replicates following 
chronic AngII activation. 
 
It is estimated that a single miRNA orchestrates post-transcriptional regulation of 
≈100-200 genes in a cell, either by inhibiting the translation or by promoting the 
degradation of specific target mRNAs. A comprehensive knowledge of AngII-regulated 
miRNAs is therefore exceedingly useful in the context of RAS physiology and pathology. 
The miRNA profiles presented here may bridge the gap in our knowledge concerning the 
molecular basis of pathogenesis during chronic RAS activation, which increases 
angiotensinergic risk associated with morbidity and mortality from cardiovascular 
diseases. In many clinical settings, targeting RAS is an important therapeutic paradigm. 
Our study provides insights regarding how RAS-targeted therapies may affect miRNAs.  
 
3.2 Distinct AngII-regulated miRNA Expression Profiles 
We performed a genome-wide comparative analysis of miRNA expression in 23 
small RNA libraries prepared from mice hearts (Yue et al., 2010) and cell types of human 
or rodent origins (Table II.II. for sample details). Selection of these samples resulted in 
adequate biological and technical replicates for making global comparisons. The 
comparisons of the cardiac HL-1 line and heart tissue, HL-1 and VSMCs, VSMCs from 
different species (i.e., human and rat), and cell lines from three species (i.e., human, rat 
and mouse) served as biological replicates. As indicated in Table II.II, in all of the 
biological replicates exposure to AngII led to activation of AT1R-mediated signal 
transduction involving the JAK2/STAT3 and the ERK1/2 pathways (Figure 3.1). Samples 
not treated with AngII or treated with AT1R-specific inhibitors (Losartan or Candesartan) 
and angiotensinergic stimulation through the AT2R are technical replicates included in 
the analysis for validating the AT1R-specific regulation of miRNAs. Each library was 
constructed from high-quality RNA preparations.   
Figure 3.1. Measure of AT1R activation and inhibition. A) The signal transduction 
pathway activation of the AT1R by AngII. B) Activation of the receptor was confirmed 
by ERK1/2 phosphorylation (pERK1/2) and in some cases, JAK2-mediated STAT3 
phosphorylation (pSTAT3), following treatment with 1 µM AngII.  In addition, inhibition 
of AT1R signaling was monitored in the presence of the AT1R specific antagonist, 
losartan or the AT1R specific inverse agonist, candesartan. Total ERK1/2 (tERK1/2) and 
total STAT3 (tSTAT3) are shown as loading controls.   
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Under angiotensinergic stimulation, the miRNA expression profiling microarray 
data obtained from these samples was quantile normalized, background corrected, and 
log2 transformed (see methods).  In addition, quality control measures were taken for 
selecting probes, using the detection threshold of p < 0.05. Altogether 655 miRNAs were 
detected in our array analysis, of which 610 miRNAs met quality control measures 
described in the methods. AngII regulated the expression of 468 miRNAs in all samples.   
 
Most AngII-regulated miRNAs are evolutionarily conserved in related species 
and some even show conservation between invertebrates and vertebrates (Pasquinelli et 
al., 2000, Lagos-Quintana et al., 2001, Lau et al., 2001, Lee and Ambros, 2001). Our data 
provide evidence for AngII-regulated expression of 323 human, 334 mouse, and 109 rat 
miRNAs. When orthology relationships for these miRNAs are evaluated, 355 miRNA 
genes appear to be AngII-responsive in the mouse and rat genomes. Importantly, 237 of 
the AngII-regulated miRNA genes expressed in mouse and rat have human orthologs (as 
determined from miRBase 19). Of these, 168 human orthologs are clearly responsive to 
AngII in the two human cell types analyzed, demonstrating that genome-wide AngII-
regulation of miRNA expression is robust.  
 
Global trends evident in the miRNA expression array data are highlighted in 
Figure 3.2. The heat map shown, includes 468 miRNAs, which are significantly altered in 
at least one of the 13 experimental comparisons shown. A non-redundant set of 357 
miRNAs appeared in two or more models listed in Table II.II and 111 miRNAs are 
unique to a cell type or a treatment condition. The comparison showed that 52% of the 
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microRNAs were downregulated, while 48% of the microRNAs were upregulated. The 
miRNA number observed as a differential response in transgenic mouse hearts [192 and 
166], HASMCs [181], and HL-1-AT1R cells [144] is comparable to the response detected 
in the engineered HEK- kidney cell line [233]. The number of AngII-responsive miRNAs 
in the immortalized RASMC line [60] is lower and is slightly increased [70] upon AT1R 
overexpression (Tables III.I. – III.VII.).  
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Figure 3.2. Heat map depicting miRNA 
expression across AngII activated samples. Fold 
change in miRNA gene expression between 
untreated and AngII/AT1R samples (columns 1-8). In 
addition, comparisons for untreated and Losartan 
treated samples (columns 9-11) and untreated and 
AngII/AT2R samples (columns 12 and 13) are shown 
as controls.  A blue color indicates that the miRNA 
is downregulated in response to the treatment 
condition (see Table 1 for descriptions of 
treatments). A red color indicates that the miRNA is 
upregulated.  The gradient scale above depicts all 
colors within the expression range, +4 to -4 fold 
change.  The numbers at the bottom of each column 
indicates the number of miRNAs differentially 
regulated in a specific treatment condition.   
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Table III.I. AngII responsive miRNAs in transgenic mouse hearts (C57BL/6). 
 
let-7b* 
let-7c-1* 
let-7e 
let-7g* 
let-7i* 
miR-106a:9.1 
miR-10a 
miR-10b* 
miR-1186 
miR-1191 
 
miR-200c 
miR-201 
miR-203 
miR-206 
miR-208b 
miR-20a* 
miR-21* 
miR-214* 
miR-218 
miR-221 
 
miR-375 
miR-376a 
miR-376b 
miR-376b* 
miR-376c 
miR-377 
miR-378* 
miR-381 
miR-409-5p 
miR-411 
 
miR-671-3p 
miR-674 
miR-675-3p 
miR-676 
miR-676* 
miR-677 
miR-683 
miR-685 
miR-689 
miR-700 
 
miR-1192 
miR-1198 
miR-122 
miR-124 
miR-125a-3p 
miR-125b* 
miR-127* 
miR-128 
miR-128a:9.1 
miR-129-3p 
 
miR-222 
miR-224 
miR-24-1* 
miR-25 
miR-26b* 
miR-27b* 
miR-28* 
miR-297a 
miR-297c*, a* 
miR-299* 
 
miR-423-3p 
miR-423-5p 
miR-425* 
miR-434-3p 
miR-434-5p 
miR-450b-3p 
miR-455 
miR-465c-5p 
miR-466a-5p 
miR-466c-5p 
 
miR-708 
miR-709 
miR-744 
miR-744* 
miR-770-5p 
miR-7a 
miR-7a* 
miR-7b 
miR-801:9.1 
miR-872 
 
miR-130b 
miR-130b* 
miR-134 
miR-141 
miR-142-3p 
miR-142-5p 
miR-144 
miR-144:9.1 
miR-145* 
miR-146a 
 
miR-29b* 
miR-301a 
miR-30a* 
miR-30b* 
miR-30c-1* 
miR-30e* 
miR-31* 
miR-32 
miR-320 
miR-324-3p 
 
miR-466d-3p 
miR-466f 
miR-466g 
miR-466h 
miR-466i 
miR-467a 
miR-467a*, d* 
miR-467c 
miR-467e 
miR-467f 
 
miR-874 
miR-877* 
miR-878-5p 
miR-9 
miR-9* 
miR-93* 
solexa-103-3961 
solexa-1278-371 
solexa-1328-360 
solexa-1780-267 
 
miR-146b 
miR-147 
miR-153 
miR-154 
miR-155 
miR-15a* 
miR-15b* 
miR-16* 
miR-181a-2* 
miR-181c 
 
miR-326 
miR-33 
miR-33* 
miR-330 
miR-331-3p 
miR-335-3p 
miR-335-5p 
miR-337-3p 
miR-337-5p 
miR-338-3p 
 
miR-467h 
miR-489 
miR-494 
miR-495 
miR-497 
miR-500 
miR-501-3p 
miR-501-5p 
miR-503 
miR-504 
 
solexa-1837-257 
solexa-200-2167 
solexa-201-2163 
solexa-2564-185 
solexa-27-9416 
solexa-284-1594 
solexa-3062-153 
solexa-308-1456 
solexa-3253-144 
solexa-4153-111 
 
miR-181d 
miR-185 
miR-187 
miR-188-5p 
miR-18b 
miR-191* 
miR-193b 
miR-194 
miR-196a 
miR-200b 
 
miR-342-5p 
miR-343 
miR-345-3p 
miR-34b-3p 
miR-34b-5p 
miR-34c 
miR-34c* 
miR-362-3p 
miR-362-5p 
miR-365 
 
miR-505 
miR-542-3p 
miR-547 
miR-574-3p 
miR-582-3p 
miR-582-5p 
miR-592 
miR-615-3p 
miR-669d 
miR-669f 
 
solexa-4179-110 
solexa-622-718 
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Table III.II. AngII responsive miRNAs in transgenic mouse hearts (C3H). 
 
 
 
 
 
let-7b* 
let-7i* 
miR-1 
miR-101a 
miR-101a* 
miR-101a:9.1 
miR-101b 
miR-106a 
miR-106b 
miR-106b* 
 
miR-208a 
miR-20b 
miR-21 
miR-210 
miR-212 
miR-214* 
miR-215 
miR-217 
miR-218 
miR-221 
 
miR-434-3p 
miR-450a-5p 
miR-450b-3p 
miR-451 
miR-455* 
miR-466d-3p 
miR-466f 
miR-467a*, d* 
miR-467c 
miR-467h 
miR-470 
miR-483 
miR-483* 
  miR-485* 
miR-107 
miR-10b 
miR-1187 
miR-1198 
miR-122 
miR-125b-3p 
miR-128 
miR-128a:9.1 
miR-129-5p 
miR-133a* 
 
miR-222 
miR-224 
miR-26b* 
miR-291b-5p 
miR-296-5p 
miR-297a 
miR-29a* 
miR-29c 
miR-301a 
miR-30b* 
 
miR-490 
miR-497 
miR-501-5p 
miR-503 
miR-503* 
miR-504 
miR-505 
miR-541 
miR-582-3p 
miR-582-5p 
miR-615-3p 
miR-668 
  miR-669c 
    miR-669d 
miR-137 
miR-138 
miR-139-3p 
miR-140 
miR-142-3p 
miR-146a 
miR-146b 
miR-154 
miR-17 
miR-181a-1* 
 
miR-30c-1* 
miR-30c-2* 
miR-31 
miR-322* 
miR-324-5p 
miR-330 
miR-330* 
miR-335-3p 
miR-335-5p 
miR-337-5p 
 
miR-669f 
miR-672 
miR-673-5p 
miR-674* 
miR-675-3p 
miR-689 
miR-699 
miR-703 
miR-708 
miR-709 
miR-712 
miR-715 
miR-770-5p 
miR-7a 
 
miR-181a-2* 
miR-181b 
miR-181d 
miR-182 
miR-183 
miR-184 
miR-18a* 
miR-190 
miR-191* 
miR-193 
 
miR-338-3p 
miR-338-5p 
miR-340-3p 
miR-342-3p 
miR-343 
miR-345-3p 
miR-346 
miR-34a 
miR-34b-3p 
miR-34b-5p 
 
miR-7a* 
miR-801:9.1 
miR-872* 
miR-874 
miR-877 
miR-877* 
miR-92b 
miR-93 
miR-93* 
miR-99b* 
solexa-03-3961 
solexa-1201-400 
solexa-1278-371 
  solexa-130-3526 
miR-193* 
miR-196a 
miR-199a-3p 
miR-199a-5p 
miR-199b, b,* 
miR-19a 
miR-200c 
miR-201 
miR-204 
miR-206 
 
miR-34c 
miR-34c* 
miR-351 
miR-362-5p 
miR-409-3p 
miR-411*:9.1 
miR-421 
miR-423-5p 
miR-425 
miR-433 
 
solexa-1328-360 
solexa-1837-257 
solexa-231-1844 
solexa-308-1456 
solexa-4153-111 
solexa-447-1003 
solexa-5306-86 
solexa-783-586 
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Table III.III. AngII responsive miRNAs in primary HASMC culture.  
 
let-7f* 
let-7g* 
let-7i* 
miR-101a 
miR-101a* 
miR-101b 
miR-101b:9.1 
miR-106a:9.1 
miR-106b* 
miR-107 
 
miR-193* 
miR-194 
miR-195 
miR-196a 
miR-196b 
miR-197 
miR-19a 
miR-19a* 
miR-19b 
miR-201 
 
miR-331-5p 
miR-335-5p 
miR-337-5p 
miR-339-3p 
miR-339-5p 
miR-340-3p 
miR-340-5p 
miR-342-5p 
miR-345-3p 
miR-345-5p 
 
miR-652 
miR-674 
miR-675-5p 
miR-676 
miR-679 
miR-682 
miR-685 
miR-690 
miR-694 
miR-703 
  miR-706 
miR-10a* 
miR-10b* 
miR-1186 
miR-1187 
miR-1198 
miR-1224 
miR-125a-3p 
miR-125b* 
miR-126-3p 
miR-129-3p 
 
miR-204 
miR-206 
miR-208a 
miR-20b 
miR-21* 
miR-210 
miR-212 
miR-214* 
miR-219 
miR-22* 
 
miR-34a 
miR-34b-3p 
miR-34b-5p 
miR-34c 
miR-34c* 
miR-362-3p 
miR-362-5p 
miR-378 
miR-384-3p 
miR-384-5p 
 
miR-709 
miR-718 
miR-720 
miR-760 
miR-7a* 
miR-7b 
miR-801:9.1 
miR-872 
miR-874 
miR-877* 
miR-878-5p 
 
miR-130b 
miR-132 
miR-133a 
miR-138 
miR-141 
miR-142-5p 
miR-144:9.1 
miR-145* 
miR-146a 
miR-146b 
 
miR-224 
miR-24-1* 
miR-24-2* 
miR-26b* 
miR-27a* 
miR-27b* 
miR-28* 
miR-293 
miR-297a 
miR-297c*, a*, b-3p 
 
miR-423-3p 
miR-423-5p 
miR-449a 
miR-450b-3p 
miR-451 
miR-465c-5p 
miR-466a-5p 
miR-466f 
miR-466f-3p 
miR-466g 
 
miR-9 
miR-92b 
miR-93 
miR-96 
miR-99a 
miR-99b 
miR-99b* 
solexa-103-3961 
solexa-1201-400 
solexa-1328-360 
solexa-173-2522 
 
miR-146b* 
miR-149 
miR-150 
miR-16* 
miR-181a-1* 
miR-181b 
miR-181c 
miR-181d 
miR-182 
miR-183 
 
miR-29b 
miR-29b* 
miR-29c* 
miR-301b 
miR-30a 
miR-30a* 
miR-30b* 
miR-30c-1* 
miR-30c-2* 
miR-30d 
 
miR-466i 
miR-467a 
miR-483* 
miR-484 
miR-489 
miR-491 
miR-497 
miR-499 
miR-501-5p 
miR-503 
 
solexa-1780-267 
solexa-1837-257 
solexa-200-2167 
solexa-2011-236 
solexa-231-1844 
solexa-239-1823 
solexa-2564-185 
solexa-27-9416 
solexa-3062-153 
solexa-308-1456 
solexa-3253-144 
 
miR-185 
miR-186 
miR-187 
miR-188-3p 
miR-188-5p 
miR-18a* 
miR-18b 
miR-191* 
miR-192 
miR-193 
 
miR-32 
miR-320 
miR-324-5p 
miR-325 
miR-325* 
miR-326 
miR-33 
miR-33* 
miR-330 
miR-331-3p 
 
miR-503* 
miR-532-5p 
miR-504 
miR-542-5p 
miR-509-5p 
miR-574-5p 
miR-582-5p 
miR-592 
miR-598 
miR-615-5p 
 
solexa-403-1161 
solexa-4153-111 
solexa-4179-110 
solexa-447-1003 
solexa-622-718 
solexa-783-586 
solexa-897-515 
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Table III.IV. AngII responsive miRNAs in HL-1-AT1R cell line.  
 
let-7f* 
let-7i* 
miR-1 
miR-101a 
miR-101a:9.1 
miR-107 
miR-10a 
miR-1187 
miR-1191 
miR-1196 
 
miR-219 
miR-22* 
miR-24-1* 
miR-24-2* 
miR-27a* 
miR-27b* 
miR-28* 
miR-29a* 
miR-29b 
miR-29b* 
 
miR-499 
miR-500 
miR-503 
miR-505 
miR-542-3p 
miR-671-3p 
miR-677 
miR-684 
miR-690 
miR-699 
 
miR-1198 
miR-125a-3p 
miR-125b* 
miR-125b-3p 
miR-126-3p 
miR-128 
miR-129-3p 
miR-130b 
miR-133a* 
miR-133b 
 
miR-301a 
miR-301b 
miR-30b* 
miR-32 
miR-33 
miR-33* 
miR-330 
miR-331-3p 
miR-335-5p 
miR-339-3p 
 
miR-709 
miR-715 
miR-741 
miR-742 
miR-743b-3p 
miR-770-5p 
miR-801:9.1 
miR-802 
miR-871 
miR-872 
 
miR-138 
miR-139-5p 
miR-140* 
miR-141 
miR-150 
miR-15a* 
miR-16* 
miR-181a-1* 
miR-181a-2* 
miR-181b 
 
miR-339-5p 
miR-340-5p 
miR-342-5p 
miR-343 
miR-345-3p 
miR-345-5p 
miR-34b-5p 
miR-34c 
miR-362-5p 
miR-365 
 
miR-873 
miR-878-3p 
miR-878-5p 
miR-880 
miR-9 
miR-9* 
miR-92b 
miR-96 
miR-99b* 
solexa-103-3961 
 
mmu-miR-181c 
mmu-miR-183* 
mmu-miR-188-3p 
mmu-miR-188-5p 
mmu-miR-190b 
mmu-miR-191* 
mmu-miR-192 
mmu-miR-194 
mmu-miR-196a 
mmu-miR-196b 
 
miR-378 
miR-421 
miR-423-3p 
miR-423-5p 
miR-425* 
miR-450b-5p 
miR-463* 
miR-465a-3p family 
miR-465a-5p 
miR-465b-5p 
 
solexa-1201-400 
solexa-1278-371 
solexa-130-3526 
solexa-173-2522 
solexa-1837-257 
solexa-201-2163 
solexa-231-1844 
solexa-2564-185 
solexa-4153-111 
solexa-447-1003 
 
miR-199a-3p:9.1 
miR-199b* 
miR-19a 
miR-19a* 
miR-19b 
miR-200a 
miR-208a 
miR-20a* 
miR-21* 
miR-210 
 
miR-465c-5p 
miR-466f-3p 
miR-467f 
miR-470 
miR-471 
miR-471:9.1 
miR-486 
miR-490 
miR-491 
miR-497 
 
solexa-5067-90 
solexa-622-718 
solexa-783-586 
solexa-897-515 
 
 
 
 
 
Table III.V. AngII responsive miRNAs in HEK-AT1R kidney cell line.  
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let-7b* 
let-7d* 
let-7f* 
let-7g* 
let-7i 
let-7i* 
miR-101b 
miR-106a:9.1 
miR-107 
miR-10a* 
 
miR-190 
miR-190b 
miR-191* 
miR-192 
miR-193 
miR-193b 
miR-194 
miR-195 
miR-196a* 
miR-199a-5p 
 
miR-30a 
miR-30b* 
miR-30c-1* 
miR-30c-2* 
miR-32 
miR-323-3p 
miR-324-5p 
miR-328 
miR-33 
miR-33* 
 
  miR-465c-5p 
  miR-466a 
  miR-466f 
  miR-466h 
  miR-467a 
  miR-467h 
  miR-485* 
  miR-486 
  miR-487b 
  miR-494 
  miR-495 
  miR-497 
  miR-499 
  miR-501-5p 
  miR-503 
  miR-532-3p 
  miR-539 
miR-10b* 
miR-1186 
miR-1187 
miR-1192 
miR-1197 
miR-1224 
miR-124 
miR-125b* 
miR-128 
miR-128a:9.1 
 
miR-19a* 
miR-200a 
miR-200b 
miR-200b* 
miR-200c* 
miR-203 
miR-204 
miR-208b 
miR-20b 
miR-21* 
 
miR-330 
miR-330* 
miR-331-3p 
miR-335-3p 
miR-335-5p 
miR-337-5p 
miR-338-3p 
miR-338-5p 
miR-339-3p 
miR-341:9.1 
 
miR-540-3p 
miR-540-5p 
miR-542-3p 
miR-542-5p 
miR-543 
miR-551b 
miR-551b:9.1 
miR-574-5p 
miR-582-3p 
miR-592 
miR-615-3p 
miR-615-5p 
miR-652 
miR-653 
miR-654-3p 
miR-654-5p 
miR-667 
 
miR-129-3p 
miR-129-5p 
miR-132 
miR-134 
miR-135b 
miR-137 
miR-138 
miR-138* 
miR-139-5p 
miR-140 
 
miR-210 
miR-211 
miR-212 
miR-214* 
miR-215 
miR-216b 
miR-217 
miR-22* 
miR-223 
miR-23a 
 
miR-342-5p 
miR-345-3p 
miR-345-5p 
miR-34a 
miR-34b-3p 
miR-34c 
miR-362-3p 
miR-362-5p 
miR-363 
miR-369-3p 
 
miR-668 
miR-671-5p 
miR-676 
miR-679 
miR-684 
miR-690 
miR-692 
miR-694 
miR-702 
miR-703 
miR-706 
miR-707 
miR-708 
miR-715 
miR-718 
miR-719 
miR-744* 
 
miR-141 
miR-142-3p 
miR-142-5p 
miR-143 
miR-144 
miR-144:9.1 
miR-145 
miR-146b* 
miR-147 
miR-150 
 
miR-24-1* 
miR-24-2* 
miR-26b* 
miR-27a* 
miR-27b* 
miR-28* 
miR-290-3p 
miR-291a-3p 
miR-293 
miR-295* 
 
miR-369-5p 
miR-375 
miR-376a* 
miR-376b 
miR-376c 
miR-376c* 
miR-377 
miR-379 
miR-381 
miR-382 
 
miR-760 
miR-762 
miR-7b 
miR-801:9.1 
miR-872* 
miR-873 
miR-874 
miR-878-3p 
miR-878-5p 
miR-879 
miR-92b 
miR-96 
miR-98 
miR-99a 
miR-99b* 
solexa-103-3961 
solexa-173-2522 
 
miR-154 
miR-154* 
miR-155 
miR-16* 
miR-17* 
miR-183* 
miR-184 
miR-187 
miR-188-3p 
miR-18a* 
 
miR-296-3p 
miR-296-5p 
miR-297a 
miR-299 
miR-299* 
miR-29a 
miR-29a* 
miR-29b* 
miR-29c* 
miR-302b 
 
miR-382* 
miR-409-3p 
miR-409-5p 
miR-410 
miR-411 
miR-411*:9.1 
miR-423-5p 
miR-449b 
miR-450b-3p 
miR-451 
 
solexa-1837-257 
solexa-200-2167 
solexa-2011-236 
solexa-201-2163 
solexa-2054-231 
solexa-2564-185 
solexa-3062-153 
solexa-403-1161 
solexa-4153-111 
solexa-4179-110 
solexa-5067-90 
solexa-5593.81 
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Table III.VI. AngII responsive miRNAs in immortalized RASM cell line. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
let-7i* 
miR-101a* 
miR-107 
miR-1198 
miR-125a-3p 
miR-128 
miR-129-3p 
miR-138 
miR-142-3p 
miR-146a 
miR-17* 
miR-188-5p 
 
miR-19a* 
miR-214* 
miR-218-1* 
miR-24-1* 
miR-26b* 
miR-32 
miR-322* 
miR-324-5p 
miR-33 
miR-330 
miR-330* 
miR-331-3p 
 
miR-331-5p 
miR-345-5p 
miR-34a 
miR-34b-3p 
miR-34b-5p 
miR-34c 
miR-449a 
miR-449b 
miR-450b-3p 
miR-466h 
miR-503* 
miR-504 
 
miR-532-3p 
miR-542-5p 
miR-551b 
miR-551b:9.1 
miR-615-5p 
miR-652 
miR-684 
miR-685 
miR-706 
miR-709 
miR-7a* 
miR-801:9.1 
 
miR-872 
miR-874 
miR-99b* 
solexa-103-3961 
solexa-1837-257 
solexa-201-2163 
solexa-308-1456 
solexa-4153-111 
solexa-4179-110 
solexa-447-1003 
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Table III.VII. AngII responsive miRNAs in RASMC-AT1R cell line.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
let-7b* 
met-7i* 
miR-101a* 
miR-106a:9.1 
miR-10a* 
miR-1186 
miR-1187 
miR-1198 
miR-125b* 
miR-141 
let-7b* 
let-7i* 
miR-142-5p 
miR-149 
miR-17* 
miR-184 
miR-187 
 
miR-188-5p 
miR-193 
miR-194 
miR-196b 
miR-20b 
miR-142-5p 
miR-149 
miR-21* 
miR-212 
miR-217 
miR-224 
miR-27a* 
miR-297c 
miR-297c*, a*, b-3p 
miR-301b 
miR-325 
  miR-330* 
miR-21* 
miR-212 
miR-335-3p 
miR-335-5p 
miR-339-3p 
miR-345-5p 
miR-34a 
miR-425* 
miR-450b-3p 
miR-450b-5p 
miR-466f 
miR-466f-3p 
miR-335-3p 
miR-335-5p 
miR-466g 
miR-466h 
miR-466k 
 
miR-467a*, d* 
miR-467b* 
miR-483* 
miR-489 
miR-500 
miR-501-5p 
miR-503* 
miR-615-5p 
miR-669c 
miR-669f 
miR-685 
miR-709 
miR-760 
miR-872 
miR-874 
miR-877* 
miR-878-5p 
 
miR-92b 
miR-99b* 
solexa-103-3961 
solexa-1201-400 
solexa-173-2522 
solexa-200-2167 
solexa-239-1823 
solexa-2564-185 
solexa-308-1456 
solexa-4179-110 
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We further observed that AT1R stimulation with AngII affects multiple human 
miRNA clusters, defined as regions of the genome harboring two or more miRNAs that 
are transcribed from adjacent genes within 10 kb of each other.  We observed that 24 
known miRNA clusters in the human genome (Zhang et al., 2012, Yu et al., 2006), 
located on 14 different chromosomes respond to AT1R stimulation as shown by only one 
or a few specific miRNAs expressed from each cluster (Table III.VII.).  
 
In addition to determination of AngII-regulated miRNAs previously determined, 
we identified 30 new miRNAs that have only been predicted in the Solexa sequencing 
database (www.switchtoi.com) with unclear functional annotation (Table III.VIII.). Only 
the mature sequence is known for each miRNA species reported, which was annotated 
from the illumina-sequencing chip.   
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Table III.VIII. Human miRNA clusters differentially regulated upon AngII 
treatment. 
 
Cluster 
# 
miRNA Cluster Chromosome miRNAs Differentially 
Regulated in 
Untreated v. AngII models 
1 miR-29b-2 ~ 29c 1 miR-29c 
2 miR-200 1 miR-200b, miR-200a 
3 miR-181b-1-181a-1 1 miR-181b-1 
4 miR-466-467-669 2 
 
miR-466f-1, miR-669d, miR-
467b*, miR-466c-1, miR-467e, 
miR-466a, miR-466d, miR-
297a 
5 miR-15b ~ 16-2 3 miR-15b, miR-16-2 
6 miR-106b-93-25 5 miR-106a, miR-93, miR-25 
7 miR-29b-1 ~ 29a 6 miR-29a 
8 miR-290 ~ 293 ~ 295 7 miR-290, miR-291a, miR-
291b, miR-293 
9 miR-25 ~ 93 ~ 106 7 miR-25, miR-93, miR-106b 
10 miR-23a ~ 27a ~ 24-2 8 miR-23a, miR-27a*, miR-24-
2* 
11 let-7a-1 ~ 7f ~7d 9 let-7f* 
12 miR-8 ~ 141 ~ 200 12 miR-200c, miR-141 
13 miR-379 ~ 411 ~ 758 12 
 
miR-379, miR-329, miR-667, 
miR-668, miR-154, miR-410 
14 miR-23b-27b-24-1 22 miR-27b*, miR-24-1 
15 miR-16-1 ~ 15a 13 miR-15a 
16 miR-17-19a-92a-1 13 miR-17*, miR-18a, miR-19a, 
miR-20a,  
17 miR-106a-92a-2 14 
 
miR-92a-1*, miR-106a, miR-
18b, miR-20b, miR-19b-2*, 
miR-92a-2*, miR-363 
18 miR-222 ~ 221 X miR-222, miR-221 
19 miR-98 ~ let-7f-2 X miR-98 
20 miR-181c-181d X miR-181c, miR-181d 
21 miR-99b ~ 125 ~ let-7e 19 miR-99b, miR-125, let-7e 
22 miR-23a ~ 27a ~ 24-2 19 miR-24-2, miR-23a, miR-27a 
23 miR-99a ~ let-7c 19 miR-99a, let-7c 
24 let-7a-3 ~ 7b ~ miR-4763 21 let-7b 
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Table III.IX. Novel miRNAs regulated in response to AT1R activation by AngII.  
 
 miRNA Mature Sequence 
1 Solexa-103-3961 TCCTCGTTAGTATAGTGG 
2 Solexa-1201-400 GGTCAAGAGGCGCCTGGGAAC 
3 Solexa-1278-371 GTAAAGGCTGGGCTTAGACGTGG 
4 Solexa-130-3526 CAAGAAGTAGTTTAATTAGA 
5 Solexa-1328-360 ACGCCCTTCCCCCCCTTCTTCA 
6 Solexa-173-2522 ACCGTGGCTTTCGATTGTTACT 
7 Solexa-1780-267 GAACATCACAGCAAGTCTGTGCT 
8 Solexa-1837-257 TATGGAGGTCTCTGTCTGACTT 
9 Solexa-200-2167 GTCAGGATGGCCGAGCGGTCTAAG 
10 Solexa-201-2163 ACCTTGGCTCTAGACTGCTTACT 
11 Solexa-2011-236 AATCAGCAAGTATACTGCCCTA 
12 Solexa-2054-231 AGCGAGGTTGCCCTTTGTATATT 
13 Solexa-231-1844 ATCTCCATAGTGACCA 
14 Solexa-239-1823 CTAGCCCTAGCCCTACA 
15 Solexa-2564-185 ACCTGGCATACAATGTAGATTTCTGT 
16 Solexa-27-9416 TCCCTGGTGGTCTAGTGGTTAGGATTCGGC 
17 Solexa-284-1594 GGCTCGTTGGTCTAGGGGTATGATTC 
18 Solexa-3062-153 TGGATATGATGACTGATTACCTGAGA 
19 Solexa-308-1456 GCCCGGCTAGCTCAGTCGGTAGA 
20 Solexa-3253-144 GGGCTGGAGAGATGGCTCAGCCGTT 
21 Solexa-403-1161 GTCTACGGCCATACCACCCTGA 
22 Solexa-4153-111 GACCTCGTGGCGCAATGG 
23 Solexa-4179-110 CTCACTGAACAATGAATGCAA 
24 Solexa-447-1003 GTCAGGATGGCCGAGTGGTCTAAGG 
25 Solexa-5067-90 GAAGTTCTGTTATACACTCAGG 
26 Solexa-5306-86 ACCCGTCCCGTTCGTCCCCGGA 
27 Solexa-5593-81 GCTGGGAAGGCAAAGGGACGT 
28 Solexa-622-718 GGGGATGTAGCTCAGTGGTAGA 
29 Solexa-783-586 GTGCAGTGCTGCATCTC 
30 Solexa-897-515 TTGGAGTTCATGCAAGTTCT 
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3.3 AT1R Specificity of miRNA Expression 
AngII activation of the AT2R in the human kidney cell line affected only four 
miRNAs, out of which the regulation of three miRNAs was antagonistic to regulation by 
AT1R (Figure 3.3 A). In contrast, 32 miRNAs were affected by AngII activation of the 
AT2R in RASMC. The expression pattern of 18 miRNAs common to AT1R and AT2R 
data (Figure 3.3 B) was mostly indicative of the well known antagonistic signaling by 
these AngII receptors (de Gasparo et al., 2000). In addition, treatment with the AT1R 
blocker, Losartan, altered 90% of the VSMC miRNAs in a manner opposite from that of 
AngII treatment. Thus, the AT1R specificity of regulation of miRNAs in our analysis is 
clear. 
 
The results discussed in this chapter demonstrate global miRNA expression 
profiling in biological replicates following chronic AngII activation. The miRNA 
changes in individual comparisons showed a range between 60 and 234 miRNA genes 
per sample. This finding is consistent with the miRNA expression profiles characterized 
in complex tissues, sorted cells and individual cell lines, which demonstrated that on 
average ≈70-150 miRNA genes were expressed per sample (Landgraf et al., 2007, 
Chiang et al., 2010). The inclusion of RNA derived from tissue, primary cells and 
established cell lines in our analysis demonstrates that this miRNA fingerprint is not 
derived from complex heterotypic cell-cell interactions nor influenced by a multitude of 
endocrine, paracrine or autocrine and neuronal influences, a common confounding 
problem in many analyses.  
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Figure 3.3. Venn diagrams of miRNAs altered in response to AngII treatment. A) 
AngII activation of the AT2R in the human kidney cell line affected only four miRNAs, 
out of which the regulation of three miRNAs was antagonistic in HEK-AT2R compared 
to regulation in HEK-AT1R. B) AngII activation of the AT2R in the immortalized 
RASMCs affected 32 miRNAs.  Eighteen of those miRNAs are common to the 
expression fingerprint observed in the AT1R RASMCs, albeit the manner of expression is 
antagonistic.  Arrows pointing up () are indicative of an increase in expression while 
those pointing down () indicate a decrease in expression.  A solid line denotes no 
change. 
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Demonstrating miRNA specificity is important in elucidating the regulation of 
these small RNAs, which is our reasoning for determining the miRNA expression pattern 
in response to the AT2R and following treatment of the AT1R with losartan.  In both 
instances, we showed that expression of miRNAs was antagonized following AT2R 
activation by AngII and Losartan blockade of AT1R in both VSMCs and HEK-AT1R 
cells, thus displaying that the miRNA profiles generated across each model system with 
AngII treatment are AT1R specific.   
 
In addition, several miRNAs mapped to multicopy miRNA genes. Expression of a 
specific miRNA or a select few from the cluster suggests stimulus-specificity of 
processing of individual miRNAs from polycistronic pri-miRNA transcripts, as 
previously observed in human studies (Baskerville and Bartel, 2005). With the global 
miRNA profile known, we sought to identify a common set of miRNAs expressed in all 
cell types in response to AngII activation of the AT1R.   
 
 
 
 
 
 
 
 
CHAPTER IV 
ANGII-REGULATED MIRNAS 
 
 
4.1 Introduction 
The tissue and cell-type specific regulation of miRNAs points to the vast role of 
these small regulatory RNAs in physiology and in various diseases. As an important RAS 
hormone, AngII must play a wider role in regulating the relative abundance and 
specificity of expression of miRNAs in order to regulate a variety of physiological and 
adaptive tissue remodeling processes. Thus, the miRNA regulation is a critical aspect of 
effectiveness of hormones such as AngII in various cells.  
 
Regulation of miRNAs in VSMCs by a local increase in AngII can adversely 
affect vessel functions due to the high density of the AT1R on VSMCs. Distinct VSMC 
phenotypes accumulate within arteries of individuals with disorders such as systemic and 
pulmonary hypertension, atherosclerosis, and asthma. During insult, VSMCs switch to a 
proliferative phenotype of poor contractility/excitability, exhibit changes in lipid 
metabolism, and have high extracellular matrix production leading to vessel remodeling. 
In contrast, the phenotype of healthy adult VSMCs is restricted cellular plasticity, in 
which the cells are geared for contraction with a unique repertoire of contractile proteins, 
agonist-specific receptors, ion channels, and signaling molecules. Thus VSMCs are an 
interesting model system for studying miRNA-modulated mechanisms of cell 
maintenance, differentiation, and phenotypic modulation (Rensen et al., 2007, Daugherty 
and Cassis, 2004). Regulation of specific miRNAs as contributors to vascular disease 
(e.g., miR-155, -143, -145, -21, -126) has been studied (Urbich et al., 2008), but a 
comprehensive analysis targeting AngII-regulation of miRNAs in VSMCs and its 
associated diseases is lacking. 
 
4.2 MiRNAs Regulated Universally by AngII 
Understanding the miRNA expression fingerprint in various cell and tissue types 
is an important step in elucidating miRNA function. Two miRNAs, let-7i* and solexa-
103-3961 were AngII-responsive in all AT1R activated models consisting of six cell lines 
and two TG hearts. The AngII-responsive miRNA number increased to six when we 
relaxed the cut-off to 7 out of 8 AT1R activated samples. Since regulation of miRNA 
expression in a tissue, such as the heart is complex, we evaluated instances of the same 
miRNA appearing specifically in the cellular models. 
Eighteen miRNAs were differentially altered in 5 out of 6 AT1R activated cell 
lines, which represent three mammalian genomes in the context of three different cell 
types (Table IV.I). Thirty-two miRNAs are differentially expressed in at least 6 AT1R 
activated models including both cell lines and heart tissue from TG mice.  These 32 
miRNAs are AT1R-specific because all of these were not expressed upon AngII 
activation of the AT2R in HEK-293 cells and in VSMCs. In addition, AngII-regulated 
pattern of expression of these miRNAs was antagonized by blockade of the AT1R by 
Losartan. We designated these 32 miRNAs as a common set of novel endogenous 
molecules that regulate in vivo responses to AngII activation of the AT1R, and may also 
modulate the effectiveness of AT1R blockade used to treat various pathologies. 
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Table IV.I. AngII-responsive miRNAs across AT1R overexpressing model systems. 
 
miRNA Manner of 
Expression 
Heart VSMCs HEK 
let-7i* ∆‡*◊ + + + 
miR-330 ∆‡*◊ + + + 
Solexa-103-3961 ∆‡*◊ + + + 
Solexa-4153-111 ∆‡*◊ + + + 
Solexa-1837-257  ∆‡*◊ + + + 
miR-874 ∆‡*◊ + (tissue only) + + 
miR-34a ∆*◊ + (tissue only) + + 
miR-142-5p ∆* + (tissue only) + + 
miR-345-5p ∆* + + + 
miR-21* ∆* + + + 
miR-138 ∆* + + + 
miR-34c ∆* + + + 
miR-99b* ∆* + (tissue only) + + 
miR-92b ∆* + + + 
miR-19a* ∆* + + + 
miR-709 ∆ + +  
miR-33 ∆ + + + 
Solexa-308-1456 ∆ + (tissue only) +  
miR-335-5p ∆ + + + 
miR-497 ∆ + + (human only) + 
miR-801:9.1 ∆ + + + 
miR-345-3p ∆ + + (human only) + 
miR-34b-5p ∆ + +  
miR-503 ∆ + + (human only) + 
miR-214* ∆ + (tissue only) + + 
miR-1198 ∆ + +  
miR-34b-3p ∆ + + + 
miR-423-5p ∆ + + + 
Solexa-2564-185 ∆ + + + 
miR-450b-3p ∆ + + + 
miR-615-5p *  + + 
miR-27a* * + (cell line only) + + 
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4.3 MiRNA Signature in Human and Rat VSMCs 
Relationships between the expression patterns of miRNAs in the biological 
replicates in our analysis are shown by pairwise sample comparisons shown in Figure 
4.1. The profile of each AngII treated compared to the respective untreated control 
showed a strong correlation (>0.95). Comparison of profiles between unrelated replicates 
(e.g., SK-1 and SK-24) produced a scatter plot with weak correlation (<0.7).  
Interestingly, the miRNA expression in the human and rodent VSMC model systems 
(purple box) yielded correlation coefficients >0.95, indicating a unique pattern of 
expression. This pattern arises from data consisting of >30 upregulated and >30 
downregulated miRNAs in all sixteen possible comparisons, demonstrating a robust 
AngII responsive miRNA signature in VSMCs. 
 
Comparison of miRNA expression in the VSMCs to all other samples examined 
in this study indicates that 26 miRNAs are highly specific for smooth muscle cells. The 
volcano plot de-convoluted the miRNA signature as log2 fold change in expression of 
miRNA whose abundance is significantly (p > 0.0001) altered in response to AngII. 
Twenty-one miRNAs were significantly down regulated and 5 were significantly 
upregulated, following AT1R activation by AngII (Figure 4.2 A). The chromosomal 
locations of the 22 VSMC-specific miRNAs are shown.  Many of these miRNAs are 
encoded within intronic regions in the mouse genome, in which the parent gene is also 
known and annotated (Figure 4.2 B).   
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Figure 4.1. Pairwise plot of sample comparisons.  Differential miRNA expression in 
all AngII activated AT1R model systems compared. Each blue bar graph represents the 
overall miRNA profile for a given sample (starting with SK-1 in the upper left hand 
corner).  The corresponding scatter plot shows the general trend of miRNAs altered when 
comparing the untreated sample to the AngII treated sample.  The unique miRNA 
expression pattern in the human and rodent VSMC model systems, indicated in purple 
box.  The correlation coefficient is listed for each comparison.  In addition, the numbers 
of miRNAs that are upregulated (>2) are shown in red and the numbers of miRNAs that 
are downregulated (>2) are shown in blue for the VSMC model systems (lower purple 
box). 
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Figure 4.2. Characteristics of VSMC-specific miRNAs. Profiles of miRNAs pooled 
from all VSMCs either treated for 24 hours with 1µM AngII or left untreated. A) The 
volcano plot shows the log2 fold change in expression of miRNA whose abundance is 
significantly altered in response to AngII.  Twenty-one miRNAs were significantly 
downregulated (highlighted in blue) and 5 were significantly upregulated (highlighted in 
red), following AngII receptor activation. B) The mouse chromosomal locations of the 
twenty-two VSMC-specific miRNAs.  Many of the miRNAs are encoded within intronic 
regions in the mouse genome, in which the parent gene is also known and annotated in 
the corresponding figure legend. 
 126 
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Conserved expression of several miRNAs observed in three species in our study 
was previously unknown (Table IV.I.). The mouse genome is known to contain the 
VSMC-specific miRNAs listed; however, the gene assignment for the human equivalent 
for 11 of the miRNAs is not yet available by genome BLAST analysis (shown with a 
hyphen). However, the expression of miRs-682, -1187, -297c*, -466g, and -1198 were 
experimentally detected in the HASMC samples although the genes are not annotated for 
these miRNAs. Interestingly, 7 miRNAs are clustered to a single region of the genome, 
the miR-466-467-669 cluster (Table III.I).   
 
The results discussed in this chapter importantly demonstrate that thirty-two 
miRNAs were AngII regulated in most human and rodent samples, which we deemed as 
universally responsive to AngII activation of the AT1R. Expression of these miRNAs 
were antagonized following AT2R activation by AngII and Losartan blockade of AT1R in 
both VSMCs and HEK-AT1R cells, suggesting that expression of these miRNAs is a 
hallmark of AngII action through the AT1R, which is targeted in most clinical settings.  
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Table IV.II.  Genomic characteristics of VSMC-specific miRNAs. 
 
miRNA 
 
Mature Sequence 
 
Fold 
Change 
(VSMCs) 
Fold 
Change 
(HEKs) 
Chromosome #  
for Human 
Homologue 
miR-675-5p UGGUGCGGAAAGGGCCCACAGU -1.47 0.93 11 
miR-343 UCUCCCUUCAUGUGCCCAGA -1.33 0.66 - 
miR-669c AUAGUUGUGUGUGGAUGUGUGU -1.22 0.82 - 
miR-467b* AUAUACAUACACACACCAACAC -1.29 0.15 - 
miR-218-1* AAACAUGGUUCCGUCAAGCACC 1.24 0.04 4 
miR-32 UAUUGCACAUUACUAAGUUGCA 1.86 0.45 9 
miR-682 CUGCAGUCACAGUGAAGUCUG -1.22 0.99 - 
miR-1187 UAUGUGUGUGUGUAUGUGUGUAA -1.55 0 - 
miR-297c*, 
297a*, 297b-3p UAUACAUACACACAUACCCAUA -1.92 0.81 - 
miR-188-5p CAUCCCUUGCAUGGUGGAGGG 1.30 0.58 X 
miR-106a:9.1 CAAAGUGCUAACAGUGCAGGUA -1.29 0 X 
miR-466g AUACAGACACAUGCACACACA -1.52 0.19 - 
miR-325 UUUAUUGAGCACCUCCUAUCAA 1.28 0.99 X 
miR-467a*, 
467d* AUAUACAUACACACACCUACAC -1.51 1 - 
miR-1198 UAUGUGUUCCUGGCUGGCUUGG -2.23 0.06 - 
miR-301b CAGUGCAAUGGUAUUGUCAAAGC -1.51 0.12 22 
miR-21* CAACAGCAGUCGAUGGGCUGUC -1.40 0.35 17 
miR-483-3p UCACUCCUCCCCUCCCGUCUU -1.48 0.93 11 
miR-297c AUGUAUGUGUGCAUGUACAUGU -1.37 0.99 - 
miR-669f CAUAUACAUACACACACACGUAU -1.23 0.99 - 
miR-208a AUAAGACGAGCAAAAAGCUUGU -1.29 0.99 14 
miR-33 GUGCAUUGUAGUUGCAUUGCA 1.23 0.31 22 
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Our analysis of AngII-regulated miRNAs in rat and human VSMC cell lines 
(Table IV.III.) indicated for the first time a unique fingerprint consisting of novel 
miRNAs and miRNAs with known functions. As shown, a significant number of the 
AngII-regulated miRNAs have been implicated in pathogenesis of other organs and 
tissues, implying that a systematic study of their role in vasculature is important. Many of 
the miRNAs have been previously implicated in various forms of cancer (e.g., miRs-218-
1, -32,  -297b-3p, -106a, -483-3p), while some have been shown to play in a role in 
cardiac and vascular disturbances (e.g., miRs-218-1, -188-5p, -208a, -483-3p). Using this 
AngII-induced VSMC miRNA profile will allow for enhancement of our understanding 
of RAS-mediated vascular abnormalities.  
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Table IV.III. Involvement of VSMC-specific miRNAs in various tissues and disease 
states. 
 
miRNA Expression Context (Manner of Alteration) 
  
miR-675 NA 
miR-343 NA 
miR-669c NA 
miR-467b* Hepatic steatosis in non-alcoholic fatty liver 
disease (downregulated) 
miR-218-1 Vascular patterning (upregulation), gastric cancer, 
oral squamous cell carcinoma (downregulated)  
miR-32 Androgen-regulated prostate cancer (upregulated), 
antiviral defense, human myeloid leukemia 
(upregulated) 
miR-682 Muscle regeneration (upregulated) 
miR-1187 TNFα-mediate hepatic apoptosis (upregulated) 
miR-297b-3p Lymphoma/carcinogenesis (upregulated) 
miR-188-5p Homocysteine-induced cardiac remodeling 
(upregulated) 
miR-106a Malignant bronchial epithelial, human T-cell 
leukemia, gastric cancer (upregulation), colon 
cancer (downregulation) 
miR-1198 NA 
miR-325 Stress-induced suppression of luteinizing hormone 
secretion (upregulated) 
miR-301b Stimulates induced pluripotent stem cells 
(upregulated) 
miR-467a Growth regulation of mouse embryonic stem cells 
(upregulated) 
miR-669f NA 
miR-208a Cardiac hypertrophy/diastolic dysfunction, 
electrical conductance, acute myocardial infarction 
(upregulated) 
miR-483-3p Wilms’ tumors, hepatocellular carcinoma, 
colorectal cancer, adrenocortical tumours, 
pancreatic cancer, proliferation in wounded 
epithelial cells (upregulated), myocardium of 
obesity-prone rats, melatonin synthesis in pineal 
gland (downregulated) 
miR-33 Cholesterol homeostasis in macrophages, 
atherosclerosis (upregulated) 
 
CHAPTER V 
REGULATION OF MIRNAS BY ANGII 
 
 
5.1 Introduction 
 Validation of expression patterns is an important aspect of miRNA biology that 
must always be considered.  Recapitulating the manner of expression observed by 
microarray (i.e., upregulated or downregulated) in independent samples sets is crucial for 
teasing out the functional roles of individual miRNAs.  In the current study, we have 
demonstrated a robust miRNA response following chronic AngII treatment and activation 
of the AT1R.  Confirming expression of the VSMC-specific miRNAs determined in the 
profiling experiment will be useful to determine the important players for regulation of 
cellular activities and RAS pathologies where VMSC gene expression is altered.    
 
5.2 Validation of VSMC miRNAs by RT-qPCR 
To validate the microarray data and confirm the VSMC-specific miRNA 
signature, the stemloop primer-based real-time RT-qPCR analysis was performed on 
independent RNA samples.  The levels of miR-483-3p, miR-32, miR-669f and miR-1198 
compared in untreated samples revealed that basal levels of these miRNAs changed in 
RASMC-AT1R compared to RASMC (Figure 5.1. A). The change in the level of these 
four miRNAs in AngII treated samples followed similar pattern in RASMC-AT1R 
compared to RASMC, suggesting that the AngII dependent effects are not altered due to 
AT1R over expression in the RASMC-AT1R. 
 
Figure 5.1 B shows ligand-dependent changes in the levels of 20 VSMC-specific 
miRNAs, following treatment with either AngII or Candesartan for 24 hours (n = 3). 
Since basal levels of miRNAs were altered in the RASMC-AT1R cells due to mere 
overexpression of the AT1R, the inverse agonist, Candesartan was used to inhibit the 
basal AT1R-specific effect. The result was then compared to the AngII-induced effect in 
each case. Of the VSMC candidate miRNAs that were identified from the microarray, 17 
showed the same trend in expression (i.e., upregulated or downregulated) in the 
independent samples in response to AngII. In addition, Candesartan treatment produced 
distinct response for these miRNAs.  Either the miRNA expression was reversed or 
miRNA expression was less diminished compared to treatment with AngII (Figure 5.1 
B).  Both types of responses suggest that these miRNAs do respond to AngII activation of 
the AT1R, however, the variability in the type of response may point to additional 
regulatory events downstream of the receptor. Taken together, our data demonstrate that 
AngII activation of AT1R in VSMCs produces a specific miRNA signature that is 
validated independently.  
Figure 5.1. RT-qPCR validation of VSMC miRNAs. A) Relationship of AT1R cellular 
levels and miRNA expression analyzed by the stem-loop primer-based real-time RT-
qPCR. Expression of 4 representative miRNAs was monitored in RASMCs and RASMC-
AT1R cells (n = 3). Data are presented as fold over U6 RNA internal control following 
normalization. B) MiRNA expression modulated by AT1R-specific ligands. Change of 
expression of 20 miRNA in the AT1R RASMCs following 1uM AngII or Candesartan 
treatment for 24 hours (n = 3).  Data are presented following normalization to U6 RNA, 
the cellular levels of which did not vary under different experimental conditions and 
standardization to an untreated control. 
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5.3 Modulation of the AngII-regulated VMSC miRNA Pool 
Transcriptional regulation of miRNA genes and posttranscriptional processing of 
pri-miRNA could be affected by AT1R-regulated kinases. Therefore, we blocked PKCζ, 
MEK1, JAK2, JNK, and p38 cascades during AngII activation of the AT1R and measured 
the effects on cellular miRNA levels. Inhibitors of PKCζ, JNK, and p38 did not interfere 
with AngII-mediated miRNA regulation, but inhibitors of JAK2 and MEK1 had a 
significant effect. 
 
To examine whether the AT1R-activated MEK1 and JAK2 pathways regulate the 
miRNA pool globally or if miRNAs are regulated individually, the RASMC-AT1R cells 
were pretreated with inhibitors of MEK1 or JAK2 and were then treated with AngII and 
processed.  As shown in Figure 5.2 A and B, the effect of MEK1 inhibition (iMEK1) was 
monitored by a decrease in ERK1/2 phosphorylation and the effect of JAK2 inhibition 
(iJAK) was monitored by a decrease in phosphorylation of STAT3. Under conditions of 
inhibition, both blockers had an effect that was of equal strength or exceeded the 
inhibition of the AT1R caused by Candesartan.  We observed no significant change in the 
expression of the endogenous U6 control RNA under the same experimental conditions.  
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Figure 5.2. Inhibition of AngII-mediated ERK1/2 and STAT3 phosphorylation. A) 
Activation of phospho-ERK1/2 and phospho-STAT3 (Y705) in AT1R RASMCs samples 
untreated (lane 1), treated with 1µM AngII (lane 2), 1µM Candesartan +0.1µM AngII 
(lane 3), 30µM MEK1 inhibitor +1µM AngII (lane 4), and 5µM JAK inhibitor +1µM 
AngII (lane 5) was visualized. B) Densitometry quantification of iMEK1 and iJAK 
effects on phosphorylation of ERK1/2 and STAT3.  The MEK1 inhibitor (iMEK1) 
completely inhibited ERK1/2 phosphorylation and the JAK inhibitor (iJAK) inhibited 
approximately 98% of STAT3 phosphorylation (n = 3, p < 0.01). 
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The RT-PCR data in Figure 5.3 shows that levels of miR-483-3p, miR-33 and 
miR-301b increased, but the levels of miR-188-5p and miR-208a were not significantly 
altered by MEK1 blockade. In contrast, inhibition of JAK2 had the opposite effect. When 
JAK2 was blocked, the levels of miR-188-5p and miR-208a increased while the levels of 
miR-483-3p, miR-33, and miR-301b did not significantly change.  
 
Combined iMEK1 and iJAK2 impacted all five miRNAs, demonstrating that 
MEK1 and JAK2 are essential for the AngII-mediated modulation of distinct miRNAs. 
Furthermore, loss of any individual protein kinase function is not compensated by the 
remaining cellular kinases, which suggests a parallel, non-overlapping effect of different 
signaling circuits on miRNA regulation. Our data identifies non-redundant roles played 
by MEK1 and JAK2, emphasizing non-canonical pathways. 
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Figure 5.3. Effect of kinase inhibition, iMEK1 and iJAK2, on miRNA levels. Levels 
of miRNA in AT1R RASMCs monitored by qRT-PCR after inhibition of the AngII-
specific kinases, MEK1 and JAK. The 5 candidate miRNAs tested exhibited a distinct 
changes, for instance changes in miR-483-3p (p < 0.0001), miR-188-5p (p = 0.0005), and 
miR-301b (p < 0.0001) expression observed under iMEK1 and changes in miR-33 (p = 
0.0002) and miR-208a (p = 0.004) expression observed under iJAK2 condition (n = 3).   
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Kim et al showed that the proteins involved in miRNA biogenesis (e.g., Drosha, 
TRBP, Dicer, Ago 2) could be phosphorylated by protein kinases. Accordingly, AngII-
activated kinases may potentially target Drosha, TRBP, Dicer, or Ago 2 to regulate 
biogenesis or degradation of miRNAs (Kim et al., 2010) (Figure 5.4 A). As a means to 
understand the mechanism of AngII-induced miRNA regulation, we looked at AngII-
mediated signaling molecules that could alter expression of miRNA biogenesis proteins 
and thereby alter the expression of the miRNAs.  In RASMC-AT1R samples, we 
analyzed total protein levels of Drosha, TRBP, and Ago2 by western immunoblotting to 
determine if these miRNA maturation proteins were affected by inhibition of MEK1 and 
JAK2.  We observed that upon inhibition of these kinases, there was no change in total 
protein levels of Drosha, TRBP, or Ago2 when compared to AngII treated samples 
(Figure 5.4 B). This suggests that post-translational modification of these biogenesis 
proteins is the driving force behind altering the miRNA pool or that other components all 
together are participating in altering the AngII/AT1R induced expression of miRNAs.   
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Figure 5.4. Mechanism of AngII-induced miRNA regulation. A) Pri-miRNAs are 
processed by a number of proteins within the nucleus and cytoplasm to yield the mature 
miRNA. A recent review reported that protein factors, which are involved in the miRNA 
biogenesis pathway, can be subjected to various posttranslational modifications (Kim et 
al., 2010). B) Total protein levels for Drosha, TRBP, and Ago2 in RASMC-AT1R 
samples untreated (lane 1), treated with 1µM AngII (lane 2), 1µM Candesartan +0.1µM 
AngII (lane 3), 30µM MEK1 inhibitor +1µM AngII (lane 4), and 5µM JAK inhibitor 
+1µM AngII (lane 5) was visualized. The corresponding plots show densitometry values 
for each protein normalized to actin. There is no change in total levels of these three 
proteins  (n = 1).  
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The results presented in this chapter display evidence of unconventional 
regulation of miRNA levels in VSMCs through AT1R signaling. Our data indicate that 
AT1R signaling through JAK2 and MEK1 regulate two completely independent miRNA 
pools. Both MEK1 and JAK2 inhibitors inhibited ERK1/2 activation, but these inhibitors 
affected distinct miRNAs, suggesting that the AngII-activated JAK2 and MEK1 signaling 
alters non-canonical and perhaps miRNA-specific regulatory steps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI 
MIR-483-3P: A NOVEL ANGII-REGULATED MIRNA 
 
 
6.1 Introduction 
 The genome-wide miRNA expression profiling provided us with a subset of 
AngII-responsive miRNAs across various model systems. For this study, we focused our 
efforts on a single VSMC-specific miRNA, miR-483-3p, which until now had an 
unknown functional role in SMC biology.  
 
 The role of miR-483-3p in SMC physiology and pathology is unknown. Since 
2010 several groups have reported a functional role for miR-483-3p in various in vitro 
and in vivo systems, which gives us confidence that this miRNA could also possess an 
important function in our model system. Veronese and colleagues observed that miR-
483-3p was overexpressed in 100% of Wilms’ tumors and highly expressed in 30% of the 
cases of colon, breast, and liver cancers (Veronese et al., 2010).  Coregulation with IGF2 
mRNA was detected in some, but not all tumors, suggesting that the miRNA can act 
concomitantly or autonomously as an oncogene.  MiR-483-3p was observed to regulate 
the proapoptotic protein PUMA, acting as an antiapoptotic oncogene.  The same group 
reported that miR-483 expression could be induced independently of IGF2 by the 
oncogene beta-catenin.  They also show that beta-catenin is a target of miR-483-3p, 
triggering a negative feedback loop that becomes ineffective in cells harboring a beta-
catenin mutation (Veronese et al., 2011).  It has been reported that miR-483-3p is 
strongly enhanced in pancreatic cancer and that Smad4 is a direct target of miR-483-3p, 
promoting cell proliferation and colony formation in vitro (Hao et al., 2011).  In a non-
cancerous disease state, miR-483-3p was implicated in regulating melatonin synthesis 
and expression in adipose tissue of diabetics (Ferland-McCollough et al., 2012). Most 
recently, miR-483-3p was observed to target CDC25A and contribute to cell-cycle arrest 
(Bertero et al., 2013). 
 
Important for our purposes, researchers demonstrated that miR-483-3p is 
upregulated in 2 distinct epithelial models of wound healing (scratch and wounded skin).  
They show that 483-3p expression peaks at the final stage of wound closure (Bertero et 
al., 2011).  In addition, the study determined that miR-483-3p inhibits keratinocyte 
migration and proliferation and use of an antagomir rescues this observation.  Kinase 
MK2, proliferation marker MK167, and transcription factor YAP1 were confirmed to be 
direct targets of miR-483-3p in this study.  Finally, it has been observed that Igf2 derived 
miR-483 can induce proliferation in hepatocellular carcinoma cells (Ma et al., 2012).  
The group showed that suppressor of cytokine signaling 3 (Socs3) is a target of miR-483.   
 What has yet to be determined regarding miR-483-3p is its role as an AngII 
responsive miRNA in VSMC behavior. In this chapter we describe the logic behind 
choosing miR-483-3p for in-depth analysis and the importance that this miRNA could 
have in terms of AngII biology.   
 
6.2 Selection of miR-483-3p for Analysis 
We performed extensive bioinformatic analyses on each of the 26 VSMC-specific 
miRNA that we obtained from our genome-wide miRNA expression profiling 
experiment. We completed miRNA target prediction analyses using Target Scan, 
DIANA, PITA, and MicroCosm databases.  Additionally, we utilized Ingenuity Pathway 
Analysis (IPA) to construct functional networks of the miRNAs with their predicted 
targets.  We eliminated miRNA candidates that had already been extensively studied and 
focused on those VSMC-specific miRNAs that would have some role in SMC 
physiology. Of the 21 downregulated miRNAs and 5 upregulated miRNAs, we chose 
miR-483-3p, which is significantly downregulated in response to chronic AngII treatment 
(Figure 6.1).  
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Figure 6.1. Volcano plot of VSMC-specific miRNAs. The volcano plot shows the log2 
fold change in expression of miRNAs whose abundance is significantly altered in 
response to AngII.  MiR-483-3p was observed to be significantly downregulating in 
response to AngII receptor activation (depicted with a solid arrow).  
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Tissue RAS activation is known to be a major cause of SMC disease. Therefore, 
we sought to explore the involvement of miRNAs in potentially targeting components of 
RAS. We examined the 3’-UTRs of each RAS component (e.g., Renin, Renin Receptor, 
AGT, ACE-1, ACE-2, AGTR1, AGTR2, AT4 receptor, Ang(1-7) Receptor)  to see which 
of the VSMC-specific miRNAs could potentially target these genes. We observed that 
miR-33 could potentially target the AT1R. MiR-33, an intronic miRNA located within the 
gene encoding sterol-regulatory element-binding factor-2 (SREBF-2), has been 
extensively studied and has been shown to be a regulator of cholesterol metabolism. The 
miRNA targets the adenosine triphosphate-binding cassette transporter, thereby 
attenuating cholesterol efflux to apolipoprotein A1. In mouse macrophages, miR-33 also 
targets ABCG1, reducing cholesterol efflux to nascent high-density lipoprotein (Rayner 
et al., 2010).  In addition, we observed that miR-188-5p could potentially target ACE-2.  
This miRNA was previously implicated in homocysteine-induced cardiac remodeling 
during heart failure, wherein the miRNA is downregulated, which upregulates MMP-2, -9 
and TIMP-1, and -3 (Mishra et al., 2009).    
 
MiR-483-3p is one of the 26 VSMC-specific miRNAs that was predicted to 
potentially target 4 key components of the RAS; thereby, regulating the whole pathway. 
The seed sequence of miR-483-3p is complementary to regions within the 3’-UTR of 
AGT, ACE-1, ACE-2, and AGTR2 (Figure 6.1). In addition, complementary regions for 
miR-483-3p exist within the coding regions of AGT and ACE-1, suggesting that this 
miRNA could act most potently in vivo on these genes.   
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Figure 6.1. MiR-483-3p target prediction. Using multiple target prediction databases, 
miR-483-3p was predicted to target the 3’-UTR of AGT, ACE-1, ACE-2, and AGTR2 
with near complete complementarity.  The regions of potential miRNA (red) binding to 
the 3’-UTR (black) of each gene is shown below.  
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During our bioinformatic analysis, we also determined that miR-483-3p does not target 
any of the components of the ANF system, which is a counter-regulatory system to RAS 
with similar complexity. Taken together, this suggests that miR-483-3p could be a 
selective mechanism for regulating tissue RAS.  
 
In addition to miR-483-3p being predicted to target multiple components of tissue 
RAS, it is also known that the gene for miR-483 is encoded within intron 2 of Insulin-like 
growth factor 2 (IGF2). IGF2 is an imprinted gene with expression resulting favorably 
from the paternally inherited allele. It has growth-regulating, insulin-like and mitogenic 
activities. IGF2 is believed to be a major growth factor during gestation, as it promotes 
development of fetal pancreatic islet cells (Bergman et al., 2012).  Perhaps most 
importantly, IGF2 is a signaling molecule that is known to interact with AngII signaling.  
Studies have shown that an increase in Igf2 expression in the left ventricle corresponds to 
blood pressure increase (Kadlecova et al., 2008) and that AngII-induced IGF2 gene 
expression has been positively correlated with cardiomyoblast apoptosis in animals with 
hypertension (Lee et al., 2006). In addition, targeted expression of Igf2 transgene in 
SMCs shortens life span, leading to bradycardia and hypotension (Zaina et al., 2003). We 
have observed that in response to chronic AngII treatment, the transcript levels of IGF2 
are enhanced in RASMC-AT1R cells (Figure 6.2).  
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Figure 6.2. IGF2 abundance in VSMCs after AngII treatment. Transcript levels of 
IGF2 were quantitated by RT-qPCR, following treatment of RASMC-AT1R cells with 1 
µM AngII for 24 hours (n = 3). Data are presented following normalization to GAPDH, 
the cellular levels of which did not vary under different experimental conditions and 
standardization to an untreated control. IGF2 is synergistically enhanced, following 
treatment with AngII.  
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Upon transcription of IGF2 in the 3’ direction, 11 transcripts are produced, all of 
which contain intron 2 and the coding region for miR-483 (Figure 6.3). The pri-miRNA 
is independently produced from intron 2 and is processed in the nucleus to yield a 
precursor-miRNA stem-loop structure.  This pre-miR is exported into the cytoplasm 
where it is cleaved to form a double-stranded miRNA duplex of miR-483-5p and miR-
483-3p.  The guide strand of this duplex, which is miR-483-3p (or the antisense strand) in 
our case, is loaded into RISC and carries out its function by binding to target mRNAs, 
resulting in translational repression.   
 
  Additional observations were made during our bioinformatic analyses of miR-
483-3p, which suggested that this miRNA is favored over its hairpin counterpart, miR-
483-5p. First and foremost, the AngII stimulated miRNA profile showed only miR-483-
3p as being significantly altered in the VSMC model systems.  RNA sequencing 
databases also consistently show that miR-483-3p is the most frequently expressed and 
conserved miRNA across a range of species (Figure 6.4).  Finally, by looking at the 
sequence of the miRNA itself, we see that miR-483-3p is very AU-rich, which makes it a 
perfect candidate for seed recognition by Ago2 and loading into RISC for translational 
silencing.  
 
The results described in this chapter provide the logic and reasoning for selection 
of the novel AngII-regulated miR-483-3p from the 26 VSMC-specific miRNAs.  Due to 
the ability of this miRNA to potentially target and regulate multiple components of the 
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RAS and its location within the genome, miR-483-3p is a prime candidate for 
understanding the functional role of AngII-responsive miRNAs in SMC biology.   
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Figure 6.3. MiR-483 encoded in intron 2 of IGF2. Pri-miR-483 is encoded in and 
produced from intron 2 of IGF2.  Following processing by canonical miRNA biogenesis 
proteins, pre-miR-483 is exported into the cytoplasm where it is further processed to 
yield the mature miR-483-3p, which has a functional role.  
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Figure 6.4. MiR-483-3p expression is favored over miR-483-5p expression. Deep 
sequencing efforts by miRBase have shown IGF2 encoded miR-483-3p to be expressed 
by all species, but miR-483-5p has only been shown to be experimentally expressed in 
human and mouse.  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VII 
EXPRESSION AND FUNCTIONAL ROLE OF MIR-483-3P 
 
 
7.1 Introduction 
Characterization of individual miRNAs is important in order to fully understand 
the biological role that these small, non-coding RNAs possess.  Therefore, it is imperative 
to examine both the expression pattern of the miRNA of interest and also to determine its 
functionality, in terms of ability to translationally suppress predicted target genes.  In this 
chapter we describe both of these aspects for miR-483-3p as a means to understand its 
role in regulating tissue RAS.   
 
7.2 Validation of miR-483-3p 
Using two independent assays, we were able to validate miR-483-3p expression in 
RASMC-AT1R samples treated with AngII.  In the RNA solution hybridization assay, we 
detected and visualized miR-483-3p expression using a 32P labeled antisense probe 
specific for miR-483-3p.  Following time-course treatment with AngII, total RNA was 
isolated and hybridized to the miR-483-3p probe.  Recovered hybrids were analyzed on a 
denaturing polyacrylamide gel (Figure 7.1. A). The densitometry for miR-483-3p and 
miR-16 (control) for a single experiment (upper panel) and the calculated fold change in 
expression of miR-483-3p compared to miR-16 is shown in triplicate (lower panel) in 
Figure 7.1 B.   
 
We have also detected this miRNA by RT-qPCR using a miR-483-3p specific 
primer. Following treatment with either AngII or Candesartan, levels of miR-483-3p 
were quantified in RASMC-AT1R cells (Figure 7.2). We observed a decrease in miR-
483-3p expression upon treatment with AngII and an increase in expression upon 
treatment with Candesartan.   
 
In both assays, miR-483-3p showed the same trend in expression (i.e., 
downregulated) in the independent samples in response to AngII as we observed in the 
profiling experiment. In addition, Candesartan treatment produced a distinct response, in 
which miR-483-3p expression was reversed.  Validation of this miRNA in independent 
VSMC samples gives us confidence that miR-483-3p is robustly regulated by AngII 
receptor activation.   
Figure 7.1. Detection of miR-483-3p by solution hybridization. A) Following 
treatment with 1µM AngII at various time points, total RNA from RASMC-AT1R cells 
was hybridized to a miR-483-3p radiolabeled probe and analyzed by denaturing 
polyacrylamide gel electrophoresis (lanes 6-10, red box). The miR-16 probe was utilized 
as a control and detected in mouse kidney RNA (lane 3). Each probe was loaded without 
(lanes 1 and 4) and with (lanes 2 and 5) RNase digestion. B) The corresponding plots 
show the densitometry analysis of miR-483-3p (closed bar) and miR-16 (open bar) for a 
single experiment (upper panel) and the calculated fold change for miR-483-3p 
normalized to miR-16 (n = 3; ** p = 0.0005, *** p = 0.0001) (lower panel).  
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Figure 7.2. Quantitation of miR-483-3p by RT-qPCR. MiRNA expression modulated 
by AT1R-specific ligands. Change of expression of miR-483-3p in the AT1R RASMCs 
following 1uM AngII or Candesartan treatment for 24 hours (n = 3).  Data are presented 
following normalization to U6 RNA, the cellular levels of which did not vary under 
different experimental conditions and standardization to an untreated control. 
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7.3 Muscle Cell Lineage Expression of miR-483-3p 
We demonstrated that miR-483-3p is selectively expressed in various human and 
rodent VSMCs and validated its expression by two distinct methods. As a means to 
determine its expression across a broad range of cell types, we utilized the solution 
hybridization technique to detect miR-483-3p.  Interestingly, we have found miR-483-3p 
to be present at basal levels in cardiac (HL-1, H9C2), kidney (NRK52E), and carcinoma 
cell lines (MCF-7, NC1-H295R) (Figure 7.3).  Each of the cell types in which miR-483-
3p is present at basal levels are important in tissue RAS, suggesting that miR-483-3p may 
be an important regulator of the RAS in these cell types.   
 
Importantly, we do not detect miR-483-3p in HEK 293 or HEK-AT1R cells after 
treatment with AngII via solution hybridization (Figure 7.4).  This observation, along 
with selective expression of miR-483-3p in VSMCs and cardiomyocytes (HL-1) allows 
us to be further confident in classifying this miRNA as a muscle cell lineage specific 
miRNA.     
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Figure 7.3. Basal miR-483-3p expression across various cell lines. A) Solution 
hybridization of total RNA from multiple cell lines shown below to a radiolabeled probe 
specific to miR-483-3p was performed. B) Densitometry analysis in provided in the 
corresponding plot for each sample. Expression in the RASMC line was considered basal 
expression for our purposes. Anything at or above that level was important.   
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Figure 7.4. MiR-483-3p is undetectable in HEK-AT1R cells.  Using RASMC-AT1R 
cells for comparison, we performed solution hybridization of total RNA from HEK-AT1R 
cells to miR-483-3p specific probe, following treatment with 1 µM AngII at various time 
points (lanes 6-15).  miR-16 probe was used as a control and detected in mouse kidney 
RNA (lane 3). Each probe was loaded without (lanes 1 and 4) and with (lanes 2 and 5) 
RNase digestion.  miR-483-3p was undetectable in the HEK cell line.  
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7.4 Functionality of miR-483-3p 
 To determine the functionality of miR-483-3p in vitro we constructed 3 
independent cell lines using the miR-483 expression cassette.  HEK-293T, RASMC, and 
RASMC-AT1R cells were nucleofected with pRNA U6.1-miR483.  Cells were cultured 
in selection medium containing hygromycin and clones were screened for miR-483-3p 
expression by solution hybridization.  We chose clones with the highest detectable level 
of miR-483-3p for use in our functional assay.  Clone #5 in HEK-293T cells (Figure 7.5), 
clone #3 in RASMC, and clone #10 in RASMC AT1R cells (Figure 7.6) was chosen as 
the highest expressing clone and used for further analyses.  Control cell lines were also 
constructed with the pRNA U6.1 empty expression vector and exposed to hygromycin 
selection. 
 
The HEK-293T-miR483 cells were primarily used for analysis of miR-483-3p 
targets in a functional luciferase assay.  We cloned the 3’UTRs of AGT, ACE-1, ACE-2, 
and AGTR2 into a dual luciferase expression vector. Following transfection of the HEK-
293T-miR483 cells with the 3’-UTR constructs, the cells were subjected to a luciferase 
substrate and firefly luciferase activity was measured.  The cell lysates were then 
subjected to a second luciferase substrate and Renilla luciferase activity was measured. 
The Renilla luciferase expression was then normalized to firefly luciferase activity.   
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Figure 7.5. Stably expressing miR-483-3p in HEK-293T cells. Of the 10 clones that 
were picked for HEK-293T cells, we chose clone #5 as having the highest level of miR-
483-3p expression, which was determined by solution hybridization. Phase-contrast 
images (15X) of live cells in culture are shown for both the vector control and miR-483 
lines.  
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Figure 7.6. Stably expressing miR-483-3p in RASMC and RASMC-AT1R cells. Of 
the 10 clones that were picked for both RASMC and RASMC-AT1R cells, we chose 
clone #3 and clone #10, respectively as having the highest level of miR-483-3p 
expression as determined by solution hybridization. Phase-contrast images (15X) of live 
cells in culture are shown for both the vector control and miR-483 lines.     
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In our vector system, Renilla luciferase expression is stabilized by the presence of 
the 3’UTR, and activity decreases in each case in the presence of miR-483-3p.   In 
addition, in the presence of an antagomiR specific to miR-483-3p, we are able to rescue 
the luciferase expression in each 3’-UTR example (Figure 7.7).  Thus, miR-483-3p can 
effectively initiate the RNAi process on the target 3’-UTR, suggesting that this miRNA 
could be a global regulator of tissue RAS.  
 
In addition to the functional readout for the luciferase assay, we also monitored 
levels of endogenous AGT and ACE-1 by western immunoblotting in the RASMC-AT1R 
cells stably expressing miR-483-3p. We demonstrated that in the presence of the miRNA 
protein levels of AGT and ACE-1 decreased, which can be rescued with the antagomir 
for miR-483-3p (Figure 7.8). The suppression of ACE-1 levels was not as dramatic as the 
effect of miR-483-3p on AGT, suggesting that miR-483-3p more strongly regulates AGT 
endogenously. Unfortunately the AGTR2 and ACE-2 primary antibodies utilized were 
not functional. We also looked at mRNA levels of the 4 targets and observed no change 
in AGT, ACE-1, ACE-2, or AGTR2 transcripts in the presence of miR-483-3p. Thereby 
suggesting that miR-483-3p is acting post-transcriptionally on these target genes.  
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Figure 7.7. MiR-483-3p targets components of tissue RAS. HEK-293T-miR483 cells 
were transfected with a 3’-UTR construct and both firefly and Renilla activity were 
measured. In each 3’-UTR target assay, Renilla luciferase activity decreased in the 
presence of miR-483-3p. When a miR-483-3p specific antagomir was introduced into the 
system, the dampened luciferase activity was rescued to basal levels.     
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Figure 7.8. MiR-483-3p alters expression of endogenous AGT and ACE-1. A) 
Western immunoblotting for endogenous AGT and ACE-1 in RASMC-pRNA (lane 1), 
RASMC-miR483 (lane 2), and RASMC-miR483 + antagomir (lane 3) was visualized.  B) 
Densitometry quantification of AGT and ACE-1 levels. Transfection of an antagomir 
specific for miR-483-3p significantly reduced the levels of AGT, but had a lesser effect 
on ACE-1 levels (n = 3; *p < 0.05).    
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We have demonstrated that upon stimulation with AngII, the AT1R is activated, 
leading to a decrease in miR-483-3p expression, which would ultimately result in an 
increase in the RAS targets of this miRNA. In our initial efforts of understanding the 
mechanism by which the VSMC-specific miRNAs are regulated by AngII, we utilized 
MEK1 and JAK2 inhibitors and monitored miRNA expression. We observed that upon 
inhibition of MEK1 only, miR-483-3p expression increased. An increase in miR-483-3p 
expression would lead to a decrease in RAS target expression (Figure 7.9 A).   Following 
inhibition with MEK1 and JAK2, we monitored levels of AGT and ACE-1 by western 
immunoblotting.  We determined that MEK1 inhibition causes a decrease in endogenous 
AGT, but we don’t see the effect with ACE-1 (Figure 7.9 B).   This result further 
solidifies the idea that miR-483-3p acts most potently on AGT.   
 
The results presented in this chapter provide significant insight into the expression 
pattern and functional role of miR-483-3p in targeting and regulating tissue RAS.  We 
have demonstrated expression of this miRNA in multiple cell types of muscle cell 
lineage, which is important for cardiovascular biology and for fully understanding the 
effects that AngII has on those tissues. Additionally, we have shown that miR-483-3p, 
which is in part regulated by the AngII-mediated kinase MEK1, functions biologically to 
inhibit multiple components of the RAS. From our studies, endogenous AGT appears to 
be most altered in response to miR-483-3p expression.  Demonstrating that this VSMC-
specific miRNA has a functional role prompted us to determine whether miR-483-3p 
could affect VSMC behavior and phenotype.  
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Figure 7.9. Effect of MEK1 inhibition on endogenous AGT and ACE-1. A) AngII 
stimulation of the AT1R causes activation of the AngII-mediated kinase MEK1, which 
leads to a decrease in miR-483-3p expression and a subsequent increase in RAS target 
genes.  Conversely, inhibition of MEK1 leads to an increase in miR-483-3p, which 
should lead to a decrease in RAS target genes. B) Following kinase inhibition of 
RASMC-AT1R-miR483 cells, we detected a decrease in AGT, but not ACE-1 by western 
immunoblotting (lane 4, n = 1).  
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CHAPTER VIII 
MODULATING VSMC PHENOTYPE 
 
 
8.1 Introduction 
To further characterize the function of miR-483-3p, we have observed its effects 
on VSMC phenotype.  It is well known that various stimuli, including AngII, can cause 
VSMCs to switch between contractile and proliferative states due to global gene 
expression changes, which play a central role in cell motility and diverse vascular 
diseases. Understanding the extent to which miR-483-3p plays a role in this phenomenon 
will reveal if this miRNA acts as a critical regulator of cellular phenotype as a potential 
player in various vascular pathologies (Figure 8.1).  
Figure 8.1. Effect of miR-483-3p on VSMC phenotypic switching. Due to the high 
density of AT1 receptors on VSMCs, AngII is able to induce VSMCs to switch from a 
contractile to the synthetic state, which can ultimately lead to increased cell motility and 
vascular abnormalities.   
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8.2 Effects of miR-483-3p on VSMC Migration 
To determine the involvement of miR-483-3p in VSMC in vitro migration we 
utilized the RASMC-AT1R cells, stably expressing miR-483-3p.  Using a standard 
wound-healing assay, we monitored cell movement into a wounded or cleared area for a 
period of 24 hours.  We performed this experiment in the presence of 1 µM AngII and 
Candesartan to understand the effects that AT1R-specific ligands would have on this 
phenomenon.   
 
In cells that were left untreated, there was no significant difference in the 
wounded area when comparing presence and absence of miR-483-3p. We observed that 
by 8 hours, miR-483-3p action significantly decreased AngII-mediated VSMC migration 
when compared to conditions where the miRNA was absent (Figure 8.2 A).  This same 
effect was observed under treatment with Candesartan.   The area of the wound was 
determined, in relation to the total area, for each well and the percent wound area was 
calculated (Figure 8.2 B).  
 
The results discussed in this chapter examine a novel role of miR--483-3p in 
mediating VSMC phenotype. In response to AngII, VSMCs enter into the synthetic and 
migratory phenotype, giving rise to vascular pathologies. MiR-483-3p functions to slow 
the rate of AngII-mediated VSMC migration in culture, thereby suggesting that when this 
miRNA is downregulated in response to AngII molecules involved in cellular movement 
would be independently and adversely increased. This effect could ultimately give rise to 
vascular abnormalities in vivo.   
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Figure 8.2. MiR-483-3p decreases AngII-mediated cell migration. A) Wound healing 
was observed in RASMC-miR483 and RASMC-pRNA untreated (panel 1), treated with 1 
µM AngII (panel 2), or 1 µM Candesartan (panel 3) for a period of 24 hours. By 8 hours, 
RAMSC-miR483 cells exhibited a decrease in AngII-mediated migration (red box). In 
addition, in cells containing miR-483-3p and treated with Candesartan, the cell migration 
was decreased. B) The corresponding plot shows the quantitation of the results using 
ImagePro Plus software.  The area of the wound and the total area at time 0h and 8h were 
determined for 2 different positions in each well (n = 3; ns, not significant, *** p = 
0.0003, ** p = 0.0045).   
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CHAPTER IX 
FUTURE DIRECTIONS 
 
 
9.1 Comprehensive Description of miR-483-3p 
As a means to fully characterize the function of miR-483-3p, we will turn to 
monitoring the effects of miR-483-3p on additional phenotypic phenomena, including 
adhesion and proliferation via thymidine (DNA) or leucine (protein) incorporation.  
Additionally, we aim to determine the ability of this miRNA to regulate the cell cycle.  
We have performed one cell cycle analysis and observed that miR-483-3p has the ability 
to alter the number of cells in the G2 phase; however, additional experiments need to be 
performed in order to wholly demonstrate the effect of miR-483-3p on cell cycle control.  
A critical aspect of our study is to understand the mechanism by which miR-483-3p 
effects AngII-mediated VSMC migration.  In so doing, we will determine changes in 
contractile proteins (e.g., α-actin, myosin) and possible secretion of SMC-specific ECM 
components (e.g., collagen, fibronectin, laminin, tenascin) that would be important in 
regulating phenotypic alterations. Further, we will determine if miR-483-3p affects the 
secretion of AngII-specific cytokines (e.g., MCP-1, IL-1, IL-6, TNF-α) and chemokines  
(e.g., RANTES, IP-10, CyPB) and accumulation of reactive oxygen species, all of which 
have been previously shown to play a role in VSMC physiology and pathology.  Taken 
together, these future studies will allow us to determine the full capacity of the AngII-
regulated miR-483-3p on vascular biology.   
 
Ultimately, our goal is to see if the effect miR-483-3p has in the cellular system 
(i.e., inhibition of RAS components and ability to decrease VSMC migration) is also a 
phenomenon that can bee seen in vivo. We would expect that expression of the miRNA 
would protect the vessels against activation of tissue RAS, creating an overall beneficial 
effect. Thereby, preventing VSMCs from entering into the synthetic migratory 
phenotype.  Using a lentiviral system, we will first recapitulate the effect of miR-483-3p 
in VSMCs infected with the lentivirus produced from a viral vector (Figure 9.1). The 
BLOCK-IT™ technology from Life Technologies is designed to express artificial 
miRNAs. Using this system, a double-stranded DNA oligonucleotide encoding miR-483 
would be cloned into one of the BLOCK-iT™ entry expression vectors and the miRNA 
cassette would be transferred into the lentiviral destination vector by Gateway® 
recombination. The vectors would be transfected into the viral producer cells to produce 
viral stocks, which can be used immediately or stored at –80°C. The viral supernatants 
would be harvested and the viral titer determined. Finally, the lentiviral stocks could be 
transduced to any cell type, specifically VSMCs.  
 We will then monitor the effect of miR-483-3p in a hypertensive mouse model by 
injecting the virus into the tail vein (Figure 9.2).  One mouse model utilized in hypertensive 
research consists of crossbreeding a transgenic mouse containing the human renin gene (hRN 
8-12; 10 copies of a 15 kbp human DNA fragment containing the renin gene) with a 
transgenic mouse for human angiotensinogen (hAG 2-5; 100 copies of a 14 kbp human DNA 
fragment containing the angiotensinogen gene).  This results in a mouse with high blood 
pressure.   
 
By monitoring the phenotype of these animals, through either determining that this 
miRNA could prevent or reduce development of hypertension (by measuring blood pressure) 
and vascular changes (by examining vessel wall thinning), we would be able to determine if 
tmiR-483-3p has the capability of regulating a physiological phenomenon in vivo, such as the 
RAS.  
 
Overall, observing the full effect of miR-483-3p in vitro and in vivo will allow us to 
understand its capacity as a regulatory molecule.  Most importantly, we will be able to 
discern its involvement in RAS pathologies within the cardiovascular system.   
 
Figure 9.1. Lentiviral expression system. Viral delivery of RNAi vectors is a powerful 
alternative to transfection for primary cell types as well as for in vivo applications. The 
procedure for creating a lentiviral expression system consists of cloning the double-stranded 
DNA oligonucleotide encoding a miR RNAi into one of the BLOCK-iT™ entry expression 
vectors. The RNAi cassette is transferred into the lentiviral destination vector by Gateway® 
recombination and transfected into the viral producer cells to produce viral stocks, Viral 
supernatants are harvested and titers are determined. Finally, the lentiviral stocks can be 
transduced into any cell type of used in vivo (From Life Technologies).  
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Figure 9.2. Genetic murine models constructed to exhibit increased blood pressure. 
Through manipulation by overexpression (yellow) or knockout (orange) of various 
components of the RAS, hypertensive mouse models exist and are useful for understanding 
biological functions in vivo From (Lerman et al., 2005).  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
CHAPTER X 
DISCUSSION 
 
10.1 The Implications of Genome-wide MiRNA Profiling in Response to AngII 
It has become increasingly apparent over time that the complexity of RAS is 
immense.  Securing AngII through its interaction with the AT1R as a powerful regulator 
of gene expression has given much insight into the potent role for this vasoactive 
hormone in cardiac biology and disease. Intracellular signaling mediated through AT1R 
activation by AngII has a prominent place in vascular and endothelial physiology and 
dysfunction. 
 
The unbiased miRNA profiles presented here may bridge the gap in our 
knowledge concerning the molecular basis of pathogenesis during chronic RAS 
activation, which increases angiotensinergic risk associated with morbidity and mortality 
from cardiovascular diseases. In many clinical settings, targeting RAS is an important 
therapeutic paradigm. Our study provides insights regarding how RAS-targeted therapies 
may affect miRNAs. This study was designed for global miRNA expression profiling in 
biological replicates following chronic AngII activation. Thirty-two miRNAs were AngII 
regulated in most human and rodent samples. Expression of these miRNAs were 
antagonized following AT2R activation by AngII and Losartan blockade of AT1R in both 
VSMCs and HEK-AT1R cells, suggesting that expression of these miRNAs is a hallmark 
of AngII action through the AT1R, which is targeted in most clinical settings. The 
inclusion of RNA derived from tissue, primary cells and established cell lines in our 
analysis demonstrates that this miRNA fingerprint is not derived from complex 
heterotypic cell-cell interactions nor influenced by a multitude of endocrine, paracrine or 
autocrine and neuronal influences, a common confounding problem in many analyses. 
 
The identified miRNA profile discussed in this study reflects common AngII-regulated 
changes in humans and rodents, a miRNA fingerprint of RAS action through the AT1R. 
Though we did not determine how alterations in these miRNAs functionally affect the in 
vivo response to AngII, we propose that these miRNAs play a significant role in AngII 
mediated physiology and pathogenesis. If the miRNAs we identified can be shown to 
play a role in RAS function in vivo, they may represent new biomarkers of injury caused 
by RAS and should serve as useful prognostic markers during RAS targeted therapy.  
 
10.2 Specificity of MiRNA Expression 
Demonstrating miRNA specificity is important in elucidating the regulation of 
these small RNAs. Inclusion of losartan treated AT1R as well as AngII treated AT2R 
expressing control samples demonstrated specificity of the AngII effect through the 
AT1R in our profiling experiments. The miRNA changes in individual comparisons 
showed a range between 60 and 234 miRNA genes per sample (Fig. 3.2 & 3.3).
This finding is consistent with the miRNA expression profiles characterized in complex 
tissues, sorted cells and individual cell lines, which demonstrated that on average ≈70-
150 miRNA genes were expressed per sample (Landgraf et al., 2007, Chiang et al., 
2010). Our finding of ≈30 miRNAs (Table IV.I) ubiquitously expressed in cell lines and 
tissue samples from rodents and human is also consistent with the observation in model 
studies for basic mechanisms of stem cell maintenance, hormonal differentiation, and 
malignant transformation to organ systems, in which the authors estimated ≈30-40 
ubiquitously expressed miRNAs per sample (Chiang et al., 2010, Landgraf et al., 2007).  
 
In addition, several miRNAs mapped to multicopy miRNA genes (Table III.VIII). 
Expression of a specific miRNA or a select few from the cluster suggests stimulus-
specificity of processing of individual miRNAs from polycistronic pri-miRNA 
transcripts, as previously observed in human studies (Baskerville and Bartel, 2005). A 
third of the remaining miRNAs were expressed with a high degree of cell specificity 
(e.g., miRs-365, -699, -490, -434-3p, -675-3p are cardiomyocyte-specific).  
 
 Additionally, the expression of some miRNAs was only altered under one 
treatment condition (e.g., miRs-546, -100, -92a are strictly Losartan modulated) or only 
altered in one cell type (e.g., miRs- 376a*, -487b, -154*, -539, -376c* are expressed in 
HEK-AT1R cells only).  Tissue-specific factors might be essential for biogenesis of 
tissue-specific miRNAs, and therefore might be sensitive to the potential absence of such 
factors in some cells and tissues. Taken together, these findings are consistent with the 
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tissue and cell-type specific regulation of miRNAs in response to AngII and the potential 
role of these miRNAs in physiology and in various diseases.  
 
As an important RAS hormone, AngII must play a wider role in regulating the 
relative abundance and specificity of expression of miRNAs in order to regulate a variety 
of physiological and adaptive tissue remodeling processes. Thus, the miRNA regulation 
is a critical aspect of effectiveness of hormones such as AngII in various cells.  
 
10.3 A SMC-specific MiRNA Signature 
Regulation of miRNAs in VSMCs by a local increase in AngII can adversely 
affect vessel functions due to the high density of the AT1R on VSMCs. Distinct VSMC 
phenotypes accumulate within arteries of individuals with disorders such as systemic and 
pulmonary hypertension, atherosclerosis, and asthma. During insult, VSMCs switch to a 
proliferative phenotype of poor contractility/excitability, exhibit changes in lipid 
metabolism, and have high extracellular matrix production leading to vessel remodeling. 
In contrast, the phenotype of healthy adult VSMCs is restricted cellular plasticity, in 
which the cells are geared for contraction with a unique repertoire of contractile proteins, 
agonist-specific receptors, ion channels, and signaling molecules. Thus VSMCs are an 
interesting model system for studying miRNA-modulated mechanisms of cell 
maintenance, differentiation, and phenotypic modulation (Rensen et al., 2007, Daugherty 
and Cassis, 2004).  
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Regulation of specific miRNAs as contributors to vascular disease (e.g., miR-155, 
-143, -145, -21, -126) has been studied (Urbich et al., 2008), but a comprehensive 
analysis targeting AngII-regulation of miRNAs in VSMCs and its associated diseases is 
lacking. Our analysis of AngII-regulated miRNAs in rat and human VSMC cell lines 
(Table IV.III) indicated for the first time a unique fingerprint consisting of novel 
miRNAs and miRNAs with known functions. As shown in Table IV.III, a significant 
number of the AngII-regulated miRNAs have been implicated in pathogenesis of other 
organs and tissues, implying that a systematic study of their role in vasculature is 
important. Confirmation of the VSMC candidates identified miRNAs that were both up 
and downregulated by AngII signaling through the AT1R.  
 
10.4 Regulation of the AngII-induced MiRNA Pool 
Our data indicate that AT1R signaling through JAK2 and MEK1 regulate two 
completely independent miRNA pools (Figures 5.2 & 5.3). The amount of a specific 
miRNA that exists within a cell is determined by its biogenesis and decay. The 
biogenesis of miRNAs is critically regulated at the level of transcription similar to those 
of protein-coding genes. Regulation of miRNA expression through the MEK/ERK1/2 
interaction with PEA-15 cascade is known.  PEA-15 sequesters ERK1/2 in the cytoplasm, 
thereby inhibiting the ability of ERK1/2 to localize to the nucleus and modulate miRNA 
gene transcription (Romano et al., 2012). Many miRNA genes are transcribed by a 
transcription factor binding to upstream promoters. However, transcriptional regulation 
of miRNA pools by AngII appears unlikely to us for two reasons: (i) transcription of 
miR-483 and IGF2 (the gene that harbors miR-483) were not altered by AngII activation 
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of the RASMC-AT1R cells (data not shown); and (ii) ERK1/2 phosphorylation leads to 
translocation into the nucleus, where gene transcription and pri-miRNA processing are 
regulated.  
 
In our study, both MEK1 and JAK2 inhibitors inhibited ERK1/2 activation, but 
these inhibitors affected distinct miRNAs, suggesting that the AngII-activated JAK2 and 
MEK signaling alters non-canonical and perhaps miRNA-specific regulatory steps. Pri-
miRNA sequence-specific recruitment of Smad proteins (Smad-1 and -5) to the p68–
DROSHA complex in pulmonary artery smooth muscle cells has been reported (Davis et 
al., 2010, Davis-Dusenbery and Hata, 2011). The association between Smads and pri-
miRNAs is primarily controlled by Smad nuclear localization upon TGF-β activation. 
This non-canonical pathway relies on the interaction of the Smad amino-terminus MH1 
domain with R-SBE. R-SBE contains a consensus RNA binding sequence (5’ – CAGAC 
– 3’), which is present in the stem region of miR-21, miR-100, miR-199a-5p, and miR-
27a (Davis et al., 2010).  
 
AngII regulation of distinct miRNAs may involve novel non-canonical pathways. 
Our results suggest a novel Tyr-kinase pathway in miRNA regulation. Kim et al showed 
that the proteins involved in miRNA biogenesis (e.g., Drosha, TRBP, Dicer, Ago 2) 
could be phosphorylated by protein kinases. Accordingly AngII-activated kinases may 
potentially target Drosha, TRBP, Dicer, or Ago 2 to regulate biogenesis or degradation of 
miRNAs (Kim et al., 2010). However, this type of regulation would be expected to alter 
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the miRNA pool in a cell not individual miRNAs, hence this may not be the mechanism 
in our model system.  
 
10.5 MiR-483-3p is a Novel AngII-regulated MiRNA 
In our unbiased genome-wide screen of miRNAs modulated by AngII, we 
identified a subset of 22 miRNAs differentially regulated in VSMCs by AngII activation 
of the AT1R, including one whose predicted gene targets are involved in RAS 
homeostasis.   
 
Identifying miR-483-3p as a novel AngII-regulated miRNA has given us some 
insight into the complexity of miRNA biology.  Not only can many miRNA genes be 
expressed in any given cell type, but they also can regulate a multitude of cellular 
processes within a cell type (Bartel, 2004).  Sequence alignment revealed that one of the 
VSMC candidate miRNAs, miR-483-3p, is encoded within intron 2 of IGF2, a gene that 
encodes a key mitogenic factor (Figure 6.3). Furthermore, the pri-miRNA is highly 
conserved in mammals (Figure 6.4), prompting us to select miR-483-3p for further 
characterization of its role in altering global gene networks, cellular metabolism, and 
VSMC phenotype. 
 
We found that in VSMCs, miR-483-3p is downregulated, whereas, IGF2 
expression is upregulated, suggesting that miR-483-3p is independently regulated by 
AngII signaling (Figure 6.2). Furthermore, VSMCs treated with the AT1R-specific 
inverse agonist, Candesartan showed upregulation of miR-483-3p. Analysis of the 
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kinetics of miR-483-3p induction revealed that upon acute treatment with AngII (0.5 h), 
the miRNA levels increase, however with chronic AngII treatment (24 h), miR-483-3p 
levels are significantly decreased (Figure 7.1), pointing toward a role for this miRNA in 
tissue RAS, which is substantially involved in AngII-mediated vascular pathologies.  We 
next determined whether miR-483-3p was expressed in any other cell types that are 
commonly and adversely affected by local action of AngII. Our observations 
demonstrated that miR-483-3p is expressed in various cell types of muscle cell lineage, in 
addition to a kidney and multiple carcinoma cells types (Figure 7.3), and to a lesser 
extent in epithelial cells (Figure 7.4). Taken together these data reveal that miR-483-3p 
could have a distinct role in mediating vascular abnormalities that arise as a result of 
tissue RAS activation.    
 
10.6 Regulation of the RAS by miR-483-3p 
To gain insight into the function of miR-483-3p, we analyzed its potential gene 
targets, using several miRNA target prediction algorithms (Brennecke et al., 2005). We 
identified putative binding sites for miR-483-3p in the 3′UTR of several genes involved 
in the RAS, including AGT, ACE-1, ACE-2 and the type II receptor, AGTR2, suggesting 
that miR-483-3p coordinates RAS homeostasis (Figure 6.1). To test this hypothesis, we 
determined the effect of miR-483-3p on the expression of AGT, ACE-1, ACE-2 and 
AGTR2 in HEK-293T cells and RASMCs. To assess the effects of miR-483-3p on the 3’-
UTR of human AGT, ACE-1, ACE-2, and AGTR2, we used luciferase reporter 
constructs.  Transfection of HEK-293T-miR483 cells with 3’-UTR constructs for the 
RAS target genes repressed luciferase activity of all 4 targets. These effects of miR-483-
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3p were reversible by co-transfection with an antisense inhibitor of miR-483-3p (anti-
miR-483) (Figure 7.7). MiR-483-3p also repressed AGT and to a lesser extent ACE-1 
protein in RASMCs, indicating that its effects are robust on endogenous protein levels as 
well.  Inhibition of miR-483-3p by anti-miR-483 increased the expression of AGT and 
ACE-1 in RASMCs (Figure 7.8), which is consistent with the hypothesis that miR-483-
3p has a physiological role in regulating the expression of these components of the RAS.  
 
Determining the molecular mechanism by which AngII, through receptor 
activation, can lead to a change in miR-483-3p expression was of importance in this 
study. We showed that miR-483-3p is regulated in part by the AngII-specific kinase 
MEK1.  Levels of miR-483-3p were upregulated upon inhibition of MEK1, which was 
the opposite response seen with AngII stimulation (Figure 5.3).  Additionally, under 
pharmacological inhibition of MEK1, the miR-483-3p target AGT was increased (Figure 
7.9). Together, these results give us confidence that AGT is a direct target of miR-483-3p 
and that the regulation of this miRNA is in fact through MEK1 activation.  
 
The ability of miR-483-3p to target multiple components of the RAS is profound.  
Most importantly, the effect of miR-483-3p on AGT is the most convincing and points to 
a third portion of the RAS that could be a potential therapeutic target.  Both ACE-1 
inhibitors and ARBs are utilized to date to effectively treat hypertension and related 
abnormalities caused by over activity of tissue RAS (Ritter, 2011); however, targeting 
AGT has not been shown until now.  Suppressing angiotensinogen would ultimately 
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block production of AngII, similar to ACE-1 inhibitors, but may have fewer side effects.  
Without in vivo studies, however, we will not know the true capacity of targeting AGT.   
 
10.7 Modulation of VSMC Phenotype 
The RAS is known to be highly active during vascular insult.  Specifically, AngII 
when over active plays a significant role in inducing a synthetic phenotype in adult 
VSMCs (Bader et al., 2001).  In this state, cells synthesize growth factors and other 
proteins that enhance their proliferative and migratory potential.  A critical aspect of this 
study was to determine the extent to which miR-483-3p could alter VSMC phenotype and 
thereby modify migration of VSMCs in the presence of AngII. Using a wound-healing 
assay, we demonstrated that RASMCs overexpressing miR-483-3p had the capability of 
suppressing AngII-mediated cell migration (Figure 8.2). In the presence of Candesartan 
the effect of miR-483-3p is maintained and cell migration is also slowed.   
 
A single miRNA has the potential to orchestrate post-transcriptional regulation of 
approximately 100-200 genes in a cells, either by translational inhibition or degradation 
of the target mRNA (Bartel, 2009).  We postulate that miR-483-3p targets VSMC-
specific cytoskeletal proteins involved in cellular movement, thereby causing suppression 
of cell migration even in the presence of AngII.  Characterizing miR-483-3p, as a 
causative agent in VSMC phenotypic switching is a significant aspect of AngII biology 
that will aid in understanding tissue RAS further.   
 
10.8 Final Remarks 
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The results of the current work have shown that AT1R activation by AngII 
produces signals that regulate specific miRNA expression.  A distinct AngII-regulated 
miRNA signature emerged in VSMCs, which was validated in independent samples.  
Further insight into how miRNAs modulate phenotype of cells in different tissues will be 
valuable for a greater understanding of AngII biology, as well as in determining the 
intrinsic regulatory influence of RAS on cardiovascular disease.  
 
Following our previous profiling study in human heart failure (Naga Prasad and 
Karnik, 2010, Naga Prasad et al., 2009) it was increasingly apparent that understanding 
the complex network involving miRNAs and their targets, which leads to a coordinated 
pattern of gene expression, will undoubtedly provide important tools to develop novel 
therapeutic strategies.  This will enhance knowledge of physiological regulation, 
dysregulated vascular remodeling, and mechanism for atherosclerotic disease 
progression.  In addition, selective regulation of particular miRNAs targeting vascular 
diseases is a promising prospect for future therapy. Much work remains to be 
accomplished to advance our knowledge of the involvement of miRNAs in RAS 
pathogenesis of cardiovascular disease and to develop therapeutic strategies to ultimately 
affect morbidity and mortality. 
 
Although the pathways regulating the RAS are well characterized, AngII-induced 
miRNAs and the molecular mechanisms of their expression remain poorly defined. 
Having focused our efforts on understanding the functional role and mechanism by which 
miR-483-3p is regulated is only one example of an AngII-responsive miRNA having a 
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substantial impact.  As we move forward with this work, we will be able to distinguish 
additional RAS regulated miRNA that could have an important function in cardiovascular 
biology.  Our work identifies miR-483-3p as a potential regulator of tissue RAS 
homeostasis, which has an important impact on VSMC biology. Because tissue RAS is 
highly active in vascular disease, there has been intense interest in therapeutically 
targeting the RAS (Paul et al., 2006). Our study suggests that modulating endogenous 
levels of miR-483-3p may be a useful therapeutic strategy for regulating RAS and 
controlling VSMC phenotypic switching.   
 
CHAPTER XI 
FUTURE DIRECTIONS 
 
 
11.1 Introduction 
 The results presented in this dissertation have shown a class of 32 miRNAs that 
are universally responsive to AngII in humans and rodents, a fingerprint of miRNA 
expression in VSMCs regulated by AngII, and evidence of unconventional regulation of 
miRNA levels in VSMCs through AT1R signaling. This study as a whole has allowed us 
to appreciate the capacity of AngII signaling through the AT1R in mediating the 
transcriptome and the miRNome.  Further in-depth analyses of the AngII-responsive 
miRNAs will answer questions regarding the function of these miRNAs in modulating 
phenotype in other cell systems.   
 
We also present our initial efforts of characterizing the biological function of a 
single AngII-regulated miRNA in VSMCs, as a means to understand its role in vascular 
physiology and progression of AngII-mediated pathologies.  In addition to fully 
characterizing miR-483-3p, in future studies we will examine whether additional 
miRNAs identified as differentially regulated in the genome-wide analysis are able to 
modulate VSMC phenotypes, such as vascular inflammation and remodeling in response 
to AngII.  
 
11.2 Complete Transcriptional Characterization  
With the more recent advent of techniques for direct sequencing of the 
transcriptional output of the genome, we can now begin to think about a complete 
transcriptional characterization of all the cells of an organism, following AngII 
stimulation. RNA sequencing (RNA-Seq) is direct high-throughput sequencing that 
enables researchers to examine transcriptome fine structure.  Transcript sequences are 
mapped back to a reference genome and then counted to assess the level of gene 
expression, the number of mapped reads being the measure of expression level for that 
gene or genomic region (Malone and Oliver, 2011). Because RNA-Seq provides direct 
access to the sequence, junctions between exons can be assayed without prior knowledge 
of the gene structure, RNA editing events can be detected, and knowledge of 
polymorphisms can provide direct measurements of allele-specific expression (Malone 
and Oliver, 2011).  
 
Since the completion of the Human Genome Project, our perception of our 
genome has dramatically shifted. That is, the number of protein-coding genes in our 
genome has been revised down, whereas the number of non-protein coding transcripts 
has significantly increased. Long non-coding RNAs (lncRNAs) are one group of non-
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protein coding transcripts that were generally considered transcriptional ‘noise’ until the 
advent of RNA-Seq technologies.  These RNAs are longer than 200 nucleotides, making 
them distinguishable from small regulatory RNAs such as miRNAs. The function and 
activity of these lncRNAs remain poorly understood; therefore, future studies must seek 
to examine their role within our genome. What is known is that these RNAs are involved 
in a variety of biological processes as regulatory molecules (Moran et al., 2012, Yan and 
Wang, 2012). Much like miRNAs, lncRNA expression profiles are altered in human 
disease states, including several types of cancer (Brunner et al., 2012).  Deciphering the 
role of AngII in mediating expression of lncRNAs would be beneficial in elucidating the 
complete effect of AngII stimulation and AT1R activation on regulating the cellular 
transcriptome.   
 
The ability of the peptide hormone AngII to induce transcription by signaling 
through the AT1R is an area of research that is constantly being expanded.  Elucidating 
the full capacity of AngII as a cellular agonist in inducing gene expression of additional 
non-coding RNAs will likely provide further insight into the tissue-selective modulation 
of AngII effects in disease states.      
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